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Abstract 
 
MDM2 is a proto-oncogene well known for its role as a negative regulator of the 
p53 tumour suppressor. It has also been demonstrated that co-upregulation of 
MDM2 and wild-type p53 is linked with reduced disease specific survival in renal 
cell carcinoma (RCC). Moreover, MDM2 expression has been shown to promote 
cell motility and invasiveness in several cancer cell types including RCC cells in a 
p53- and RING-finger- independent manner, suggesting a role for protein-protein 
interactions in mediating this effect. The work presented in this thesis has aimed to 
study the role of MDM2 interaction with other proteins, in particular with 
members of the NME (Non-metastatic protein) family of metastasis suppressing 
genes, in order to decipher the mechanisms of action by which MDM2 may 
contribute to a more aggressive phenotype in cancer cells. To accomplish this we 
have used a range of methodologies including investigating the consequences of 
MDM2 expression using exon array analysis in an attempt to identify changes in 
gene expression induced by wild type MDM2 (Clone 9) and an MDM2 RING-
mutant (RFM9) expressed stably in clonal derivatives of H1299 cells. In parallel 
studies in our research group, an interaction was identified between MDM2 and 
NME2. Since NME2 is a member of a family of genes that has been implicated in 
metastasis suppression, and since metastatic spread is a primary determinant of 
patient survival, we also focused on an analysis of this interaction. Thus the 
primary aim of this work became an examination of the mechanistic details and 
consequences of MDM2-NME interaction in cancer cells. The two most highly 
expressed forms of NME genes in most cell types are the highly related NME1 
and NME2 genes which both encode nucleoside diphosphate kinase (NDPK) 
activity, essential for maintaining cellular pools of nucleoside triphosphates. They 
are also metastasis suppressor genes with an ability to suppress cellular motility. 
Since MDM2 possesses an E3 ubiquitin ligase activity, we have investigated 
whether MDM2 has an ability to modify NME proteins by ubiquitinating them and 
also whether MDM2 modulates the NDPK activity of NME proteins and/or their 
motility suppressing activity. Our results suggest that MDM2 may abrogate 
motility suppressive effects of NME2 through down-regulation of NME2 (and also 
of NME1) protein levels with potential consequences for suppression of NDPK 
activity. More interestingly, our studies have identified NM23-LV, which is 
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derived from a specific read-through transcription and alternative splicing event of 
the adjacent NME1 and NME2 genes, as an MDM2-interacting protein. In 
addition, we have identified NM23-LV as a novel substrate for MDM2-mediated 
ubiquitination that occurs in an MDM2 E3 ligase activity-dependent manner. 
Ubiquitination of NM23-LV by MDM2 seems to be highly specific, since neither 
NME1 nor NME2 are substrates for MDM2-mediated ubiquitination. Furthermore, 
our results have also shown that NM23-LV can substantially promote MDM2 
stabilisation and enhance MDM2-dependent p53 inactivation, adding another layer 
of complexity to the interactions between MDM2 and NME family members. 
Functional studies of NM23-LV have suggested that NM23-LV plays a role in 
promoting cell motility, which contrasts with the canonical role of NME1 and 
NME2 as metastasis suppressors. Taken together, studies presented in this thesis 
have identified a novel relationship between MDM2 and NM23-LV, which could 
provide valuable insights into the underlying mechanisms leading to increased cell 
motility promoted by MDM2 and suggests that new studies examining how 
MDM2-NME interactions may regulate cell motility and cancer metastasis are 
needed. Given the role of MDM2 in promoting more aggressive RCCs, insights 
gained from these studies may ultimately identify opportunities for therapeutic 
interventions for RCC, as well as for other human cancers. 
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1. Introduction 
1.1 Background on Cancer 
Cancer is a broad group of diseases that share some common characteristics [1]. 
The main defining characteristic of cancer cells is that they divide and grow in an 
uncontrolled manner. Some tumours, if detected late or left untreated will become 
malignant, that is they are able to invade adjacent tissues and spread throughout 
the organism via the lymphatic system or blood stream. Cancer cells achieve these 
abnormal phenotypic traits largely by having defects in normal cellular programs 
that govern cell proliferation, migration, apoptosis and homeostasis [2, 3]. These 
regulatory defects are due to changes in the cell genome, leading to transformation 
of normal cells into malignant cancer cells. Therefore, broadly speaking, cancer is 
a genetic disease [2]. Changes in the genome can be caused by both internal 
factors, such as inherited mutations; and/or environmental or acquired factors, 
such as tobacco, diet, viruses, and UV radiation [4]. 
 
Different types of genetic alterations, such as subtle mutations at the nucleotide 
level, aberration in chromosome number (aneuploidy), chromosome translocations 
and gene amplifications [5] affecting growth, senescence and apoptosis have all 
been related to tumorigenesis [6]. Generally, genes altered in tumorigenesis can be 
grouped into three key types: oncogenes, tumour suppressor genes and genomic 
stability genes [7, 8]. Oncogenes are genes that typically promote cell growth and 
differentiation. Upon mutation, oncogenes become activated and can cause 
uncontrolled cell proliferation, which is fundamental for the development of 
cancer. On the other hand, tumour suppressors refer to genes that typically 
regulate cell division, promote apoptosis, and suppress metastasis. Inactivation of 
tumour suppressor function may lead to cancer by inhibiting normal cell death or 
cell cycle arrest [9, 10]. Tumour formation occurs when the regulatory balance 
between oncogene and tumour suppressor functions is lost. Typically, oncogenic 
mutations that occur in one allele of an oncogene are sufficient to drive selective 
cell growth advantage, and thus these are usually dominant [10]. Mutations in 
tumour suppressors, however, are typically considered to be recessive; which 
means two copies of a gene must be inactivated for a phenotypic effect to occur 
[10].  
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The third class of genes responsible for tumorigenesis are the genomic stability 
genes or housekeeping genes, which mainly function in detecting DNA damage 
and repairing errors made during DNA replication or induced by external 
mutagens [10]. The genomic stability genes, which include the mismatch repair 
(MMR), nucleotide-excision repair (NER) and base-excision repair (BER) genes, 
serve to keep genetic alterations to a minimum level [10]. Mutations that 
inactivate DNA repair genes can lead to the occurrence of multiple random 
mutations and propagation of genetic defects. This increase in genome instability 
allows for the outgrowth of abnormal cells which will then find it easier to acquire 
additional mutations, giving them a selective advantage over their normal 
counterparts [2].  
 
Cancer is an intricate collection of specific genetic diseases acquiring a common 
set of hallmarks [2, 3, 11]. The foundation of the malignant process, as proposed 
by Hanahan and Weinberg include: self-sufficiency in growth signals, insensitivity 
to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis, evading immune 
destruction, genome instability and mutation, tumour-promoting inflammation, 
and deregulating cellular energetics [2, 11]. These properties, shared by all types 
of human cancers, are acquired successively and the sequence in which they 
appear may vary in specific types of cancer or within the same type of cancer 
(Figure 1.1.1) [2, 11].  
 
Cancer arises through a usually long, multistep, mutagenic process. Since most 
cancers are sporadic resulting from somatic mutations and that accumulation of 
genome alterations takes time, cancer is more likely to develop during later stages 
in life. However, when germline mutations are present, the time required to 
develop cancer is shortened by enabling the transfer of parental genetic defects 
from one generation to another. Therefore, people who are born with hereditary 
predisposition to cancer syndromes, such as Li Fraumeni (mutations in p53 gene) 
and von Hippel-Lindau (mutations in VHL gene), have higher chances of 
developing cancer at a younger age [10, 12, 13]. 
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Figure 1.1.1: Hallmarks of cancer. Acquired functional capabilities common in 
all types of cancer cells, which establish the foundation of malignant process, 
together with enabling characteristics which are important to the acquisition of 
these hallmarks. Figure reproduced from references [11, 14]. 
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 In the process of carcinogenesis normal cells undergo malignant transformation 
and acquire multiple capabilities, which allow for their unrestricted growth. These 
“superpowers” or “hallmarks” of cancer, described by Hanahan and Weinberg in their 
review (1), are summarised in Figure 1.2 and include: self-sufficiency in growth 
signals (autocrine signalling), insensitivity to growth-inhibitory signals, evasion of 
apoptosis (cell suicide), limitless replicative potential (immortality), sustained 
angiogenesis (formation of new blood vessels) and tissue invasion and metastasis (1). 
More recently additional hallmarks of evading immune destruction (11) and 
deregulating cellular energetics (12) have been proposed. It is believed that these traits 
are shared by most types of human cancer. 
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Figure 1.2: The hallmarks of cancer. Acquired functional capabilities of cancer cells, which 
establish their malignancy, and enabling characteristics crucial to the acquisition of these 
hallmarks. Figure adapted from reference (12).  
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1.2 Renal Cell Carcinoma (RCC) 
Kidney cancer accounts for about 3% of all cancers. Cancer Research UK reported 
that around 9,600 people were diagnosed with kidney cancer and around 4,100 
people have died of kidney cancer in 2010 in the UK (Table 1.2.1). The incidence 
rates for kidney cancer in Britain have more than doubled since the mid 1970s. 
Worldwide, it is estimated that more than 250,000 new cases of kidney cancers are 
diagnosed annually [15]. The majority of the kidney cancers (80-85%) are renal 
cell carcinomas (RCC) originating from the renal parenchyma [16]. 
 
 
 
Table 1.2.1: Kidney Cancer Statistic. Table reproduced from Cancer Research 
UK’s Statistical Information Team [17]. 
 
Kidney Cancer Statistics Males Females Persons Country Year3 
Number of new cases per year 5,906 3,733 9,639 
Incidence rate per 100,000 population1 15.7 8.4 11.8 
UK 
  
2010 
  
Number of deaths per year 2,451 1,611 4,062 
Mortality rate per 100,000 population1 6.2 3.1 4.5 
UK 
  
2010 
  
One-year survival rate2 71.5% 71.4% 71.4% England 2005-2009 
Five-year survival rate2 53.3% 54.8% 53.9% England 2005-2009 
Ten-year survival rate2 43.0% 44.3% 43.5% England & Wales 2007 (predicted) 
1 European age-standardised 2 Adults diagnosed 3 Latest statistics available  
 
 
 
RCC is a heterogeneous disease. It comprises a group of tumours arising from the 
epithelium of the renal tubules, that not only display distinct histology and clinical 
behaviour, but are also caused by different genetic alterations [15, 16]. Recent 
reports show that different histological subtypes of RCC have different clinical 
outcomes and respond differently to therapy [18]. According to the 2004 (updated 
later in 2009) World Health Organisation classification, the three most common 
histological subtypes of RCC are: clear cell (ccRCC), papillary (pRCC), and 
chromophobe RCCs (chrRCC) [18, 19]. ccRCC is the commonest histologic 
subtypes and is believed to account for 75% of all RCCs. This is followed by 
pRCC, which accounts for 10% of RCC and is subclassified into type I and type 
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II, depending on the morphology of the cells covering the papillary lesions [20]. 
Both ccRCC and pRCC are thought to originate from cells in the proximal 
convoluted renal tubule (Figure 1.2.1) [21-23]. chrRCC is the third commonest 
subtype and accounts for 5% of the RCCs. chrRCC is believed to originate from 
type B intercalated cells of renal collecting ducts [22, 24].  
 
Most cases of RCCs are sporadic and usually occur in the sixth decade of life. 
Only a small proportion of RCCs (2-4%) are heritable [25, 26]. Different inherited 
RCC syndromes, for example, von Hippel-Lindau disease, paraganglioma 
syndrome, hereditary leiomyomatosis, and Hogg-Dubé syndrome, have been 
classified based on their histopathological and genetic characteristics [27].  
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Figure 1.2.1: Classification of RCC subtypes. The nephron consists of the renal 
corpuscle (1) and renal tubule. The renal tubule is classified into four histo-
physiological zones: proximal convoluted tubule (2), loop of Henle (3), distal 
convoluted tubule (4) and collecting tubule (5). The different RCC subtypes 
originate from different parts of the renal tubular system. For example, clear cell 
RCC (2a) and papillary RCC (2b) originate from the proximal convoluted tubule 
whereas chromophobe RCC (5a), collecting duct carcinoma (5b), and mucinous 
tubular and spindle cell carcinoma (5c) are believed to originate from the 
collecting tubule. Haematoxylin and eosin (H&E) staining shows that (2a) clear 
cell RCC consists of clear cytoplasm with an eosinophilic or granular appearance; 
(2b) papillary RCC is characterised by papillae covered by small cells with scanty 
cytoplasm, arranged in a single layer on the papillary basement membrane; (5a) 
chromophobe RCC is composed of large polygonal cells with a transparent 
slightly reticulated cytoplasm for numerous invaginated vesicles; (5b) collecting 
duct carcinoma is characterised by tubulopapillary architecture that consists of an 
admixture of dilated tubule and papillary structures commonly lined by a single 
layer of cuboidal cells; and (5c) mucinous tubular and spindle cell carcinoma is 
composed of tightly packed tubules separated by pale stroma and a spindle cell 
component with mucinous material [28]. Figure reproduced from [16]. 
Finally, patients with certain inherited disorders such as
von Hippel-Lindau disease, hereditary papillary renal cancer,
a hereditary leiomyoma RCC syndrome and Birt-Hogg-Dubé
syndrome, show an enhanced risk of RCC [37–39]. These
inherited disorders show specific genetic abnormalities (see also
Section 2).
1.3. Classification
The majority of kidney cancers (80–85%) are RCCs
originating from the renal parenchyma. The remaining 15–20%
are mainly transitional cell carcinomas of the renal pelvis. Other
less frequent malignant tumors of the kidney are metanephric
adenosarcomas, mesenchymal tumors, mixed mesenchymal and
epithelial tumors, neuroendocrine tumors, hematopoietic and
lymphoid tumors, germ cell tumors and metastatic tumors.
Though nephroblastomas (Wilms tumor) are the most common
renal tumors of childhood, few cases have been reported in
adulthood [40–42].
RCC is almost exclusively a cancer of adults and is rare in
the first two decades of life, comprising only 2% of pediatric
renal tumors.
RCC is not a single entity (see Fig. 1), but comprises a group
of tumors, which arise from the epithelium of renal tubules.
Extensive histological and molecular evaluation has resulted in
the development of a consensus classification of different RCC
subtypes. In 1996, the Heidelberg classification of RCC was
proposed, which intends to integrate the understanding of ge-
netic alterations and readily recognizable histological criteria
[43]. In this classification, three major histological subtypes of
Fig. 1. Classification of RCC subtypes: cell of origin. The nephron, consists of the renal corpuscle (1) and renal tubule, which is divided into four histo-physiological
zones: proximal convoluted tubule (2), loop of Henle (3), distal convoluted tubule (4) and collecting tubule (5). The different RCC subtypes are thought to originate
from different parts of the renal tubular system: mainly the proximal convoluted tubule (2a clear cell RCC and 2b papillary RCC) and the collecting tubule
(5a chromophobe RCC, 5b collecting duct carcinoma, and 5c mucinous tubular and spindle cell carcinoma).
135M.M.L. Baldewijns et al. / Biochimica et Biophysica Acta 1785 (2008) 133–155
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1.3 Von Hippel-Lindau (VHL) disease 
VHL disease is the most studied and commonest hereditary RCC syndrome [27]. 
RCCs that occur in people with heritable VHL syndrome are exclusively of the 
clear cell subtype [29-31]. VHL disease is an autosomal dominant inherited 
disorder. The disease is caused by germline mutations in the VHL tumour 
suppressor gene, accompanied by the inactivation or silencing of the second wild-
type VHL allele in a susceptible cell, in accord with the Knudson Two-Hit Tumour 
Suppressor Model [21, 32-34]. The VHL gene product participates in the 
regulation of several cellular pathways, such as extracellular matrix assembly, 
cell-cycle control and oxygen sensing [21]. It has been suggested that one of the 
critical roles of VHL is its ability to interact with an E3 ubiquitin ligase complex 
and regulate the transcription of activator hypoxia-inducible factor 1α (HIF-1α) 
[35-38]. Under normoxic conditions, HIF-1α subunits become hydroxylated, and 
this allows binding and ubiquitination by VHL protein and subsequently 
degradation by the proteasome [37]. Under hypoxic conditions, however, HIF-1α 
subunits are non-hydroxylated and are able to heterodimerise with HIF-2β. The 
stabilised HIFα-β heterodimers are free to bind DNA at hypoxia responsive 
elements (HREs) and transcriptionally activate genes that are important in 
regulating angiogenesis, cell growth and apoptosis [31, 39]. Thus, in VHL-
defective ccRCC, HIF-1α is constitutively stabilised and its accumulation leads to 
overexpression of proteins that are normally inducible with hypoxia, such as 
transforming growth factor α and β  (TGF-α and -β, respectively), vascular 
endothelial growth factor-α (VEGF-α), and platelet-derived growth factor (PDGF) 
[40]. Over-expression of these proteins targets neighbouring vascular cells and 
promotes tumorigenesis [40]. 
 
Whilst heritable ccRCC is caused by a germline mutation of one allele and an 
acquired mutation of the remaining allele of VHL, sporadic ccRCCs are 
predominantly caused by biellelic VHL inactivation (Figure 1.3.1), which can be a 
consequence of somatic mutations, deletions, loss of heterozygosity (LOH) or 
epigenetic inactivation, such as promoter DNA methylation [16, 31, 41, 42]. 
Nevertheless, mutation of the VHL gene is an important event in the pathogenesis 
in both heritable and sporadic ccRCCs [43]. 
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Figure 1.3.1: Development of clear cell RCC. (A) Sporadic RCC; (B) hereditary 
RCC (B). Figure adapted from [40]. 
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Figure 3. Steps in the Development of Renal-Cell Carcinoma. 
 
In contrast to sporadic renal-cell carcinoma (Panels A and C), fewer steps are required for the development of renal-cell carcinoma in the in-
herited forms of the disease (Panels B and D), because all of the patient’s cells have a mutation that predisposes the patient to the disease. 
As a result, the disease associated with the familial syndromes occurs earlier and is often multifocal. Each familial renal cancer syndrome is 
autosomal dominant. In von Hippel–Lindau disease, a cellular recessive mechanism is involved, since both copies of the 
 
VHL
 
 gene are inac-
tivated (Panels A and B). 
 
VHL
 
 is a classic tumor-suppressor gene. In hereditary papillary renal carcinoma, one copy of the 
 
MET
 
 gene has an 
activating mutation, which is inherited (Panel D). Chromosome 7, which includes the defective 
 
MET
 
 allele, becomes duplicated, increasing 
the level of expression of the activated MET protein, which is a receptor tyrosine kinase for hepatocyte growth factor. Activated 
 
MET
 
 is a clas-
sic oncogene. A plus sign represents the wild-type allele; a minus sign represents a null allele. A plus sign in red type represents a mutated, 
activated allele; two plus signs in red type represent duplication of that allele.
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1.4 An introduction to MDM2 
The MDM2 (Mouse Double Minute) gene was initially identified on acentric 
double-minute chromosomes of spontaneously transformed mouse 3T3 fibroblasts 
[44]. These abnormal chromosomes were later discovered to contain more than 
50-fold amplified genes that contribute to cellular proliferation and tumorigenesis 
[45]. It was found that amplification of the MDM2 gene contributes to 
tumorigenicity as demonstrated in studies in which it was experimentally 
overexpressed in NIH3T3 cells and in Rat2 cells [45]. It was first thought that 
MDM2 primarily acted to inhibit the tumour suppressor p53-mediated 
transcriptional activation through direct interaction [46]. The ability of MDM2 to 
promote proteasomal degradation of p53 (as described Section 1.4.2.1) was not 
realised for a number of years [47, 48]. The importance of the interaction of 
MDM2 with p53 can be seen in gene targeting studies, which have demonstrated 
that mouse embryos lacking Mdm2 die early after implantation, but this lethality 
can be completely rescued in a p53-null background, indicating that the embryo 
lethality was due to the lethal effects of unregulated p53 [49, 50]. This has also 
demonstrated that Mdm2 is a major negative regulator of p53, at least during 
embryonic development.  
 
A homolog of MDM2, called MDMX (also known as MDM4), also plays a 
critical role in the negative regulation of p53 during embryonic development [51, 
52]. Similar to mice deficient in MDM2, MDMX-null mice also suffer p53-
dependent embryonic lethality [53]. Whilst it was demonstrated that homozygous 
deletion of MDM2 significantly elevates p53 protein levels in MEFs, homozygous 
deletion of MDMX in an MDM2 heterozygous background also resulted in an 
increase in p53 levels, but to a lesser extent [52]. Considering the fact that MDMX 
lacks the E3 ligase activity, it is widely accepted that MDM2 regulates p53 
primarily through governing p53 protein stability, whereas MDMX does so 
through alternative mechanisms (see Section 1.4.4 for more details), for example, 
inhibiting p53 transcriptional activity via interaction with the p53 transactivation 
domain [51, 54-56].  
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1.4.1 MDM2 structure 
Human MDM2 consists of 491 amino acids and of several major domains, 
including a p53-interacting domain, RING (Really Interesting New Gene) domain, 
nuclear localisation sequence (NLS), nuclear export sequence (NES), nucleolar 
localisation sequence (NoLS), and acidic domain (Figure 1.4.1.1) [57]. Located on 
the amino-terminus of MDM2, the p53-interacting domain, as suggested by its 
name, is able to interact with the transactivation domain of p53 [58]. This 
interaction permits MDM2 to inhibit p53 from binding to the basal transcriptional 
machinery, thus impeding p53-mediated transcriptional activation of its target 
genes [46, 59]. Additionally, through interaction with p53, MDM2 also facilitates 
nuclear export of p53 in a RING domain-dependent manner [60]. The evolutionary 
conserved carboxy-terminal RING domain of MDM2 is mainly responsible for its 
intrinsic E3 ligase activity. The RING domain contains a conserved cysteine-rich 
sequence motif, usually Cis3-His-Cis4, which forms two interleaved zinc-binding 
sites. The zinc-binding sites contain four pairs of cysteine and histidine residues in 
a ‘cross-brace’ configuration (Figure 1.4.1.2), which serve to coordinate two zinc 
ions for proper folding [61-64]. Mutations of these key cysteine or histidine 
residues have been shown to abolish the intrinsic E3 ubiquitin ligase activity of 
MDM2 [62, 65]. Apart from E3 ligase activity, the RING domain is also important 
for nucleotide and RNA binding, as well as protein-protein interaction, such as 
dimerisation between MDM2 and MDMX through their mutual RING domains 
[66-68]. Binding of ATP at the RING domain has also been reported to facilitate 
nucleolar localisation of MDM2 [68]. The nuclear localisation and nuclear export 
signals are responsible for nucleo-cytoplasmic shuttling of MDM2, providing 
another mechanism regulating p53 activity [69, 70]. MDM2 can export active p53 
from the nucleus (where p53 can transactivate its target genes) to the cytoplasm, 
where p53 can no longer induce transcription but only exert other cytoplasmic 
functions [55, 71, 72]. MDM2 also contains a NoLS at its carboxy-terminal, which 
may be necessary for MDM2 to polyubiquitinate p53 [73]. The central acidic 
domain of MDM2 is required for interaction with the ribosomal protein L5 and 
p300/CBP (CREB-binding protein). Studies have found that an MDM2 mutant 
defective in p300-binding can promote ubiquitination but not degradation of p53 
[74, 75]. This suggests the importance of p300 in regulation of MDM2-mediated 
p53 ubiquitination and proteolytic processes [76].  
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Another evolutionarily conserved domain of MDM2 is the zinc finger domain, 
which is believed to play a role in MDM2 interaction with ribosomal proteins and 
in MDM2-mediated degradation of p53 [77]. MDM2 zinc finger mutants are 
defective at mediating nuclear export and p53 degradation, but retain an ability to 
abrogate p53 transcriptional activity [77]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1.1: Schematic structure of full-length MDM2 protein and splice 
variant MDM2-B. NLS, nuclear localisation signal; NES, nuclear export signal; 
Zn-finger, Zinc-finger; NoLS, nucleolar localisation signal; N, amino-terminal; C, 
carboxyl-terminal. Figure adapted from [57, 78]. 
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Figure 1.4.1.2: Zinc coordination topology for RING domain. The zinc-binding 
sites contain four pairs of cysteine (C) and histidine (H) residues in a ‘cross-brace’ 
configuration, which serve to coordinate two zinc ions (Zn2+) for proper folding. 
The first pair of ligands (C1 and C2) together with the third pair (C5 and C6) 
coordinates one Zn2+, and the second (C3 and H4) and fourth (C7 and C8) pairs 
bind the second Zn2+. Figure adapted from [63]. 
 
 
1.4.2 MDM2 as an E3 ubiquitin ligase  
One of the major roles of MDM2 is to act as a negative regulator of p53 by 
directly controlling p53 protein degradation rate (see Section 1.4.2.1 for more 
details) [48, 79-83]. As mentioned in Section 1.4.1, MDM2 possesses p53-specific 
E3 ubiquitin ligase activity within its carboxy-terminal RING-finger domain [62]. 
This E3 ligase activity allows MDM2 to transfer ubiquitin moieties onto other 
protein, in a process called ubiquitination. Similar to many other post-translational 
modifications, ubiquitination is an inducible and reversible process crucial for 
altering the properties of modified substrate [84, 85]. This inducible and reversible 
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process allows ubiquitination to modulate cellular homeostasis and signaling, 
including sub-cellular localisation, stability or enzymatic activity [84, 85].  
Ubiquitination involves the covalent attachment of an 8.5 kDa polypeptide to 
lysine residues present on substrate protein [84]. It takes place according to a 
cascade of enzymatic reactions catalysed by three enzymes: ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3) 
(Figure 1.4.2.1) [86, 87]. E1 initiates the activation of ubiquitin in an ATP-
dependent manner and forms a thioester bond between the carboxy-terminal 
carboxyl group of ubiquitin and the cysteine residue within the active site of E1 
[88]. This generates a high-energy thiol ester intermediate and the ubiquitin 
molecule is subsequently transferred to the catalytic cysteine of E2, which also 
generates a thioester linkage [84, 88, 89]. The last step of ubiquitination involves 
an E3 ubiquitin ligase catalysing the attachment of the activated ubiquitin to its 
specific substrate, through forming an isopeptide between the lysine residue within 
the substrate and the carboxy-terminal carboxyl group of the ubiquitin [84, 88, 
89].  
 
Two main types of ubiquitination are mono-ubiquitination and poly-ubiquitination 
(Figure 1.4.2.2). Mono-ubiquitination involves the attachment of a single ubiquitin 
moiety on a lysine residue within a substrate, or of multiple single ubiquitin 
moieties on different lysine residues within the same substrate [84]. Mono-
ubiquitination has been implicated in many fundamental non-proteolytic cellular 
processes, for example, sub-cellular localisation, DNA repair, endocytosis and 
histone regulation [84]. On the other hand, poly-ubiquitination is the formation of 
ubiquitin chain on a substrate protein. Ubiquitin itself has seven lysine residues 
that can serve as linking points for forming ubiquitin chains, of which Lysine (K) 
48 and K63 are two of the best studied residues [90]. K48-linked ubiquitin chains 
usually serve as the primary targeting signals for proteolytic degradation by 26S 
proteasome [85, 91, 92]. K63-linked chains, however, do not support protein 
destruction, but are instead responsible for coordinating processes, such as DNA 
repair and protein sorting [85, 93]. Thus the type of ubiquitination has a huge 
influence on the fate of ubiquitinated substrates in signalling pathways.  
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Figure 1.4.2.1: Ubiquitination cascade. Ubiquitination occurs according to a 
three-step catalytic cascade of three enzymes: ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). Ubiquitin is coupled 
to the cysteine residue within the active site of E1 enzyme in an ATP-dependent 
manner to form a thioester. Secondly, ubiquitin is transferred to the catalytic 
cysteine of E2 enzyme, and again, forming a thioester. The third step is catalysed 
by E3 ubiquitin ligase and involves the covalent attachment of the activated 
ubiquitin to a lysine residue within the substrate. Figure reproduced from [88]. 
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Figure 1.4.2.2: Types of ubiquitination and their cellular functions. 
Attachment of a single ubiquitin (Ub) moiety to a single lysine (K) residue results 
in protein mono-ubiquitination (mono-Ub). Addition of several single Ub 
molecules to different lysine residues is called multiple mono-ubiquitination 
(multi-Ub). These modifications are involved in a range of non-proteolytic cellular 
functions, including endocytosis, endosomal sorting, histone regulation and DNA 
repair. Poly-ubiquitination (poly-Ub) involves the addition of ubiquitin chain to 
one or more lysine residues. Ub chain forms via lysine 48 (K48) of Ub and usually 
represent a signal for proteasomal degradation of modified substrates. On the other 
hand, K63-linked ubiquitin chains are implicated in DNA repair and protein 
kinases activation.  Figure adapted from [85, 94]. 
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NFκB-binding sites of target genes and a transactiva-
tion domain responsible for transcriptional activation. 
By contrast, NFκB1 and NFκB2 have a DNA-binding 
domain but lack a transactivation domain. Therefore, 
to promote efficient gene transcription in vivo they 
either form a heterodimer with RelA, RelB or c-Rel, or 
recruit the co-activator BCL3 (B-cell CLL/lymphoma 3),
which pr v des the transactivation domain. A central 
step in the regulation of NFκB activity is its transloca-
tion from the cytoplasm to the nucleus. This process is 
regulated by several different ubiquitin modifications to 
various members of the NFκB pathway46.
NFκB can be triggered by distinct signalling pathways 
in response to several extracellular cues such as radia-
tion, inflammation, tumour-necrosis factor-α (TNFα), 
bacterial lipopolysaccharides (LPS), interleukin 1β and 
chemotherapeuticals, and intracellular cues such as 
metabolic products causing DNA lesions. Irrespective of 
the activating agent, or whether the signalling cascade is 
initiated in the cytoplasm or the nucleus, all but one of the 
pathways described so far converge on the cytoplasmic 
IκB kinase (IKK) complex, which is responsible for the 
phosphorylation of IκB leading to NFκB liberation and 
activation. IKK is a multiprotein complex consisting of 
catalytic subunits (IKKα and IKKβ) and a regulatory 
subunit (IKKγ) (FIG. 2a). Although IKKα and IKKβ are 
the catalytically active components of IKK, it is IKKγ that 
underlies an unorthodox system of post-translational 
regulation that involves phosphorylation, ubiquitylation 
and sumoylation47–52. Notably, the type of IKKγ modifi-
cation is dependent on the mode of IKK activation. For 
example, the stimulation of cell-surface receptors such as 
T-cell receptors (TCRs) or TNFα receptors results in the 
Lys63-linked polyubiquitylation of IKKγ 47,48, whereas 
IKKγ undergoes transient sumoylation in response to 
DNA-damaging agents or stress conditions such as heat 
shock and hydrogen peroxide51,52 (FIG. 2a). To achieve NFκB 
activation, the SUMO tag on IKKγ has to be replaced by 
monoubiquitin. This requires the action of another pro-
tein that is induced by DNA double-strand breaks: the 
protein kinase ATM, which is a well-known regulator 
of the cell cycle, DNA repair and cell death. ATM binds 
to nuclear IKKγ and phosphorylates it at Ser85, which is 
followed by the addition of monoubiquitin53. This 
Box2 | Different types of modifications
The types of ubiquitin (Ub) modifications are diverse, as are their functions. In the simplest form, a single ubiquitin molecule 
is attached (part a), which is defined as monoubiquitylation. It is involved in several processes including endocytosis, 
endosomal sorting, histone regulation and DNA repair. Alternatively, a substrate that contains several lysine (K) residues 
can be tagged with several single ubiquitin molecules (part b), which has a role in endocytosis.
Furthermore, ubiquitin itself has seven Lys residues that can be involved in chain formation in vivo. Ubiquitin chains linked 
through Lys48 and 63 are the best characterized. Linkage through Lys48 (part c) has been shown to represent a signal for 
the proteasomal degradation of modified substrates. Lys63-linked chains (part d) seem to have completely different, 
degradation-independent functions that are involved in processes such as DNA repair and protein sorting3. Besides these 
well-characterized types of ubiquitylation, new, less well-understood modes have been reported that involve Cys instead 
of Lys as the ubiquitin acceptor113, or mixed ubiquitin chains that consist of Lys48 and Lys63 linkages114.
Although the 3-dimensional structures of ubiquitin-like (Ubl) modifiers are similar to that of ubiquitin, their functions are 
quite different. Monosumoylation (S) was shown to have roles in the regulation of subcellular localization, DNA repair, 
chromatin remodelling and the regulation of transcription (part e), whereas the function of SUMO chains that were 
observed for SUMO paralogues 2 and 3 is still unknown (part f)87.
Fatylation (F) has recently been shown to mediate rapid degradation by the proteasome (part g)115. Neddylation (N) has 
been observed for only a few proteins (part h). Interestingly, several ubiquitin-E3 ligases were reported to be neddylated, 
which provides a close link between neddylation and ubiquitylation events36,112. In addition to neddylation, conjugation 
with the Ubl ISG15 (I) was shown to interfere in the ubiquitin modification system by modifying an E2. Furthermore, 
ISGylation regulates the immune response and is inducible by interferons (part i).
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1.4.2.1 MDM2-mediated ubiquitination of p53 and other proteins 
MDM2 can act as an E3 ubiquitin ligase for tumour suppressor p53. Mono-
ubiquitination of p53 by MDM2 can cause changes in localisation of p53 through 
unmasking an intrinsic NES as a result of dissociation of p53 tetramers, whilst 
poly-ubiquitination of p53 by MDM2 leads to proteasomal degradation of p53 [47, 
48, 80, 95]. Mono-ubiquitination of p53 by MDM2 plays an important role in 
facilitating nuclear export of p53 [96]. MDM2-mediated mono-ubiquitination of 
p53 has been shown to mediate cytoplasmic translocation of p53 in unstressed 
cells, which can inhibit p53 transcriptional activity in the nucleus [96, 97]. 
Furthermore, mono-ubiquitination of p53 can also result in localisation of p53 to 
mitochondria, where p53 can trigger a direct and transcription-independent 
apoptotic program [98]. 
 
It was initially thought that proteasomal degradation of p53 was exclusively 
cytoplasmic and thus MDM2-p53 nuclear export was indispensable for p53 
degradation [69, 99]. However, it is increasingly evident that MDM2-mediated 
degradation of p53 can occur in either the nucleus or cytoplasm, omitting the need 
for nuclear export in p53 ubiquitination and degradation [100, 101]. Increased 
levels of ubiquitinated p53 have been observed in cells treated with the nuclear 
export inhibitor leptomycin B, suggesting that nuclear export is not required for 
p53 ubiquitination and that the ubiquitination process occurs in the nucleus [60]. 
In addition, Joseph et al. showed that during the down-regulation of a p53 
response after multiple forms of DNA damage, degradation of endogenous p53 
occurs in both nucleus and cytoplasm [100]. When DNA damage has been 
successfully repaired, an active p53 response is no longer required and could be 
deleterious to cell survival. Both nuclear and cytoplasmic proteasomes are 
recruited to efficiently degrade the elevated p53 proteins to restore normal 
homeostasis [100]. Recent studies have shown that MDM2-mediated degradation 
of p53 may also occur in the nucleolus, and that the transit of MDM2 through the 
nucleolus appears to be essential for p53 ubiquitination and export [102]. 
 
Apart from p53, MDM2 has various other ubiquitination substrates, including 
MDM2 itself (auto-ubiquitination), MDMX, retinoblastoma protein (pRB), 
dihydrofolate reductase (DHFR), E-cadherin, NUMB, Notch 1 receptor, Forkhead 
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box O 4 (FOXO4), glucocorticoid receptor (GR), and insulin-like growth factor 1 
receptor (IGF-IR) [65, 103-110]. Recent studies have shown that auto-
ubiquitination of MDM2 facilitates stronger recruitment of E2 conjugating 
enzymes, thereby enhancing the efficiency of ubiquitination [111]. MDM2 was 
initially proposed to regulate its own stability via auto-ubiquitination [62, 112, 
113]. However, the observation was later challenged by studies using mouse 
models lacking the E3 ligase function, which demonstrated that auto-
ubiquitination is not necessary for degradation of MDM2 in vivo [79, 114]. 
Instead, MDM2 degradation may be regulated by other E3 ubiquitin ligases, such 
as SCFβ-TRCP [115]. MDMX, can also be ubiquitinated by MDM2 leading to 
proteasomal destruction [116, 117]. Studies have demonstrated that upon DNA 
damage, MDM2 promotes ubiquitination and degradation of MDMX to ensure 
optimal p53 activation [116]. Additionally, MDM2 has also been reported to 
mono-ubiquitinate histones H2A and H2B, causing transcriptional repression of 
p53 target genes [118].  
 
Like most post-translational modifications, the process of ubiquitination can be 
reversed, commonly by deubiquinating enzymes (DUBs). Deubiquitination allows 
for a binary switch between mono- and poly-ubiquitination or to switch off the 
ubiquitin signal completely [85, 86, 119]. For instance, deubiquinating enzyme, 
HAUSP (Herpesvirus-associated ubiquitin-specific protease), has been shown to 
deubiquitinate and stabilise the p53, MDM2 and MDMX proteins [120]. It has 
been demonstrated that ATM (ataxia telangiestasia mutated)-mediated 
phosphorylation of MDM2 and MDMX can lead to a disrupted interaction with 
HAUSP, resulting in stabilisation of MDM2 and MDMX upon DNA damage 
[121]. Since the interaction between HAUSP and p53 was not diminished upon 
DNA damage and that ATM-mediated phosphorylation activates the p53 protein, 
this allows proper p53 activation upon DNA damage [121].  
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1.4.3 MDM2 and human cancer 
MDM2 was identified because it was oncogenic before it was known that it 
negatively regulates p53 [44, 46]. As an oncogene that is activated by increased 
expression, MDM2 gene amplification has been observed in approximately one-
third of human sarcomas [81]. In addition, the MDM2 gene is also frequently 
overexpressed in various human cancers, notably in breast, renal, colon, prostate, 
and lung cancers, as well as in lymphomas and leukaemias [122-128]. Studies 
have shown that MDM2 overexpression is associated with tumours that have a 
higher degree of invasiveness, greater metastatic potential, poorer prognosis and 
are more resistant to chemotherapeutic agents and radiation [128]. In a recent 
study, it has been suggested that high levels of MDM2 are associated with poor 
prognosis in invasive ductal breast cancer (IDC) [129]. This observation may be 
due to MDM2 overexpression inducing matrix metallopeptidase-9 (MMP-9) 
expression, leading to a rise in extracellular breakdown and subsequently 
increased tumour invasiveness [129]. However, the mechanism by which MDM2 
up-regulates MMP-9 remains unclear. In another study examining 100 samples of 
esophageal squamous cell carcinoma, MDM2 expression was identified as the 
most significant risk factor for distant metastasis [130]. These studies highlight the 
impact of MDM2 overexpression on metastasis, which is the main cause of 
cancer-associated deaths. 
 
Metastasis is a highly complex multi-step process which involves the detachment 
of tumour cells from the primary tumour, invasion of stromal tissue, migration, 
intravasation into the circulation, survival in the vasculature, extravasation and 
colonisation of a secondary site [2, 131, 132]. Different mechanisms involving 
MDM2 have been reported to promote metastasis. For example, hypoxia has been 
demonstrated to up-regulate MDM2 in a p53-independent manner to promote 
metastatic efficiency in tumour cell [133]. In addition, this up-regulation of 
MDM2 leads to a reduction in p53 levels and inhibition of the p53-mediated 
transactivation of pro-apoptotic genes, hence rendering tumour cells less sensitive 
to stress-induced apoptosis [133]. Hypoxia is a crucial stimulator of new blood 
vessel formation during tumour angiogenesis and metastasis [134]. In cancer, an 
insufficiency of tissue oxygen within solid tumours often increases 
neovascularisation, in order to supply the metabolic needs of growing tumour 
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tissue [134]. Hypoxia has also been found to mediate translocation of MDM2 from 
the nucleus to the cytoplasm, leading to increased expression of vascular 
endothelial growth factor (VEGF), a potent angiogenic factor that actively 
contributes to distant metastasis [135].  
 
There is uncertainty as to how MDM2 exerts p53-independent oncogenic effects. 
Yang et al reported an inverse correlation between MDM2 and E-cadherin protein 
levels, accompanied by an increase in cell motility in breast carcinoma cells [103]. 
The same study also demonstrated that high expression of MDM2 is significantly 
correlated with E-cadherin suppression in primary tumours of breast cancer 
patients with lymph node metastases [103]. In another study, MDM2 
overexpression was shown to confer transforming growth factor-beta 1 (TGF-β1) 
resistance by abolishing the TGF-β1-induced growth inhibitory activities in a p53-
independent manner in cells in culture [136]. Consistent with this notion, elevated 
MDM2 expression has been associated with loss of TGF-β-sensitivity in human 
breast tumour cells, indicating a potential role of MDM2 overexpression in TGF-
β-resistance in human tumours [136]. Overexpression of MDM2 has been shown 
to negatively regulate the cell cycle regulatory function of the retinoblastoma 
protein (pRB) in a p53-independent manner [137]. Down-regulation of pRB, a 
negative regulator of cell cycle progression from G1 to S phase, as a result of 
MDM2-mediated ubiquitination and degradation, has been implicated in 
carcinogenesis in human lung cancer [137]. 
 
Up-regulation of MDM2 regardless of p53 status also plays a major role in 
determining the outcome in various common cancers. In renal cell carcinomas, 
there is a strong positive correlation between MDM2 and p53 expression 
(p<0.00004), and this phenotype was associated with poor prognosis [138]. 
Consistent with this observation, a more recent study with higher numbers of RCC 
specimens supports the observation that there is an association between p53 and 
MDM2 expression and this is accompanied by a reduced disease specific survival 
(p<0.001) [139]. Interestingly, this study has also demonstrated that the up-
regulated p53 is predominantly wild-type, a situation which is distinct from most 
other cancer types whereby TP53 mutations are commonly found in up-regulated 
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p53 [139, 140]. The wild-type status of p53 in RCC is likely to promote the 
observed MDM2 co-expression, which may explain the association between p53 
and MDM2 expression [139]. Although the mechanisms leading to increased 
MDM2 and p53 expression in RCC are still largely unknown, there is a clear 
disease-specific feature in RCC, which makes combined up-regulation of wild-
type p53 and MDM2 a promising prognostic biomarker [139].   
 
1.4.4 p53-MDM2 interaction 
The importance of p53 in cancer is supported by the fact that p53 is mutated in 
nearly 50% of all human cancers, and is functionally inactivated in most of the 
remaining cancers through alterations in p53-associated signalling pathways [141]. 
Patients with Li-Fraumeni syndrome, most commonly harbour p53 germline 
mutations and have increased susceptibility to cancer [142, 143]. Furthermore, p53 
homozygous knockout mice are developmentally normal but susceptible to 
spontaneous tumours at a young age (all dead by 6 months) [144, 145]. 
 
During the past two decades, p53 has often been referred to as the ‘guardian of the 
genome’ owing to its indispensable function in maintaining cellular genetic 
stability. p53 plays a crucial role as a transcription factor for downstream target 
genes  involved in many physiological processes [146]. Depending on the different 
stages in the cell cycle, cell type and the type and/or duration of stress or DNA 
damage, p53 can selectively activate cell cycle control (p21, WAF1/CIP1, cyclin 
G), apoptosis (BAX, NOXA, PUMA), DNA replication and repair (GADD45, 
PCNA) and angiogenesis regulatory proteins (TSP-1, BAI1), just to name a few 
[147-150]. Thus, the level of p53 in a cell must be very tightly regulated to ensure 
that a delicate balance of appropriate p53 activity is maintained [55].  
 
Consisting of 393 amino acids, p53 protein contains three major functional 
domains (Figure 1.4.4.1). The acidic amino-terminal domain of p53 is responsible 
for translational activation. MDM2 binds to this transactivation domain to 
abrogate p53 transcriptional activity [151]. The central core DNA-binding domain 
of p53 is essential for the role of p53 as a sequence-specific transcription factor 
[152]. The carboxy-terminal end of p53 houses the tetramerisation domain, a 
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nuclear export signal and nuclear localisation signals [95]. p53 oligomerisation has 
been suggested to be necessary for efficient binding to MDM2 and MDM2-
mediated ubiquitination, whereby p53 mutants defective of oligomerisation ability 
have reduced affinity for MDM2 and DNA binding [153, 154].  p53 is also 
subjected to a wide and complex range of post-translational modifications, 
including phosphorylation, ubiquitination, acetylation, methylation, glycosylation 
and SUMOylation [155, 156]. These post-translational modifications, which 
usually occur at conserved residues of p53, are known to have significant 
regulatory potential, particularly in terms of stabilisation and activation of p53 
[157]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.4.1: p53 protein structure. TAD, transactivation domain; SH3, SRC 
homology 3 domain; NLS, nuclear localisation signal; NES, nuclear export signal; 
TD, tetramerisation domain. Figure adapted from [156]. 
 
 
Since the consequences of uncontrolled p53 activity can be dire (deletion of Mdm2 
in mice leads to very early embryo lethality [49, 50]) it is imperative that the 
stability of p53 is tightly regulated. Indeed, in unstressed cells, p53 exhibits a very 
short half-life (typically ~6-30 minutes) as a result of efficient degradation [47, 
158-160]. p53 protein is constantly being synthesised and continuously undergoes 
poly-ubiquitination leading to proteasomal degradation. However upon exposure 
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to diverse stress signals, p53 levels rapidly accumulate as a result of p53 rescue 
from proteasomal degradation [156].  
 
As a key negative regulator of p53, MDM2 employs several important 
mechanisms to effectively abrogate p53 functions that might otherwise lead to 
inappropriate cell cycle arrest or apoptosis. Apart from acting as an E3 ubiquitin 
ligase to regulate the localisation and degradation of p53 (as discussed in Section 
1.4.2.1), MDM2 is also capable of binding to the transactivation domain of p53. 
This allows MDM2 to hinder p53 association with the general transcription 
machinery to exert p53 regulatory effects [46, 57, 161]. Another mechanism 
employed by MDM2 to regulate p53 activity is through a process analogous to 
ubiquitination, called NEDDylation. It has been demonstrated that MDM2 
facilitates ubiquitin-like protein NEDD8 conjugation of p53 via its E3 ligase 
activity, resulting in inhibition of p53 transcriptional activity [162]. 
 
Interestingly, MDM2 is also a transcriptional target of p53. Wild-type p53 is 
capable of binding to the p53-responsive element of MDM2 to promote 
transcription of MDM2 [163]. When p53 levels increase, transcription of MDM2 
is also induced. Hence, whilst MDM2 is a negative regulator of p53, it is itself 
being regulated by p53, establishing a negative auto-regulatory feedback loop 
[163].  In the absence of stress signals, p53 levels are kept low to allow normal 
cell proliferation and maintenance of cell viability. Upon cellular stress, p53 levels 
can rise through escaping the MDM2-mediated proteasomal degradation. 
Following DNA damage, protein kinases such as ATM and checkpoint kinase 
(Chk2), have been shown to stabilise p53 by phosphorylation [164, 165]. 
Phosphorylation of p53 interferes with MDM2 binding and thus prevents p53 
ubiquitination and degradation [164, 165]. Once the stress is relieved, signals for 
p53 stabilisation are no longer required and MDM2 preferentially mediates p53 
degradation to maintain p53 at low levels again [112]. 
 
Similarly to MDM2, MDMX is also an important negative regulator of p53. It has 
been reported that MDMX acts as an oncogene that becomes activated upon 
overexpression to promote tumour formation by inhibiting p53 activity [166]. In 
fact, MDMX is overexpressed in various types of cancers that retain wild-type 
	   44	  
p53, including breast, colon and lung cancers [166]. Despite having a RING 
domain, MDMX lacks the E3 ligase activity and is unable to directly poly-
ubiquitinate p53 to promote proteasome-mediated proteolysis [67]. However, 
MDMX interacts with the p53 transactivation domain and thereby inhibits p53 
transcriptional activity [51, 54]. It has been demonstrated that MDMX can inhibit 
p300/CBP-mediated p53 acetylation, which is likely to have a suppressive effect 
on p53 activity [167]. 
 
Despite high homology between them, MDMX and MDM2 seem to play non-
redundant roles in inhibiting p53 [55]. Genetic studies show that, similarly to 
Mdm2, absence of MdmX expression in mice causes embryonic lethality that can 
be rescued by concomitant deletion of p53 [53]. Chavez-Reyes et al. demonstrated 
that the death in Mdm2-null mouse embryos due to apoptosis was partially rescued 
by the loss of Bax, a member of the Bcl-2 gene family that positively regulates 
apoptosis [168, 169]. The same study has also shown that the absence of p21, a 
p53 target gene that initiates cell cycle arrest, in MdmX-null mouse switched the 
mechanism of cell death from cell cycle arrest to apoptosis [168]. The fact that 
MdmX-null mice seem to die because of loss of cell proliferation rather than 
because of uncontrolled apoptosis in the presence of Mdm2 strongly argues that 
MDM2 and MDMX are non-overlapping regulators of p53 [53]. One possible 
explanation for this might be that whilst MDM2 is responsible for inhibition of the 
apoptotic activity of p53, MDMX may participate in the inhibition of p53-induced 
cell cycle arrest [53, 55]. For example, MDM2 and MDMX may bind different 
modified versions of p53 that could lead to the initiation of apoptosis and cell 
cycle arrest, respectively. 
  
1.4.5 MDM2 interactions with other proteins 
Despite its role as a major negative regulator of p53, MDM2 has p53-independent 
roles in tumorigenesis. Overexpression of MDM2 in tumours, accompanied by 
mutant or deficient p53, has been implicated in many cancers and has been 
associated with poor prognosis [131, 170, 171]. Analysis of a cohort of soft tissue 
sarcomas from adults has revealed that the tumours in which both MDM2 and p53 
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were overexpressed constitute 22 of the 207 screened (10.6%). Patients in this 
class also suffer the poorest prognosis and reduced survival (p<0.05) [124].  
 
Studies using mouse models have addressed the in vivo effect of MDM2 
overexpression in the absence of p53. Analysis of DNA content by Lungren et al. 
has shown that overexpression of MDM2 in epithelial cells of transgenic murine 
mammary gland led to polyploidy in 30-45% of the cells in both wild-type and 
p53-null mice [172]. This observation suggests a role for MDM2 in DNA 
replication that is independent of the ability of MDM2 to inhibit p53 activity 
[172]. In another study, the phenotype of p53-null mice was examined in the 
presence and absence of Mdm2. Intriguingly, tumour latency was prolonged in 
p53-null/Mdm2 heterozygous mice, compared with p53/Mdm2 double-null mice. 
In addition, the tumour spectrum also changed, in which the incidence of 
spontaneous sarcomas was higher in p53-null/Mdm2 heterozygous mice than in 
p53-null or p53/Mdm2 double-null mice [173]. The influence of MDM2 on the 
survival and tumour spectrum of p53-null mice supports the existence of 
additional roles for MDM2 other than inhibition of p53 function [173]. In addition, 
overexpression of an MDM2 transgene in p53-null mice displays increased 
tumorigenesis, with higher rates of sarcomas in comparison to the incidence in 
p53-null mice without MDM2 transgene expression, suggesting that MDM2 has 
fundamental p53-independent roles in tumorigenesis [174]. 
 
Furthermore, analysis of a variety of human tumours that overexpressed MDM2 
has revealed more than 40 different splice variants of MDM2 [175].  Interestingly, 
the majority of these variants lack the p53-binding domain and are incapable of 
interacting with p53, suggesting that the tumour-isolated MDM2 variants may 
contribute to transformation in a p53-independent manner [175, 176]. One 
example is the MDM2-B variant, which lacks most of the p53-binding domain (as 
illustrated in Figure 1.4.1.1), has been shown to promote p53-independent cell 
growth and inhibit apoptosis [177]. Moreover, expression of MDM2-B also 
induces tumour formation in transgenic mice, implying that an alternate spliced 
form of MDM2 can contribute to tumorigenesis through a p53-independent 
manner [177].   
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It is not surprising that MDM2 exerts some of its p53-independent biological 
effects through interaction with a number of proteins. Most of these MDM2 
interacting proteins have been identified using yeast two hybrid screening and 
immunoprecipitation methods and are involved in different cellular processes, 
such as cell cycle, differentiation, DNA synthesis, ribosome biosynthesis and 
transcription [57]. In particular, MDM2 interacts with major cell cycle regulators, 
including MDMX, alternate reading frame (ARF), E2F1/DP1 and retinoblastoma 
protein (pRB), as well as interacting proteins discovered in our laboratory, 
including MDM2 binding protein (MTBP), dihydrofolate reductase (DHFR), non-
metastatic protein 2 (NME2) and DNA polymerase ε [66, 109, 178-184].  
 
1.4.5.1 MDMX 
MDMX is able to form heterodimers with MDM2 through their mutual RING 
finger domains [66]. Hetero-oligomers of MDM2 and MDMX have been found to 
be more stable than homo-oligomers of either protein [66]. MDMX was found to 
facilitate stabilisation of MDM2, since when full length MDMX was co-expressed 
with MDM2, degradation of MDM2 was significantly suppressed. Stabilisation of 
MDM2 has been shown to be dependent on the RING finger domain of MDMX, 
since mutants of MDMX that lack a RING domain do not interact with MDM2 
and have no effect upon the half-life of MDM2 [66]. Hetero-dimerisation of 
MDMX and MDM2 has not only been shown to suppress auto-ubiquitination of 
MDM2 but promote p53 ubiquitination [67, 185-188]. Hence, the ability of 
MDMX to complex with MDM2 is important in regulating MDM2 and thus in 
determining p53 levels and keeping p53 activity low under physiological 
conditions [67, 186]. MDM2 and MDMX are functionally interdependent [189]. 
Whilst studies show that MDM2 E3 ligase activity is partially dependent on 
MDMX, MDMX function also depends on MDM2 [55]. Unlike MDM2, MDMX 
does not possess nuclear localisation and nuclear export signals, and is restricted 
to cytoplasmic localisation in the absence of MDM2 [190]. Thus, MDMX is 
dependent on MDM2 to enter the nucleus, where the MDM2/MDMX complex can 
form and inhibit p53 activity [189, 190]. 
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1.4.5.2 Alternate Reading Frame (ARF) 
ARF (p14ARF in humans and p19ARF in mice) was identified as an alternative 
reading frame in the p16INK4a tumour suppressor locus and is activated in 
response to oncogenic activity [180, 181]. ARF is a well-documented regulator of 
MDM2 and a potent activator of p53. Unlike MDM2, which mainly localises to 
the nucleoplasm, ARF is predominantly found in nucleoli [191]. Several 
mechanisms of ARF-mediated MDM2 inhibition have been documented. One 
proposed mechanism is that in response to oncogenic signals, ARF inhibits 
MDM2 E3 ligase activity towards p53, thus preventing MDM2 from promoting 
ubiquitination and subsequent degradation of p53, resulting in stabilisation and 
activation of p53 [192, 193]. It was initially thought that ARF binds to the RING 
finger domain of MDM2 and prevents nucleo-cytoplasmic shuttling of MDM2 
through sequestering MDM2 in the nucleolus, and subsequently relieving 
nucleoplasmic p53 from MDM2-mediated degradation [99, 194-196]. However, 
these findings are debatable as later studies have suggested that nucleolar 
relocalisation of MDM2 is not essential during ARF-induced growth arrest and 
that redistribution of ARF into the nucleoplasm promotes its interaction with 
MDM2 and induces p53-dependent growth-suppressive activity [197, 198].  
 
1.4.5.3 Retinoblastoma protein (pRB) 
MDM2 has been identified to bind to pRB, a tumour suppressor that guards the 
advance of cell cycle through the restriction-point into late G1 phase [178]. In its 
unphosphorylated or hypophosphorylated state, pRB binds to the E2F transcription 
factor via a pocket domain. This interaction prevents E2F from acting as a 
transcription factor to stimulate transcription of S phase-specific genes [178]. 
Upon hyperphosphorylation of pRB, E2F is released to activate transcription of 
growth-promoting genes to promote cell cycle progression from G1 to S phase 
[178, 199, 200]. MDM2 can perturb pRB function through binding to a domain 
located in the carboxy-terminal of pRB which overlaps with a domain required for 
growth suppression function of pRB and for stable interaction with E2F [201]. In a 
manner similar to p53, MDM2 also regulates pRB function by targeting it for 
ubiquitin-dependent degradation as it has been demonstrated that pRB can be 
efficiently ubiquitinated by MDM2 and then degraded via the proteasome [110]. 
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Down-regulation of MDM2 has been reported to stabilise endogenous pRB [110], 
supporting the role of MDM2 in pRB degradation. The MDM2-pRB interaction 
also plays an important role in regulating the stability and apoptotic function of 
p53 [202]. It has been suggested that MDM2 acts as a bridge that brings MDM2, 
pRB and p53 into a trimeric complex [203]. pRB prevents MDM2 from targeting 
p53 for degradation, thereby resulting in p53 stabilisation [202]. Although p53 in 
the trimeric complex is transcriptionally inactive, its apoptotic function remains 
intact [202]. Thus the trimeric complex allows pRB to selectively modulate the 
stability and function of p53 through counteracting the anti-apoptotic and 
degradation function of MDM2 [110, 202, 203]. 
 
1.4.5.4 E2F1 
In addition to inhibition of pRB-E2F1 interaction by competition, MDM2 can also 
drive cells into S phase by direct interaction with E2F1 that leads to activation of 
E2F1/DP1-mediated transactivation [204]. The E2F1 transcription factor functions 
as a heterodimer with DP1 to activate genes required for S phase entry. MDM2 
interacts with E2F1/DP1 and stimulates the transcriptional activity of the 
heterodimer and thus promotes cell proliferation [182]. On the other hand, it has 
been shown that E2F1-/- knockout mice lead to an increase in tumour formation 
[205].  Overexpression of E2F1 has also been shown to promote premature S 
phase entry and eventually lead to apoptosis [206]. These studies suggest that 
E2F1 also participates in growth-inhibitory and tumour suppressor activities [207]. 
It has been demonstrated in p53-/- cells that MDM2 promotes degradation of the 
E2F1/DP1 heterodimer, which leads to inhibition of the pro-apoptotic effect of 
E2F1/DP1 [208]. This indicates that MDM2 can prevent E2F1-dependent 
apoptosis in a fashion that is independent of p53 [208]. By blocking the apoptotic 
activity of E2F1, MDM2 turns the properties of E2F1 from a negative to a positive 
regulator of the cell cycle progression, parallels to the anti-apoptotic effect of 
MDM2 [208].  
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1.4.5.5 ATM (Ataxia Telangiectasia Mutated) and PI3 (Phosphatidylinositol 
3-OH) kinase 
Phosphorylation of MDM2 plays an important role in modulating its activity. 
Several kinases have been shown to interact with and phosphorylate MDM2, 
thereby affecting of MDM2 and p53 interaction [209]. One of these kinases is 
ATM encoded by ATM gene that is a frequently mutated in patients with a rare 
inherited disorder (Ataxia Telangiectasia) that makes them hypersensitive to 
radiation [210]. In response to cellular stresses such as ionising radiation and DNA 
damage, ATM kinase phosphorylates MDM2 and blocks its association with p53 
[211, 212]. Meanwhile, ATM is also able to directly phosphorylate p53, protecting 
it from MDM2-mediated ubiquitination [213, 214]. As a result, phosphorylation of 
both MDM2 and p53 by ATM abrogates MDM2 ability to trigger nuclear export 
and proteasomal degradation of p53, causing an accumulation of p53 levels in the 
cell. Furthermore, PI3 kinase and its downstream target, Akt/PKB serine-threonine 
kinase, also appear to bind and phosphorylate MDM2, following mitogen-induced 
activation [215, 216]. Phosphorylation of MDM2 on serine 166 and serine 186 is 
required for translocation of MDM2 from the cytoplasm into the nucleus, where 
MDM2 ubiquitinates p53 and mediates its degradation [217, 218]. Ultimately, the 
effect of phosphorylation-induced elevation of MDM2 via the mitogenic 
signalling pathway leads to suppression of p53 protein levels. 
 
1.4.5.6 MDM2 binding protein (MTBP) 
MTBP was first identified as an MDM2-interacting protein using the yeast two-
hybrid screen [179]. It has been demonstrated that MTBP is a growth regulator 
and its interaction with MDM2 may play both promoting and suppressive roles in 
tumorigenesis [131]. MTBP expression has been demonstrated to inhibit 
proliferation by inducing p53-independent G1 arrest, an effect which can be 
overcome by MDM2 [179]. On the contrary, there are also reports that suggest an 
oncogenic role of MTBP. Studies by Brady et al. demonstrated that 
overexpression of MTBP in tumour cell lines facilitates MDM2-mediated 
ubiquitination and degradation of p53, whilst reducing auto-ubiquitination and 
thus stabilising MDM2 [219]. Another study by Odvody et al. claimed that 
reduced MTBP expression decreased Myc-induced B-cell lymphomagenesis 
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[220]. The opposite roles of MTBP in cancer may indicate that MTBP’s function 
is context-dependent. In fact, the expression levels of MTBP seem to be specific to 
the types of cancer. In B-cell lymphomas, an elevated MTBP expression is 
observed in comparison to normal human lymphoid tissue controls [220]. On the 
other hand, the loss of MTBP has been associated with a reduced survival in head 
and neck carcinoma patients, and serves as an independent prognostic factor when 
p53 is mutated in tumours [221].  
 
To understand the physiological function of MTBP, mice with deletions of critical 
exons in the Mtbp gene were generated [222]. The loss of both alleles of Mtbp 
resulted in early embryonic lethality [222]. In contrast to Mdm2 deletion, the 
lethality of homozygous Mtbp deletion could not be rescued by concomitant 
deletion of p53, indicating that this phenotype is p53-independent [222]. Mtbp 
heterozygous mice were viable and do not present with any obvious phenotype 
[222]. However, when these mice were predisposed to tumorigenesis in the p53+/- 
background, Mtbp+/-p53+/- mice significantly increase invasiveness of 
osteosarcoma cells [222]. Moreover, overexpression of Mtbp in Mtbp+/-p53+/- 
osteosarcoma cells inhibited invasiveness, suggesting the role of MTBP as a 
metastasis suppressor [222]. The mechanism by which MTBP inhibits cancer 
metastasis is not entirely clear. The same study also demonstrated that 
overexpression of MTBP in human osteosarcoma cell lines lacking wild-type p53 
has no effect on primary tumour growth in mice, but significantly inhibits tumour 
metastases [222]. MTBP down-regulation significantly increased the migratory 
potential of MDM2-/-p53-/- mouse embryonic fibroblasts, suggesting the MTBP 
suppresses cell migratory potential independently of MDM2 and p53 [223]. Using 
immunoprecipitation and mass spectrometry, alpha-actinin-4 (ACTN4) was 
identified as an MTBP-interacting protein [223]. ACTN4 plays important role in 
cytoskeleton organisation of the actin network and has been implicated in cancer 
cell migration and metastasis [224-226]. Co-expression of MTBP and ACTN4 has 
been shown to inhibit ACTN4-induced cell migration, suggesting that MTBP 
affects cell migratory potential, at least partly, through suppressing ACTN4 
function [223]. 
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1.4.5.7 p300/CBP  
The transcriptional co-activator p300/CBP can both elevate p53 transactivation 
activity and promote MDM2-mediated degradation of p53. In particular, 
p300/CBP interacts with and acetylates p53 to facilitate p53-mediated 
transactivation [227]. On the other hand, p300/CBP promotes p53 degradation 
through interaction with the central acidic domain of MDM2 [76]. MDM2 lacking 
its p300/CBP-binding domain failed to destabilise p53 [75]. This suggests a dual 
role of p300/CBP in regulation of p53.  
 
1.4.5.8 Dihydrofolate Reductase (DHFR) 
DHFR plays an essential role in the synthesis of nucleic acids precursors. MDM2 
interacts directly with DHFR and catalyses its mono-ubiquitination, in a RING 
finger-dependent manner [109]. Mono-ubiquitination of DHFR by MDM2 leads to 
a reduction in DHFR activity, and this effect is independent of p53 [109]. 
Nevertheless, it seems that MDM2 does not promote poly-ubiquitination of 
DHFR, which may explain why MDM2 has no effect on the stability of DHFR 
[109]. 
 
1.4.5.9 Non-metastatic protein 2 (NME2) 
NME2 was identified as an MDM2-interacting protein using affinity 
chromatography and yeast two-hybrid screening, followed by validation by mass 
spectrometry [183]. The interaction between MDM2 and NME2 is highly specific, 
since NME1 which possesses high homology to NME2 does not seem to interact 
with MDM2. MDM2 and NME2 display opposing effects on motility since it has 
been demonstrated that NME2 contributes to motility suppression when MDM2 is 
expressed at normal physiological levels [183]. In addition, up-regulation of 
MDM2 in RCC cells abrogates the motility-suppressing effect of NME2 in a p53-
independent manner [183]. This provides a potential mechanism for the ability of 
MDM2 to promote tumour cell motility and metastasis, potentially linking MDM2 
expression with poor prognosis in RCC [183]. NME will be discussed in more 
details in the next few sections. 
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1.5 NME protein family 
The non-metastatic (NME) (otherwise known as NM23, NDPK or AWD) gene 
family is a very ancient gene family found in all kingdoms of life, from bacteria 
Escherichia coli to Homo sapiens, showing a strong conservation throughout the 
course of evolution [228-231]. The NME protein family has been reported to be 
involved in a plethora of molecular processes, including tumour metastasis, cell 
proliferation, differentiation, development, motility, apoptosis, and DNA repair 
[183, 232-239].  
 
Some of the members of the NME family exhibit a nucleoside diphosphate kinase 
(NDPK) activity, which corresponds to the phosphoryl transfer from a nucleoside 
triphosphate to a nucleoside diphosphate, as first described in pigeon breast 
muscle and yeast [231, 240, 241]. Sequences encoding proteins with validated 
NDPK activity and primary structures were later discovered in bacteria (Myxoccus 
Xanthus) and rat [242-244]. These proteins were originally named NDPK due to 
their NDPK activity [231, 243-245]. The NME was first identified as a cDNA 
clone that was down-regulated in highly metastatic murine melanoma cell lines, 
and hence was also named NM23 for ‘non-metastatic clone 23’ [246]. In 
Drosophila, the amino acid sequence of Abnormal Wing Discs (AWD) shares a 
high degree of conservation with the human NM23 [247]. AWD is in fact an 
NDPK kinase and the killer-of-prune mutation of AWD results in abnormalities in 
Drosophila cell morphology and differentiation [248]. For simplicity and to avoid 
confusion, as well as to follow the current official gene nomenclature, the term 
‘NME’ will be used throughout this thesis [231, 245]. 
 
To date, there are over seventy cDNA sequences for NME obtained in a wide 
variety of organisms, displaying partial or complete NDPK domains [228, 231]. In 
humans, ten genes have been documented, and are typically classified into two 
distinct groups based on their sequence homology and NDPK activity [231]. 
Group I NME proteins, which comprised of NME1 to NME4 (NDPK-A to -D or 
NM23-H1 to -H4), share 58% to 88% sequence similarity with each other with no 
gap or insertion [228]. This group of NME proteins generally exhibit a highly 
conserved domain and possess the active sites for NDPK activity [228]. On the 
other hand, members of the Group II NME proteins are highly divergent and share 
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only 25% to 45% of sequence similarity with the Group I proteins and between 
each other [228]. With the exception of NME6, all Group II genes (NME5-10) 
encode protein that are most found in ciliated structures such as primary cilia and 
sperm flagella [249]. Intriguingly, a read-through transcript for NME1 and NME2 
genes that codes for a fusion protein has been reported [250]. This fusion protein, 
called NM23-LV (for long variant, also known as NME1-NME2), consists of part 
of NME1 fused to a complete NME2 [250, 251]. A summary of the characteristics 
and properties of various isoforms of the human NME family is represented in 
Table 1.5.1.  
 
As mentioned in Section 1.4.5.9, MDM2 has been shown to interact with NME2 
and has an antagonising effect on NME2 motility suppressive effect [183]. This 
finding has formed part of the basis for our project. Due to the high degree of 
homology between NME1 and NME2, their well known roles in cancer and for the 
purpose of my thesis, I will focus mainly on NME1, NME2 and the more recently 
discovered NM23-LV. We will first discuss the properties and functions of NME3 
to NME10 proteins, followed by a more detailed discussion on NME1, NME2 and 
NM23-LV proteins in later sections. 
 
1.5.1 NME3 to NME10 proteins 
1.5.1.1 NME3  
NME3 cDNA was identified through differential screening of a chronic 
myelogenous leukemia-blast crisis (CML-BC) cDNA library [233]. The NME3 
protein has about 65% amino acid sequence similarity to the putative NME1 and 
NME2 proteins [233]. NME3 possesses an amino-terminal hydrophobic sequence, 
which is responsible for the anchorage of NME3 to membranes, in particular the 
mitochondrial outer membrane [252]. CML is a malignancy of the human 
hemapoietic stem cell that evolves in two clinically distinct stages: a chronic and a 
blast crisis phase. During the blast crisis transition of CML, NME3 mRNA was 
expressed at the early stages of myeloid differentiation [233]. When overexpressed 
by transfection, NME3 is able to inhibit granulocytic differentiation and induce 
apoptosis in myeloid precursor 32Dc13 cells [233]. These observations suggest a 
role for NME3 in hematopoiesis and CML blastic transformation [233].  
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1.5.1.2 NME4 
NME4 was identified as a human NDPK that can target mitochondria via an 
amino-specific sequence, which is cleaved to reveal catalytic activity [253]. 
NME4 is ubiquitously expressed and active as a hexamer, like other NME 
isoforms from Group I [253-255]. Interestingly, NME4 naturally possesses the 
proline to serine substitution equivalent to the K-pn mutation (P97S) of 
Drosophila [256]. This point mutation of awd causes lethality in the genetic 
context of prune eye colour mutation, but has no effect on the catalytic activity of 
the enzyme [257]. The K-pn mutation is located in a loop, and thus named K-pn 
loop, which plays an important role in the stability of the hexamers [257, 258]. 
NME4 has been shown to be associated with the inner mitochondrial membranes, 
possibly for supplying NTP/NDP for nucleic acid and protein synthesis and 
respiration [253, 259]. Schlattner et al. (2013) demonstrated that NME4 interacts 
with the mitochondrial GTPase OPA1, which suggests that NME4 has a role in 
providing a local supply of GTP [260]. In addition, NME4 has also been shown to 
interact with anionic phospholipids, particularly cardiolipin, which leads to 
inhibition of the phospho-transfer activity but allows for the intermembrane lipid 
transfer function of NME4 and sensitises cells for apoptosis [260]. Thus, NME4 
may act as a lipid-dependent mitochondrial switch with dual roles in phospho-
transfer for delivering local GTP supply and in cardiolipin transfer for apoptotic 
signalling [260]. 
  
1.5.1.3 NME5 
NME5 was first identified in spermatogonia and early spermatocytes in human 
testis [261]. NME5 encodes a 212 aa protein with 27-31% identity to other 
members of the NME family [261]. The biological roles of NME5 is not well 
documented. Studies have suggested that NME5 is involved in the differentiation 
of spermatozoa [262]. It has been shown that NME5 was down-regulated in 
several tumour types, including urothelial carcinoma and malignant breast cancer 
[263, 264]. 
 
1.5.1.4 NME6 
The mRNA expression of NME6 is found in most human tissues, particularly in 
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kidney, prostate, ovary, intestine, and spleen [265]. Of all the members from 
Group II, only NME6 has been reported to possess NDPK activity [228, 231].  It 
has been shown that overexpression of NME6 in SAOS2 cells leads to growth 
suppression and generation of abnormally shaped multinucleated cells as a result 
of mitosis failure [266]. This suggests that NME6 may have important roles in the 
regulation of cell growth and cell cycle progression [266]. 
 
1.5.1.5 NME7 and NME8 
NME7 and NME8 genes were identified by Mehus and Lambeth (unpublished 
data, reviewed in [228]). The NME7 gene contains 12 exons spanning over 180 kb, 
whereas the NME8 gene is comprised of 17 exons spanning over 50 kb. Both 
NME7 and NME8 possess a tandemly repeat kinase domain. Tissue analysis 
reveals that NME7 and NME8 are predominantly expressed at the mRNA level in 
testes. Expression of NME7 is also detected in liver, heart, brain, ovary, small 
intestine, and spleen (reviewed in [228]).  
 
1.5.1.6 NME9  
The NME9 gene encodes a protein of 330 amino acids consisting of two major 
domains: an amino-terminal domain typical of a thioredoxin (small 12 kDa protein 
that functions as a protein-disulfide reductase) and a carboxy-terminal domain 
belonging to the NME family [267]. Thus NME9 is also known as thioredoxin-
like protein 2 (Txl-2).  NME9 mRNA was ubiquitously expressed, with expression 
predominantly found in testis and cilia of lung airway epithelium [267]. Light 
electron microscopy analyses also reveal that NME9 protein is associated with 
microtubular structures [267].  
 
1.5.1.7 NME10 
The NME10 gene encodes the XRP2 protein involved in X-linked retinitis 
pigmentosa, which is an inherited affliction of the retina due to photoreceptor 
degeneration [268]. NME10 possesses a partial NDPK domain which may explain 
the lack of NDPK activity in the protein [269]. In conjunction with its 3’-5’ 
exonuclease activity, cytoplasmic NME10 has been shown to relocate into the 
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nucleus upon treatment with DNA damaging agent in the cells, suggesting a role 
of NME10 in DNA repair [269]. 
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Table 1.5.1: Summary of the characteristics and properties of various isoforms of the 
human NME family. ND, Not determined. Table modified from [228]. 
 
 
 
Group Isoform 
Tissular 
expression 
Sub-cellular 
localisation 
NDPK 
activity Remarks 
Exo-
nuclease 
activity 
 
Ref. 
 
NME1 
 
 
 
 
Ubiquitous 
(kidney, 
liver, 
intestine, 
brain) 
Cytoplasmic, 
microtubule, 
ER 
nuclear 
 
Yes 
 
 
 
 
Overexpressed in 
tumours; inverse 
correlation with 
metastatic 
potential 
 
Yes 
 
 
 
 
 
[228, 
270-273] 
 
NME2 
 
 
 
 
Ubiquitous 
(heart, liver, 
pancreas, 
kidney) 
 
 
Cytoplasmic, 
microtubule, 
ER 
 nuclear, 
nucleolar 
Yes 
 
 
 
 
Overexpressed in 
tumours; 
transcription 
factor (PuF); 
DNA repair  
ND 
 
 
 
 
 
[228, 
232, 270, 
272-274] 
 
NME3 
 
 
 
 
 
Ubiquitous 
(pituitary 
gland, 
cerebellum, 
adrenal 
gland) 
Cytoplasmic 
 
 
 
 
 
Yes 
 
 
 
 
 
Overexpression 
suppresses 
granulocyte 
differentiation and 
induces apoptosis 
of myeloid cells.  
ND 
 
 
 
 
 
 
[228] 
 
I 
 
NME4 
 
 
 
 
Ubiquitous 
(prostate, 
liver, 
muscle, 
ovary, heart) 
Mitochondrial 
 
 
 
 
Yes 
 
 
 
 
Associated with 
inner 
mitochondrial 
membranes 
 
ND 
 
 
 
 
 
[228, 
253, 259] 
 
NME5 
 
 
 
Testis 
(traces in 
brain and 
kidney) 
ND 
 
 
 
ND 
 
 
 
Expressed in male 
germinal cells 
 
 
Yes 
 
 
 
 
[228, 
272] 
NME6 
 
 
 
Ubiquitous 
(skeletal 
muscle, 
placenta) 
Cytoplasmic, 
mitochondrial 
 
 
Yes 
 
 
 
Indicated role in 
regulation of cell 
growth and cell 
cycle progression 
ND 
 
 
 
 
[228, 
266] 
NME7 
 
 
Mainly in 
testis  
ND 
 
ND 
 
Duplicated NDPK 
kinase domain 
Yes 
 
 
[228, 
272] 
NME8 
 
 
Mainly in 
testis 
Microtubule 
 
ND 
 
Triplicated NDPK 
domain 
Yes 
 
 
[228, 
272, 275] 
NME9 
 
Testis, lung 
 
Microtubule 
 
ND 
 
 
Closely related to 
NME8 
ND 
  
 
[231, 
267] 
II 
NME10 
 
Ubiquitous 
 
Cytoplasmic, 
nuclear 
ND 
 
 
Partial NDPK 
kinase domain 
Yes 
 
 
[231, 
269] 
 
NM23-
LV 
 
 
Ubiquitous 
(except 
kidney) 
 
Cytoplasmic, 
nuclear 
 
 
ND 
 
 
 
  
Long variant, a 
read-through 
transcript of 
NME1 and NME2  
ND  
 
 
 
 
[250] 
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1.5.2 Mechanism of nucleoside diphosphate kinase reaction 
Originally identified as an essential housekeeping enzyme, NDPK plays an 
essential role in a number of cellular processes, including (1) maintenance of the 
cellular pool of nucleotides via utilising ATP as a phosphate donor for the 
biosynthesis of nucleoside triphosphate precursors of nucleic acid synthesis; (2) 
regulation of the homeostasis between GTP produced in the Krebs cycle and ADP; 
and (3) supplying GTP for G-protein signalling, protein synthesis, and tubulin 
polymerisation [228, 276, 277].  
 
NDPK catalyses the reversible transfer of the terminal (γ) phosphate of nucleoside 
triphosphate (NTP) to nucleoside diphosphate (NDP), following a ping-pong 
kinetic reaction as shown in (Figure 1.5.2.1) [241, 278, 279]. It has been well 
documented that the NDPK reaction occurs via a covalent intermediate, in which 
the enzyme is first transiently phosphorylated at a conserved phospho-acceptor 
histidine 118 (H118) residue before transfering the high energy phosphate to an 
NDP [280]. Additionally, divalent metal ions, such as Mg2+, Mn2+ and Ca2+, are 
also important in the phospho-transfer reaction of NDPK since interaction with the 
metal ion helps to reduce electrostatic repulsion and stabilise the transition state 
[276, 281]. Although NDPKs are thought to be non-specific to the base moiety of 
the donor and acceptor nucleotides, steady-state experiments have demonstrated 
that guanine nucleotides are the most favourable substrates [276]. 
 
 
 
 
             
 
 
Figure 1.5.2.1: Mechanism of nucleoside diphosphate kinase (NDPK) 
reaction. Enzymatic reaction catalysed by NDPK involving the transfer of the 
terminal phosphate of a nucleoside triphosphate (NTP) to nucleoside diphosphate 
(NDP), where N1 and N2 represent any nucleosides or their deoxy- derivatives 
[278, 279]. All NDPK reaction occurs via the formation of an enzyme-bound high 
energy phosphate intermediate (NDPK~P) [280].  
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Subtrates of the phosphohistidine modification from H118 in Group I members are 
not restricted to NDPs but also to histidines located in several other target proteins 
[276, 282]. For example, NME2 can phosphorylate the β-subunit of heterotrimeric 
G proteins (Gβγ) to regulate G protein abundance and function in vivo [283]. Both 
human NME1 and NME2 are relatively small proteins, each being only 152 amino 
acids long. However, the amino acid residues responsible for NDPK activity span 
almost the entire NME protein (Figure 1.5.2.2). In particular, H118 is the key site 
for the phospho-transfer reaction, as a point mutation at this site completely 
abolishes NME NDPK activity [284, 285]. The remarkable sequence similarity, as 
well as identical active sites and crystal structures shared between the Group I 
NMEs suggest that these protein members are likely to adopt identical mechanism 
for NDPK activity [276]. Nevertheless, studies have shown that NDPK enzyme is 
relatively non-specific with varying levels of activity, depending on the tissue type 
and sub-cellular localisation [228].  
 
 
 
 
 
 
 
Figure 1.5.2.2: NDPK domain of NME2. Location of critical residues in the 
NDPK domain of NME2 (all sites are conserved in NME1) spanning almost the 
entire protein, including residues at positions 12, 52, 60, 88, 94, 105, 115, 118, 
120, 121 and 129. Histidine at position 118 (H118) is the key site for the phospho-
transfer reaction [284, 285]. Figure adapted from National Centre for 
Biotechnology Information at 
http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?INPUT_TYPE=live&SEQ
UENCE=CAG46519.1 accessed on 26th April 2014. 
!"#$%&'()*%+,-*%
!"#$%&'()(%*+,-./*0%
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1.5.3 NME1 and NME2 
NDPK enzyme was first discovered in 1953, and only later in 1988, the gene that 
encodes for NME1 was identified by Steeg et al. [240, 241, 246]. NME1 was 
identified based on its down-regulation in highly metastatic melanoma cell lines, 
leading to the speculation that NME1 constitutes a potential metastatic suppressor 
gene [246]. NME2 was subsequently discovered based on its high degree of 
homology to NME1 [286]. NME1 and NME2 proteins share 88% amino acid 
sequence identity, with a monomer mass of 17 kDa [280]. These proteins have 
different isoelectric points (6.13 and 8.64 for NME1 and NME2, respectively) and 
display two distinctly migrating protein bands when analysed by SDS-PAGE. The 
observed heterogeneity might be a consequence of differential proteolysis or post-
translational modifications such as phosphorylation [280].  
 
Although adult NME1 knockout mice exhibit an essentially normal phenotype, 
they are characterised by reduced birth weight and delayed mammary 
development [287]. On the other hand, NME2 knockout mice are also 
phenotypically normal at birth but are defective in cytokine production and have 
impaired activation of the Ca2+ activated potassium ion channel (KCa3.1) [288]. 
The fact that both NME1 and NME2 knockout mice are viable indicates that there 
might be some functional redundancy between them, although the synergistic 
function of both NME1 and NME2 may be required in the development of 
diseases, such as cancer. Double knockout mice of NME1 and NME2 are 
undersized and die perinatally, with defects in erythropoiesis [289]. It has been 
speculated that the impeded growth might be a consequence of the global effect of 
the NME1 and NME2 deletions causing a shortage of NTP precursors for nucleic 
acid synthesis [290].  
 
In general, NME1 and NME2 proteins are ubiquitously expressed (Table 1.5.1) 
but the level of expression seems to be tissue-specific [280, 290]. NME1 and 
NME2 can form various complexes in vivo [280, 291]. For example, NME 
subunits can form dimers, which in turn assemble into a tetramer in Myxococus 
xanthus, or into a hexamer in eukaryotes [277, 292]. Hexamers can be described as 
three dimers arranged about a three-fold axis, or a dimer of trimers [277]. NME1 
and NME2 in humans are active as homo- and hetero-hexamers and are believed 
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to account for at least 80% of the cellular NDPK activity [280, 290]. Unpublished 
data from Schaertl et al. suggests that monomeric human NME contributes to less 
than 5% of the NDPK activity of the equivalent single isoform oligomers, 
highlighting the importance of the oligomeric form [293]. It has also been 
suggested that different oligomeric species of NME may participate in different 
cellular processes regardless of their essentially similar intrinsic enzymatic activity 
[294]. Both NME1 and NME2 are predominantly localised in the cytosol but other 
sub-cellular localisations have also been reported (Table 1.5.1) [270, 273, 290]. 
For example, NME1 and NME2 have been shown to be associated with the 
endoplasmic reticulum (ER) and nucleus [273]. Studies have also suggested that 
both proteins are associated with cytoskeletal structures such as intermediate 
filaments and the microtubular network [270, 295, 296]. In neuroblastoma cells, 
NME1 and NME2 (as well as NM23-LV) show similar cellular distribution [250]. 
The proteins were primarily located in the cytoplasm, with perinuclear 
localisation, but were completely absent from the nucleoli [250]. By contrast, in 
breast carcinoma cells, NME2 but not NME1 was found in the nucleus and 
nucleoli [270]. This suggests that the different localisations of NME proteins are 
cell-type specific and might reflect different NME functions in the particular cell 
types. 
 
Although NME1 and NME2 share high sequence similarity and are capable of 
forming hetero-hexamers that possess housekeeping enzymatic activity, they have 
distinct cellular functions, largely owing to their substrate-specific enzymatic 
activity and interaction with other proteins [297]. Whilst low expression of NME1 
is associated with aggressive types of breast and cervical carcinomas, melanomas 
and several other neoplastic lesions, overexpression of NME1 and NME2 have 
been reported to be linked with poor prognosis in neuroblastoma, lung cancers and 
thyroid carcinoma [294, 298-302]. These findings indicate that NME1 and NME2 
may employ different mechanisms and have different roles in tumorigenesis, 
which will be discussed in the next section. 
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1.5.4 NME1 and NME2 in cancers 
Tumour metastasis and aggressive tumour phenotype often result from a perturbed 
cell-matrix and/or cell-cell communication [303]. Deregulation of these highly 
regulated communication networks may lead to uncontrolled cell division, 
aberrant apoptosis, abnormal cell shape and cell adhesion properties, and 
degradation of the surrounding extracellular matrix [294]. Following identification 
of NME1 as the first metastasis suppressor gene by Steeg et al., studies in which 
NME1 was overexpressed in metastatic cell lines (including melanoma, breast 
carcinoma, prostate, colon, hepatocellular and oral squamous cell carcinoma) 
demonstrated that these cells displayed reduced cell motility in in vitro assays and 
also reduced metastatic potential in xenograft models [246, 285, 298, 304-308]. In 
particular, Boissan et al. examined the role of NME1 in tumour development and 
metastatic dissemination by generating compound strains from NME1-/- mice 
mated with mice expressing the SV40 virus large T antigen (ASV40) in the liver, 
since the latter develop hepatocellular carcinoma (HCC) with pulmonary 
metastases [309]. The lack of NME1 gene had no effect on primary tumour 
formation despite a, possibly compensatory, increase in NME2 expression in the 
lesions of knockout mice [309]. However, the incidence of AVS/NME1-/- mice 
developing lung metastases was almost double that of AVS/NME1+/+ mice, 
suggesting that the loss of NME1 contributes to an increase in metastasic spread 
[309]. In addition, most lung metastases in ASV/NME1+/+ mice display 
considerably less labeling with an antibody specific to mouse NME1, indicating 
that metastatic dissemination of HCC is inversely associated with NME1 
expression [309]. Interestingly, overexpression of NME1 was observed during 
primary tumour formation compared to the non-tumoral tissue, but the expression 
decreased concomitant with metastatic dissemination of the primary tumour [309]. 
Thus whilst NME1 plays an important role in metastasis suppression, it is likely 
that NME1 is also involved in primary tumour development, however, this 
remains to be further elucidated. 
 
Although the role of NME2 in metastasis suppression seems to be less well 
understood, several studies have demonstrated that NME2 plays a key role in 
motility suppression, invasive growth and differentiation across different tumour 
types (reviewed in [310]). In particular, reduced NME2 expression was observed 
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in metastatic breast, colon, lung and ovarian tumours (reviewed in [310]). 
Overexpression of NME2 has been shown to suppress lung metastasis in oral 
squamous carcinoma cells [307]. Histological analysis of the pulmonary metastatic 
foci in NME2 transfected clones revealed well-differentiated cells compared to 
control clones not expressing exogenous NME2 that were composed of anaplastic 
squamous cells [307]. A reduction in vascularisation into the metastatic foci was 
also observed in the NME2 transfected clones, suggesting that NME2 
overexpression could inhibit tumour angiogenesis [307]. In addition, 
overexpression of NME2 has been shown to be involved in suppression of 
metastasis of breast cancer cells to lung [311, 312]; and to inhibit motility, 
invasiveness, and anchorage independent growth in highly metastatic breast cancer 
cells [313]. 
 
Nonetheless, as well as acting as metastasis suppressor genes, high levels of 
NME1 and NME2 have also been correlated with metastatic progression and poor 
prognosis in malignant lymphoma, neuroblastoma and osteosarcoma patients 
[314-316]. In a study comparing the level of NME1 protein with different types of 
lymphoma, patients with aggressive non-Hodgkin lymphoma and higher NME1 
levels had worse overall and progression-free survival rates than those with lower 
NME1 levels [315]. NME1 expression was significantly increased in the 
pulmonary metastatic site in comparison with the osteosarcoma primary tumour, 
suggesting a correlation between NME1 and metastatic progression in 
osteosarcoma [314]. In addition, overexpression of both NME1 and NME2 has 
been detected in colorectal carcinogenesis and during primary tumour formation of 
HCC [309, 317]. 
 
The multifaceted effects of NME in cancers suggest a cancer type-specific role for 
NME that is likely to be governed by different mechanisms and through 
differential expression of interacting proteins or enzyme substrates [316]. In fact, 
multiple proteins involved in different molecular pathways have been identified as 
NME-interacting proteins. Some of these NME binding proteins seem to disrupt 
NME metastasis inhibitory activity, whilst other proteins appear to promote 
functional NME pathways [316]. The broad consequences of changes in levels of 
NTP generation catalysed by the NME enzyme may also explain the numerous 
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effects in cancer phenotype that ensues from altered NME activity or expression. 
Here, we will focus on discussing the mechanisms employed by NME for its 
metastasis suppression function. 
 
1.5.5 Cancer/Metastasis inhibitory roles for NME function 
Despite extensive studies, the molecular mechanism underlying the ability of 
NME to regulate oncogenic transformation and metastasis is still poorly 
understood. Different functions of NME proteins have been suggested to 
contribute to its metastasis-suppressive effect, including NDPK activity, histidine 
protein kinase activity, 3’-5’ exonuclease activity, and interaction with DNA and 
proteins [247, 271, 316, 318-321]. Several studies have also demonstrated that 
NME is involved in the control of cellular responses to extracellular stimuli [294]. 
The mechanisms by which NME exerts its anti-metastatic function will be 
discussed in the following sections. 
 
1.5.5.1 NME1 and NME2 in endocytosis and signalling and in cytoskeleton 
dynamics 
1.5.5.1.1 Endocytosis and signalling 
The role of NME in endocytosis and signalling pathway has been demonstrated in 
several studies [322-326]. For example, Krishnan et al. (2001) has shown that 
enzymatically active NME is required for synaptic vesicle internalisation at the 
stage that requires the GTPase dynamin, likely by supplying GTP required for 
Shibire (Shi; dynamin homolog)-mediated endocytosis [322]. This finding was 
later supported by Dammai et al. (2003) when they investigated the role of AWD 
(abnormal wing discs; Drosophila homolog of NME) during tracheal tube 
formation [323]. In particular, the authors demonstrated that in mutants lacking 
AWD, the Breathless (Btl; FGFR homolog) levels are dramatically elevated on the 
cell surface, leading to ectopic activation of downstream pathways and abnormal 
migration in cells [323]. This suggests that AWD is involved in the inhibition of 
Btl activity by vesicle transport-mediated turnover, therefore modulating the 
receptor tyrosine kinase signalling pathway, which is crucial for controlled cell 
migration [323]. Another study has also described AWD as a negative regulator of 
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directional migration in border cells during Drosophila oogenesis by regulation of 
Pvf (the homolog of PDGF/VEGF) emanating from the oocyte [324]. AWD was 
shown to promote down-regulation of the Pvr (Pvf receptor) and Dome (essential 
for JAK/STAT functions in Drosophila), in collaboration with Shi, thus regulating 
the chemotactic signal strength to disrupt border cell migration [324]. In addition, 
AWD has also been indicated to be important for Notch signalling via its role in 
endocytic pathway [325]. Studies by Ignesti et al. (2014) have shown that AWD 
function is necessary for proper Notch signalling in follicle cells and imaginal disc 
cells [325]. It was also shown that loss of AWD function inhibits Notch from entry 
into late endosomes, causing accumulation of Notch in abnormal early endosomes 
[325]. Since Notch entry on the endocytic pathway is critical for proper Notch 
signalling, which may function either as a tumour suppressor or as an oncogene, 
the relationship between AWD and Notch may shed light into the role of NME in 
tumour progression [325]. More recently, Boissan et al. has also demonstrated that 
knockdown of NME1 and NME2 decreased clathrin-dependent endocytosis of the 
transferrin and EGF receptors, suggesting a role for NME1 and NME2 in 
dynamin-mediated membrane fission and signalling pathways [326].  
 
1.5.5.1.2 Cytoskeleton dynamics 
Since the dynamic changes to the cytoskeleton are involved in tumour cell 
motility, which is an important component of tumour invasion and metastasis, it is 
not surprising that NME proteins also have a role in the cytoskeleton machinery 
[316]. In fact, several cytoskeleton interactions of NME have been reported [238, 
247, 270, 327, 328]. For example, NME1 and NME2 have been shown to co-
immunoprecipitate with vimentin in a variety of tissues [328]. Vimentin, which is 
a member of the intermediate filament family of proteins, promotes changes in cell 
shape, adhesion, and motility during tumour invasion [329]. Activation of 
transmembrane receptors often affects cytoskeleton organisation and the 
association of NME proteins with structural proteins such as vimentin could have 
an impact on the dynamics of cytoskeleton remodeling upon external stimulation 
[327]. Studies by Otero et al. demonstrated that vimentin networks tend to form 
bundles and become more densely packed when assembled in the presence of 
NME [327]. The authors speculate that if NME has such an impact in vivo, it is 
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possible that overexpression of NME could reduce cytoskeleton plasticity and cell 
movement, thus contributing to an anti-metastatic function [327]. Microtubules 
can be considered as a dynamic structure in cells which grow at one end by the 
polymerisation of tubulin dimers, and shrink at the other end by depolymerisation, 
and thus acting as a major contributor to cell motility [316]. It has also been 
demonstrated that NME1 and NME2 can associate with microtubules in 
interphasic, but not in mitotic human breast carcinoma cell lines [270]. 
Furthermore, changes in NME expression have also been shown to influence 
tubulin polymerisation, suggesting a regulatory role of NME in tubulin 
polymerisation [330, 331]. It is possible that NME could provide a high localised 
concentration of nucleotides needed for both microtubule polymerisation and 
vesicular-dependent movement along the microtubules powered by the kinesin and 
dynein motor proteins [316]. Through co-immunoprecipitation in breast cancer 
cells, Marino et al. have identified the actin-severing protein Gelsolin as a binding 
partner of NME1 [238]. Gelsolin modulates the assembly and disassembly of actin 
filament by directly interacting with actin and severing of actin filaments at their 
fast-growing ends [332]. When co-expressed in Gelsolin-transfected cells, NME1 
inhibits the actin severing activity and dynamic functions of Gelsolin, thereby 
reducing the metastasis-stimulatory effect of Gelsolin [238]. The interaction of 
NME1 and Gelsolin would therefore appear to provide another possible 
mechanism for a tumour suppressive activity of NME1. 
 
1.5.5.2 NME-interacting proteins 
1.5.5.2.1 TGF-β  
TGF-β is well known for being a tumour suppressor in early carcinogenesis but a 
tumour promoter in later stages of cancer development [333]. Studies by Hsu et al. 
have demonstrated that NME1 can inhibit TGF-β1-mediated cell adherence and 
growth arrest in weakly tumorigenic chicken erythroblast HD3 cells, but not in 
highly tumorigenic colon carcinoma U9 cells [334]. This observation may suggest 
a role for NME1 in TGF-β-mediated growth inhibition and differentiation but not 
in TGF-β-mediated proliferation and invasion [334]. Nonetheless, recent studies 
have shown that NME1 and NME2 are involved in the regulation of anti-
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proliferative function of TGF-β signalling in fibroblasts [335]. Both NME1 and 
NME2 have been reported to down-regulate TGF-β-stimulated induction of 
cyclooxgenase-2 (COX-2) [335]. COX-2 is a key enzyme in the syntheses of 
prostaglandin E2 and is highly induced in response to cytokines, pathogens, 
irradiation, and growth factors [336, 337]. Up-regulation of COX-2 has been 
associated with tumour growth, angiogenesis, and metastasis [338-340]. 
Therefore, NME1 and NME2 inhibitory effect on COX-2 expression is consistent 
with NME roles as a metastasis suppressor, although the exact mechanism behind 
this connection with COX-2 expression remains elusive [335]. Paradoxically, 
NME1 has also been shown to up-regulate transcription of the COX-2 promoter in 
reporter assays, which is in line with the tumour-progressive property of NME1 
considering the influence of COX-2 on tumour progression [335, 341]. Such 
contradictory results/differences are difficult to reconcile and it is possible that 
they will not be explained until functional genomic studies are performed in vivo. 
TGF-β is also a key inducer of epithelial-mesenchymal transition (EMT) during 
tumour progression. NME1 has been demonstrated to negatively regulate TGF-β-
dependent induction of EMT in non-progressive lung cancer cell line [342]. Since 
EMT is often required for tumour cell migration and invasion, it is possible that 
NME1 acts as a tumour suppressor through inhibiting EMT induction [342]. 
 
1.5.5.2.2 Estrogen receptor (ER) 
ERα and ERβ belong to the steroid hormone receptor superfamily and are 
important regulators of growth and differentiation. Upon activation by estrogen, 
ER translocates to the nucleus and regulates transcriptional activity through 
interactions with estrogen response elements (EREs) [343, 344]. Although ERα 
and ERβ are structurally similar, they can be functionally specific, partly through 
interactions with different co-regulatory proteins [345]. In fact, whilst ER-α is 
generally proliferative, ER-β has anti-proliferative properties [346]. Both NME1 
and NME2 are able to interact with ER to regulate transcription from ERE in 
breast cancer and smooth muscle cells [347-349]. NME1 has been shown to 
interact with ER-α and decreases the transcription of an estrogen-responsive 
reporter plasmid [348]. A decrease in NME1 expression by siRNA leads to an 
increase in expression in a number of estrogen-responsive genes that inhibit 
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apoptosis and promote metastasis, suggesting that NME1 may inhibit metastasis 
by repressing transcriptional activation by ERα [348]. On the other hand, NME2 
selectively interacts with and acts as a co-activator of ERβ [347]. NME2 facilitates 
estrogen-induced gene transcription and attenuates cell migration by acting 
synergistically with estrogen [347]. As a result, both of these NME family 
members contribute to an the overall outcome of anti-proliferative response by 
coordinately modulating ER members [310].  
 
1.5.5.2.3 Kinase suppressor of RAS (KSR) 
The histidine protein-kinase activity of NME1 may also contribute to its 
metastatic-suppressive function [350, 351]. NME1 has been reported to co-
immunoprecipitate with the kinase suppressor of RAS (KSR) protein, which acts 
as a molecular scaffold protein for the ERK-MAPK (extracellular signal-regulated 
kinase - mitogen-activated protein kinase) signalling pathway [352, 353]. ERK 
activation plays an important role in mediating tumour invasion and metastasis 
[354, 355]. NME1 is capable of phosphorylating KSR on a histidine residue, 
resulting in decreased ERK activation levels in response to signalling [352, 355]. 
Overexpression of NME1 in breast carcinoma cells results in diminution in ERK 
activation levels [352]. Consistently, expression of an NME1 mutant lacking the 
histidine kinase activity led to an increase in the levels of activated ERK [352]. 
Thus, these findings suggest that changes in NME1 levels in tumour cells can 
affect ERK activation and metastasis through interaction with the KSR scaffold 
protein [355]. Similarly, NME2 can also have an anti-cell proliferation effect 
through regulation of the ERK signalling pathway. A decrease in the level of 
NME2 can lead to activation of ERK signalling and promote cell proliferation, 
whereas high levels of NME2 inhibit proliferation induced by EGFR and Ras 
through counteracting the ERK signalling [356]. 
 
1.5.5.2.4 Guanine nucleotide exchange factors (GEFs) 
The Rho family GTPases consists of Rho, Rac and Cdc42 subfamilies that are 
important mediators of cell signalling pathways involved in regulation of actin 
cytoskeleton and cell migration (Figure 1.5.5.2.4.1) [357]. Like all GTPases 
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involved in signalling, the Rho family of GTPases function as binary switches by 
cycling between an inactive (GDP-bound) and an active (GTP-bound) 
conformational state [358]. Guanine nucleotide exchange factors (GEFs) activate 
GTPases by stimulating the exchange of GDP for GTP, in which the activated 
GTPases are then capable of recognising their downstream signalling targets 
[358]. On the other hand, GTPase activating proteins (GAPs) accelerate the 
intrinsic GTPase activity of GTPases to inactivate the switch through hydrolysis of 
GTP [358]. Rho family GTPases are important in regulating cell morphology and 
migration in different organisms through acting as a molecular switch between 
GDP-bound inactive and GTP-bound active forms [357, 359, 360]. Interestingly, a 
number of GEFs for the Rho family GTPases have been identified as NME-
interacting proteins. 
 
NME1 has been demonstrated to associate with a Rac1-specific GEF, Tiam 1 
[361]. Overexpression of NME1 inhibits the Tiam-1-induced production of GTP-
bound Rac1, a member of the Rho family of GTPases [361]. Thus, NME1 may 
exert its effect as a tumour metastasis suppressor by acting as a negative regulator 
of Rac1 [361]. In addition, NME2 has been found to directly interact with integrin 
cytoplasmic domain-associated protein 1α (ICAP-1α), an important regulator of 
cell adhesion, in the lamellipodia and peripheral ruffles during cell spreading 
[362]. Interestingly, Rac/Tiam-1 proteins also co-localise with ICAP-1α in the 
lamellipodia, linking NME2 to the cell adhesion and migration machinery [362]. 
 
Dbl-1 is another GEF that has been identified as an NME1-interacting partner 
[363]. Through interaction with Dbl-1, NME1 can modulate the activation of 
Cdc42 by inhibiting the GDP to GTP exchange activity by Dbl-1, which can 
negatively regulate cell migration and tumour metastasis by causing cytoskeletal 
reorganisation [363, 364]. On the other hand, NME2 but not NME1, has been 
identified as an Lbc-interacting protein [365]. Lbc is a product of a transforming 
gene with RhoGEF domain identified from leukaemia cells [365]. It has been 
shown that NME2 expression can negatively regulate and suppress the stress fibre 
formation induced by Lbc expression [360]. Using microarray analysis, it has been 
demonstrated that lysophosphatidic acid (LPA) receptor, a member of the G 
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protein-coupled receptor group, is down-regulated by wild-type NME1 [366]. 
Down-regulation of LPA receptor by NME1 leads to suppression of tumour cell 
motility, and may thus play a role in NME1-mediated metastasis suppression 
[366]. 
 
A bi-directional interaction between NME1 and Ras-related GTPase Rad has also 
been identified [367]. In this complex, NME1 acts functionally as both Rad-GAP 
and Rad-GEF to stimulate both GTP hydrolysis and GTP loading of Rad, 
respectively [367]. Simultaneously, Rad regulates NME1 by promoting NME1 
NDPK activity and decreasing NME1 autophosphorylation [367]. High expression 
of Rad has been shown in human breast cancer tissues and breast cancer cell line 
with high tumorigenic and metastatic potential [368]. The positive effects of Rad 
on tumour growth can be abrogated by co-expression of NME1, suggesting that 
interaction between Rad and NME1 may modulate growth and tumorigenicity in 
breast cancer [368]. 
 
1.5.5.3 DNA binding 
NME2 can control the expression of c-MYC in cervical cancer, lung carcinoma, 
and Burkitt lymphoma cells [274, 370, 371]. However, the mechanism underlying 
this regulatory control is still unclear. Studies by Postel et al. demonstrated that 
NME2 can transactivate the human c-MYC oncogene through binding to a region 
upstream of the transcription start site, called the nuclease-hypersensitive element 
(NHE) (also termed CT element or the PuF site), in an NDPK activity-independent 
manner [274, 372]. More recently, NME2 has been shown to mediate c-MYC 
activation through interaction with a G-quadruplex DNA motif within the NHE in 
the c-MYC promoter [371]. However, the role of NME2 as a transcription factor is 
debatable since it lacks a DNA-binding domain that is common in transcription 
factors [373]. Furthermore, unlike typical DNA binding proteins that bind to a 
double-stranded DNA for transcriptional regulation, NME2 binds to single-
stranded DNA [371, 374, 375]. These observations lead to the speculation that 
NME2 anti-metastatic functions are likely due to other biochemical activities 
[373]. Interestingly, NME1 possesses 3’-5’ exonuclease activity, which is critical 
for DNA proofreading and maintenance of genome stability [271, 376]. Zhang et 
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al. has demonstrated that NME1 mutant E5A deficient in 3’-5’ exonuclease 
activity, exhibited compromised suppressor activity in spontaneous metastasis of 
1205LU melanoma cells in vivo [318]. This suggests that the 3’-5’ exonuclease 
activity of the NME1 is essential for its anti-metastatic function [318].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.5.2.4.1: The role of Rho proteins in fibroblast migration. Rho is 
more active at the trailing end of the fibroblast, and this induces stress-fibre and 
focal-adhesion formation through actin polymerisation, which may stabilise the 
trailing end of the cell as it migrates towards the external stimulus (the direction of 
growth is indicated by the red arrow). On the other hand, Rac and Cdc42 are 
dominant at the leading edge and, by depolymerising actin, they promote the 
formation of protrusions that underlie the force-mediated movement towards the 
stimulus. The dynamics of polymerisation and depolymerisation depend on the 
balance between proteins that stabilise actin and sever microfilaments. Figure 
adapted from [369]. 
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1.5.5.4 NDPK activity 
To date, literature that correlates NDPK activity and metastasis suppression is very 
limited, which has led to speculation that NME enzymatic activity may not be 
required for its function as a metastasis suppressor [377, 378]. Nevertheless, a 
recent study by Conery et al. suggests that NME1 NDPK activity is required for 
supplying a local source of GTP for the activation of GTPase dynamin during 
cytokinesis [379]. Down-regulation of NME1 results in cytokinesis failure and 
chromosome instability regardless of the status of p53 signalling [379]. 
Chromosomal instability, or the inability to segregate chromosomes equally during 
cell division, plays critical roles in the development of the majority of solid 
tumours [380]. Chromosome instability may lead to aneuploidy and an increased 
susceptibility of loss of heterozygosity, which may provide tumorigenic 
advantages by increasing the mutation rate in oncogenes, tumour suppressors or 
genomic stability genes [381, 382]. Therefore it is possible that NME1 may have a 
role in maintaining normal cytokinesis to avoid chromosome missegregation, 
which may contribute to tumour development. The same study also showed that 
whilst loss of NME1 leads to tetraploidy regardless of p53 status, the reduced 
NME1 expression only leads to scenescence only in cells with intact p53. This 
suggests that continued cycling of tetraploid cells may only occur after the loss of 
p53 signalling [379]. 
 
1.5.6 NM23-LV (NME1-NME2) 
NM23-LV (also known as NME1-NME2) was identified as a read-through 
transcript (or ‘cojoined genes’) of the tandemly located NME1 and NME2 genes 
on chromosome 17q (Figure 1.5.6.1) [250, 251]. The encoded NM23-LV fusion 
protein lacks exon 5 of NME1 and consists of the first 114 residues of NME1 
fused in-frame to the N-terminus of the full-length NME2 [250, 251]. As the exon 
5 of NME1 comprises of a β-sheet and an α-helix that play a critical role in 
oligomerisation, its absence in NM23-LV may be incompatible with 
hexamerisation [383]. Although the H118 site of the NME1 portion is also absent 
from NM23-LV, there has been no report on how this would affect NM23-LV 
NDPK activity [383]. The physiological function of NM23-LV has not been well 
characterised. A study by Valentijn et al. using qRT-PCR analysis of a panel of 
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human tissues has demonstrated that NM23-LV is ubiquitously expressed at the 
mRNA level, with the exception of reduced expression in lung and barely any 
expression in kidney [250]. In the same study, high levels of NM23-LV mRNA 
expression have also been shown in eight neuroblastoma tumours, and this result 
is also analogous to NME1 and NME2 [250]. As discussed in Section 1.5.3, 
NME1 and NME2 may employ different mechanisms and have different roles in 
tumorigenesis, at least in part, owing to their specific interaction with other 
proteins [297]. Low expression of NME1 has been associated with aggressive 
types of cancers such as, breast carcinomas and melanomas, whereas high levels 
of NME1 and NME2 are linked with poor prognosis in neuroblastoma, lung 
cancers and thyroid carcinoma [294, 298-302]. Therefore the possibility emerges 
that the expression of NM23-LV, which contains part of the NME1 and the NME2 
protein, may serve as potential prognostic marker in different types of cancer. 
Furthermore, studies on neuroblastoma cells show that NME1, NME2 and NM23-
LV are mainly located in the cytoplasm, with some nuclear expression, but were 
absent from the nucleoli and plasma membrane [250].  By contrast, localisation of 
NME2 in breast carcinoma cells was observed in the nucleoli and plasma 
membrane [270]. Therefore, studying of the localisation of NM23-LV protein 
based on the cell type studies may also serve as surrogate indicators of its function 
and tumorigenic potential. Thorough understanding of the similarities and 
differences in molecular functions and physiological roles of NME1, NME2 and 
NM23-LV may provide great prognostic potential in cancers. 
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Figure 1.5.6.1: NM23-LV (or NME1-NME2) read-through transcript. NM23-
LV is a read-through transcript of the NME1 and NME2 neighbouring genes [250]. 
NM23-LV lacks exon 5 of NME1, which contains the stop codon and H118 
phospho-transfer site for NDPK activity. Additionally, NM23-LV also lacks exon 
1 of NME2, which is an untranslated sequence. The encoded protein hence 
comprises of part of NME1 fused to a complete NME2 protein. Boxes represent 
exon sequences and are connected by thin lines, which represent the intron 
sequences. Non-coding exons are shown in grey boxes. Introns are not drawn to 
scale. Transcription starts from left to right. Figure reproduced from [231]. 
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Intron-Exon structure of Group I Nme genes in chordatesFigure 3
Intron-Exon structure of Group I Nme genes in chordates. (A) Intron-Exon structure and evolutionary depiction of 
Group I Nme gene structure among chordate lineage. (B) Intron-Exon structure of human NMELV transcript compared to 
Intron-Exon structure of human NME1 and NME2. Intron-exon structure was obtained using Ensembl database, or, when no 
information was available, by Blat of protein and cDNA sequences on genomes assemblies. Boxes corres ond to exons. Non-
coding exons are shown in grey. The size of introns and exons in nucleotides is shown. Introns are not drawn to scale.
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1.6 Aims of the study 
RCC is a heterogeneous disease and patients typically display an unpredictably 
varied disease course, which is likely to be elicited by the acquisition of specific 
molecular alterations in the developing cancer. This has prompted us to focus on 
p53 and MDM2 genes that have previously been identified as predictors of disease 
progression. As mentioned in Section 1.4.3, a recent study by Noon et al. has 
demonstrated that there is a strong positive link between MDM2 and p53 co-
expression in RCC and this is accompanied by reduced disease specific survival 
even though the up-regulated p53 is rarely mutated [139]. It remains unknown as 
to why cells could tolerate co-upregulation of p53 and MDM2 since an auto-
regulatory feedback loop exists between p53 and MDM2. One explanation could 
be that there is a defect in the p53/MDM2 pathway that prevents high levels of 
MDM2 from degrading p53. More interestingly, it is unclear as to why up-
regulation of the wild-type tumour suppressor p53 would be associated with 
promoting cancer. One explanation might be that the predominantly wild-type p53 
in RCC promotes increased expression of MDM2 and that it is the MDM2 
upregulation that provides the link with cancer progression. Considering that 
MDM2 expression has been shown to promote cell motility and invasiveness in 
RCC in a p53-independent manner [384], we hypothesised that up-regulation of 
MDM2 promotes disease progression in RCC, leading eventually to reduced 
disease specific survival and thus providing the association with poor prognosis in 
RCC.  
 
Therefore, our overall aim has been to examine how MDM2 may contribute to a 
more aggressive phenotype in RCC cells. Whilst it will ultimately be critical to 
examine the function of MDM2 in renal cells, since these routinely retain wild-
type p53 it is important to examine the effects of MDM2 in p53 null cells to 
simplify the interpretation of the results so that other pleiotropic effects of p53 do 
not confound the analysis. For this reason we have extensively utilised H1299 
(non-small cell lung carcinoma cells that lack p53) as a system to study MDM2 
function.  
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Aim 1: Investigate how MDM2 promotes cell motility using expression 
profiling 
Based on the findings that MDM2 promotes increased cell motility and invasion in 
a p53- and RING-finger-independent manner [384], we aimed to investigate how 
MDM2 promotes cell motility by performing expression profiling to detect 
consequences of MDM2 expression in derivatives of H1299 cells expressing high 
levels of MDM2 (Clone 9) and lacking E3 ligase activity (RFM9). It was 
hypothesised that genes that are mutually altered by MDM2 and RFM expressions 
would be likely to promote cell motility via the same biological pathways and 
studying these genes could provide insights into the mechanism of MDM2 in 
promoting cell motility and invasion. 
 
Aim 2: Investigation of the mechanisms and consequences of MDM2-NME2 
interaction  
It has been shown that MDM2 interacts with NME2 and abolishes the ability 
NME2 to suppress motility in RCC [183]. However, the mechanism of action 
behind this remains unknown. We therefore aimed to study the mechanism and 
consequences of MDM2-NME2 interaction for cell motility. 
 
Aim 3: Investigation of the role of MDM2 on NME ubiquitination 
In a study using stable cell lines expressing 6xHis-biotin-tagged ubiquitin for 
purification of the ubiquitinated proteome, Meierhofer et al. identified NME1 as 
one of the potential substrate for ubiquitination [385]. Furthermore, mass 
spectrometry analyses show that both NME1 and NME2 amino acid sequences 
contain a potential ubiquitination site (K100) [385]. In addition, our fractionation 
analyses of MDM2 and NME sub-cellular distribution suggest that NME proteins 
could be targets for MDM2-mediated ubiquitination. It is possible that MDM2 
mono- or poly-ubiquitinates NME and then targets the modulated NME for protein 
shuttling or degradation, respectively. Therefore despite the finding that MDM2 
motility promoting effect is independent of its E3 ligase activity [384], we aimed 
to examine whether NME1, NME2 and NM23-LV proteins could be subjected to 
MDM2-mediated ubiquitination to gain better understanding of the regulation of 
NME proteins by MDM2. 
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Understanding the mechanisms through which MDM2 expression promotes 
increased cell motility and invasiveness in cancer cells would provide valuable 
insights to allow for development of potential therapeutic targets for RCCs as well 
as other cancers. 
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2. Materials and Methods 
2.1 Molecular cloning 
2.1.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate, purify and estimate the yield of 
DNA fragments. An agarose gel was prepared to an appropriate concentration 
(Table 2.1.1.1) in Tris-acetate-EDTA (TAE) buffer (40 mM Tris-Base 
(Calbiochem), 1.142% glacial acetic acid (MERCK) and 1 mM EDTA, pH 8.0 
(BDH)). Genesieve LE agarose (Flowgen) was generally used, unless the DNA 
fragment of interest was to be extracted for downstream molecular cloning 
purposes, in which case, SeaKem®GTG®agarose (Lonza) was used instead. The 
agarose gel was supplemented with 0.5 µg/ml of ethidium bromide (Roche) so that 
DNA bands could be visualised under UV light. Gel electrophoresis was run in 
TAE buffer inside a horizontal electrophoresis unit (Scie-Plas) connected to a 
PowerPac power supply (Bio-Rad), at a voltage of 1-10 V/cm across the gel. All 
DNA samples to be run were supplemented with 10% (v/v) orange G loading 
buffer (50% glycerol with adequate orange G dye (BDH). DNA markers used are 
100 bp DNA ladder (New England Biolabs, NEB) and/or 1 kb DNA ladder 
(Invitrogen). For qualitative analysis of RNA samples, the method was similar to 
that described above, except that the electrophoresis tank, gel cast and gel comb 
were immersed in 1 M HCl (VWR) for 1h and then washed with RNase/DNase 
free water before use. 
 
 
Table 2.1.1.1: Concentrations of agarose gels for different sized DNA 
fragments. 
 
% Agarose (w/v) Effective resolution of DNA 
fragments (kb) 
0.5 >12 
0.7 1-12 
1.0 0.5-8 
1.2 0.2-5 
2 <1 
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2.1.2 Polymerase Chain Reaction (PCR) 
Amplification of DNA fragments of interest was performed using two suitable 
primers and a thermostable Phusion® High-Fidelity DNA polymerase (NEB). 
Briefly, all components of a PCR reaction (Table 2.1.2.1) were mixed and then 
loaded in a thermal cycler (Px2 Thermal Cycler, Thermo. Electron Corporation) 
and appropriate cycle conditions were used (Table 2.1.2.2). Typically, after 30 
cycles, the presence or quantity of the PCR product was checked by gel 
electrophoresis (Section 2.1.1). Primers were designed using online tools, 
including Primer3 (http://frodo.wi.mit.edu/primer3/) or Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome). In general, primers were designed to be 
18-25 nt in length, with a GC content between 40-70% and a melting temperature 
(Tm) of approximately 60°C. All oligonucleotides were synthesized by Eurofins 
MWG Operon and were reconstituted in water. 
 
 
 
 
Table 2.1.2.1: Standard components of a PCR reaction. 
 
Component / 25 µL  
Standard buffer  x 1 
dNTPs 200 µM 
Primers 0.05 µg each 
DNA polymerase 0.5-1 unit 
Template DNA 1 pg – 10 ng 
Nuclease-free H2O To 25 µL 
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Table 2.1.2.2: Standard cycle conditions for Phusion®  High-Fidelity DNA 
polymerase. 
 
 Phusion High-Fidelity DNA 
polymerase 
Initial denaturation 98°C 30 sec 
15-35 cycles 
Denaturation 
Anneal 
Extend 
 
98°C 
50-65°C 
72°C 
 
10 sec 
30 sec 
15-30 sec/kb 
Final extension 72°C 5-10 min 
Hold 4°C 
 
 
2.1.3 A-tailing reaction 
Tag DNA polymerase (Invitrogen) was used to create the 3’ A-tail overhangs 
required for ligation of PCR product into pCR2.1 vector (known as TA-cloning). 
Typically, PCR reaction was left overnight at 4°C to reduce the efficiency of 
Phusion enzyme at removing A-tails freshly synthesised by Tag DNA polymerase. 
For A-tailing reaction, 1 µL of 10 mM dATPs and 1 µL of Tag DNA polymerase 
(10 units) were added to the completed PCR reaction, which already contained the 
required buffer. The reaction was mixed and briefly centrifuged before being 
incubated at 72°C for 20 min. Once the A-tailing reaction has finished, the PCR 
products were run on a GTG® agarose gel and the DNA extracted for downstream 
cloning applications. 
 
2.1.4 Restriction endonuclease digestion 
Restriction digest of DNA was performed either for ligation reactions or for 
identification of correctly targeted recombinant clones (diagnostic purposes). For 
DNA digest reactions, restriction endonucleases were used according to the 
conditions suggested by manufacturer (NEB). Typically, 0.5-3 µg of the plasmid 
containing the insert of interest and 1 µg of the vector ‘backbone’ DNA were 
digested routinely with 10-fold excess of restriction enzyme, for example, 10 U of 
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enzyme were used to digest 1 µg of DNA. The digestion was incubated for 3h to 
overnight at the manufacturer’s recommended temperature, usually 37°C. For 
ligation purposes, the backbone DNA was further dephosphorylated to avoid self-
ligation by adding 0.5 µL Antarctic phosphatase  (NEB) and 10x Antarctic 
Phosphatase Reaction Buffer (NEB) (to a final concentration of 1x) and incubating 
at 37°C for 15 min.  The DNA digest was then examined by agarose gel 
electrophoresis (Section 2.1.1). In the case for ligation, DNA digest samples were 
run on GTG® agarose gel. The insert and backbone of interest were cut out of the 
gel using a sterile scalpel and purified using a GENECLEAN Turbo Kit 
(Qbiogene) according to the manufacturer’s instruction. 
 
2.1.5 Ligation of DNA fragments 
DNA ligation reactions were performed with T4 DNA ligase (NEB) according to 
the manufacturer’s protocols. Briefly, the components of the ligation reaction (50 
ng vector DNA, x1 ligase buffer, 1 unit T4 ligase, and DNA insert of at least 1:1 
molar ratio of vector:insert DNA) were added in a 0.2-ml PCR tube to a final 
volume of 20 µL. The reaction was mixed by a quick vortex and centrifuged 
briefly before incubation at 16°C for overnight or longer. After incubation, 1-5 µL 
of the ligation reaction was used for transformation of competent E. coli (Section 
2.1.7.2). 
 
2.1.6 Basic maintenance for bacteria 
Different strains of bacteria with specific genotypes were used for different or 
specialised purposes. Typically, TOP10 (Invitrogen, #C4040) bacteria were used 
for routine cloning, whereas XL1-Blue (Stratagene, #200130) cells were used 
when better quality and yield of DNA were needed for downstream applications, 
such as transfection into mammalian cells. All bacterial work was performed using 
aseptic techniques. E. coli were cultured in Luria Broth (LB, Sigma-Aldrich) 
liquid media that was prepared by adding 25 g/L of LB to distilled water, and was 
subsequently sterilised by autoclaving at 122°C for 15 min. Appropriate 
antibiotics were added at their recommended working concentration (Table 
2.1.6.1) once the medium has cooled down to ~ 55°C. Solid medium was prepared 
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using a similar method and formulation, with the addition of 15 g/L of agar 
(Formedium). Antibiotics were added as required at about 55°C and then poured 
into 10-cm Petri dishes and allowed to set.  
 
Initially, E. coli cells were propagated in small starter cultures and then diluted 
1:100 for larger culture volumes. To set up a starter culture, an individual bacterial 
colony was picked from an LB-agar plate, inoculated into small 5 ml liquid 
cultures containing an appropriate antibiotic in 14-ml sterile Falcon 2059 tubes 
and incubated overnight at 37°C, with vigorous shaking at 230 rpm. For larger 
scale of E. coli culture, the bacteria were inoculated into a conical flask that was at 
least five times the size of the culture volume to ensure sufficient aeration and 
grown overnight at 37°C, with vigorous shaking at 230 rpm. 
 
For long term storage of E. coli,  a freshly grown overnight culture was mixed 1:1 
with 50% glycerol (Sigma-Aldrich) and stored at -80°C. Frozen bacteria were 
revived by scraping off some of the frozen glycerol stock with an inoculation loop 
and streaking this onto an LB-agar plate which was then incubated overnight at 
37°C until individual colonies have formed. 
 
 
Table 2.1.6.1: Selective antibiotics. Each antibiotic was reconstituted in H2O and 
prepared as a concentrated stock solution, which was sterilised by filtration. The 
stock solution was subsequently aliquoted and stored at -20°C. 
 
Antibiotic Stock solution Working concentration Source 
Ampicilin 
 
x 1000 100 µg/µL Sigma-Aldrich 
Kanamycin 
 
x 250 50 µg/µL Sigma-Aldrich 
 
 
2.1.7 Introduction of plasmid DNA into bacterial cells 
2.1.7.1 Generation of electrocompetent bacteria 
To generate electrocompetent E. coli, aseptic technique was used throughout the 
following methods. A single colony of E. coli strain of interest was inoculated into 
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5 mL LB medium containing appropriate antibiotic and incubated overnight at 
37°C, with shaking at 300 rpm. 2.5 mL of this starter culture was then inoculated 
into 500 mL of LB medium and incubated at 37°C, with shaking at 300 rpm. After 
about 3-4h when an OD600 nm of 0.5 to 0.7 was reached, cells were chilled in an 
ice water-bath for 10-15 min before harvesting. From this point onwards, all 
centrifugation steps were carried out at 2°C and all reagents and equipments were 
kept pre-chilled on ice. Cells were harvested in a 500-mL centrifuge bottle in a 
Sorvell RC 5C Plus (Du Pont) Centrifuge at 3000 x g for 20 min. Promptly, the 
supernatant was poured off and the cell pellet washed with 500 mL of ice-cold 
water by re-suspending initially with 5 mL to achieve a single cell suspension. The 
remaining water was added and the cell suspension was mixed well before being 
harvested as previous steps. The cell pellet was washed with 500 mL ice-cold 
water again and then the cells were re-suspended in 40 mL of 10% (v/v) glycerol. 
The cell suspension was transferred into a narrow bottom 50-mL Falcon tube and 
was harvested in an Eppendorf Centrifuge 5804R at 3000 x g for 10 min. The 
supernatant was immediately discarded and the cells mixed with (1:1) and re-
suspended with 10% (v/v) glycerol. The electrocompetent E. coli were then 
aliquoted at 50 µL/1.5 mL micro-centrifuge tube and promptly frozen on dry ice or 
snap frozen in liquid nitrogen. The frozen cells were then kept at -80°C until 
needed. 
 
2.1.7.2 Transformation by electroporation 
Bio-Rad Gene Pulser II was used for the electro-transformation of E. coli by high 
voltage. Electroporation cuvettes (Bio-Rad) with a 0.1 or 0.2 cm gap were used 
and recycled between transformations using a washing protocol as described 
below. Super Optimal broth with Catabolite repression (SOC) media (0.5% yeast 
extract, 2% tryptone (BD Bioscience), 10 mM NaCl, 10 mM MgCl2, 10 mM 
MgSO4 (BDH AnalaR), 2.5 mM KCl (AnalaR NORMAPUR), 20 mM glucose 
(Formedium)) was prepared and sterilised by autoclaving in advance.  
 
For electro-transformation of E. coli, competent cells were first thawed on ice and 
1-2 µL of pre-chilled ligation mixture was added (or 10 pg of pUC19 control 
plasmid DNA). The transformation reaction was then carefully transferred, 
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making sure that air bubbles were avoided,  into an ice-cold eletro-cuvette. The 
outside of the cuvette was wiped to avoid condensation before being placed into 
the Bio-Rad Gene Pulser Xcell for pulse delivery (Table 2.1.7.2.1). Immediately 
after a single pulse was delivered, 1 mL of chilled SOC medium was added to the 
cuvette and the transformation mix was gently re-suspended before being 
transferred to a chilled 2-mL screw-cap Eppendorf tube. The cell suspension was 
then incubated for 1h at 37°C, with shaking at 230 rpm. Following incubation, the 
transformation mixture was spread onto LB-agar plates containing selective 
antibiotics and incubated overnight at 37°C to allow for the growth of 
transformants. Typically, 10% and 90% of the total transformants mixture volume 
were spread onto LB-agar plates. The reason for this is to optimise the growth of 
individual colonies for picking and screening of recombinant clones. 
Transformation efficiency (colony forming units per µg of pUC19 DNA) was 
calculated to check whether the transformation was performed satisfactorily. 
Using this protocol, the cells generally produced transformation efficiencies of > 1 
x 108-9 cfu/µg pUC19 DNA. 
 
For recycle use, the electro-cuvette was washed by rinsing with H2O five times, 
soaking in 0.2 M HCl for 10 min, and then rinsing with 70% ethanol for five 
times. Following the last rinse with 70% ethanol, the liquid was decanted under a 
sterile hood and air-dried for about an hour. The cuvette was re-capped and was 
ready to use again. 
 
 
Table 2.1.7.2.1: Specifications for electroporation using Bio-Rad Gene Pulser 
Xcell  
Gap size (cm) 0.1 0.2 
Capacitance (µF) 25 25 
Resistance (Ω) 200 200 
Voltage (kV) 1.5 2.4 
Pulse (kV/cm) 15 12 
Expected time constant (ms) 4.6 4.6 
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2.1.8 DNA extraction 
2.1.8.1 Basic small scale DNA extraction using alkaline lysis and PCI 
This low cost and quality plasmid DNA extraction method was used for screening 
recombinant clones, but not for sequencing purpose. This method usually yielded 
between 30-50 µg from a 4 mL liquid culture, and met the quality for analysis by 
restriction digest (Section 2.1.4). This basic protocol has the advantage of being 
able to extract DNA quickly from many clones at once, allowing for express 
screening. All reagents were prepared in advance according to Table 2.1.8.1.1.  
 
Accordingly, 4 mL of the E. coli overnight culture was harvested by batch in 2-mL 
micro-centrifuge tubes in an Eppendorf centrifuge 5415 at 6800 x g for 5 min at 
room temperature (RT). The cell pellet was re-suspended in 200 µL GTE solution 
by vortexing, and then 200 µL of the lysis buffer was added into each tube, 
followed by quick addition of 200 µL of K+Ac- solution and 500 µL of PCI 
(24:25:1). The tubes were mixed by inversion for 5 min, followed by 
centrifugation at 16,000 x g for 10 min. The aqueous phase was quickly 
transferred into a clean 1.5-mL micro-centrifuge containing 500 µL of isopropanol 
(VWR), and mixed well prior to incubation at RT for 5 min. The precipitated 
DNA was harvested by centrifugation at 16,000 x g for 10 min. DNA pellet was 
washed thoroughly by adding 1 mL of 70% ethanol and gentle vortexing to ensure 
that the pellet was dislodged into the solution. The samples were centrifuged 
briefly and the supernatant carefully removed. The pellet was air-dried for 5-10 
min depending on the pellet size, or until the white pellet appeared translucent. 
DNA was re-suspended in 20 µL of TE buffer + Ribonuclease A (RNase A). The 
DNA solution could be incubated in a 37°C water-bath for 30-60 min to help the 
DNA dissolve. The dissolved DNA was stored at -20°C. Typically 2 µL of a 1:10 
diluted (in H2O) DNA solution was adequate for analysis by restriction enzyme 
digestion. 
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Table 2.1.8.1.1: Formulation of buffers for basic DNA extraction. GTE, lysis 
buffer and K+Ac- solution were stored at RT. The lysis buffer was warmed up in a 
37°C water-bath before use to dissolve any precipitated sodium dodecyl sulphate 
(SDS). PCI (24:25:1) was stored at -20°C and defrosted before use. TE buffer + 
RNase A was stored at 4-8°C. 
 
Solution Composition Source 
GTE (re-suspension buffer) 50 mM Glucose 
25 mM Tris (pH 7.4) 
1 mM EDTA (pH 8.0) 
AnalaR 
Calbiochem 
Sigma-Aldrich 
Lysis buffer (AKA buffer P2) 1% SDS (w/v) 
200 mM NaOH 
VWR 
VWR 
K+Ac- solution (neutralisation 
buffer) 
3 M KAc 
11.5% Glacial acetic acid (v/v) 
BDH Biochemical 
MERCK 
PCI (24:25:1) 24: Phenol 
25: Chloroform 
1: Isoamylalcohol 
VWR 
VWR 
VWR 
TE buffer + RNase A 10 mM Tris.Cl (pH 8.0), 1 mM 
EDTA 
10 µg/ml RNase A 
 
QIAGEN 
Sigma-Aldrich 
 
 
2.1.8.2 Small scale, high quality plasmid DNA extraction 
The QIAprep Spin Miniprep Kit (QIAGEN) was used to isolate plasmid DNA 
when small amounts of high quality DNA were required for downstream 
applications, such as DNA sequencing. DNA extraction was performed according 
to the manufacturer’s guidelines and typically yielded 5-20 µg DNA from a 4 mL 
overnight bacteria culture. The concentration of DNA and its purity were 
determined using a UV spectrophotometer. Pure DNA should give a A260/ A280 
ratio value of 1.8. A value below 1.8 is indicative of protein contamination 
whereas a value of 2.0 is considered to be pure RNA. 
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2.1.8.3 Large scale, high quality plasmid DNA extraction 
QIAGEN-tip 2500 EndoFree Megaprep Kit was used to isolate plasmid DNA 
when large scale, high quality and ultra-pure transfection grade DNA was required 
for downstream applications. The DNA isolation procedure was performed 
according to the manufacturer’s guidelines, with minor modifications, and 
typically yielded 1.5-2.5 mg of DNA. DNA was quantified and its purity was 
determined using a UV spectrophotometer (Section 2.1.8.2). 
 
2.1.9 RNA isolation and quality testing 
Cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to 
the manufacturer’s protocol. RNA was eluted in RNase-free water and was used 
for downstream applications such as microarrays or qRT-PCR. The quantity of 
RNA was estimated by spectrometry at 260nm and 280 nm using a 
BioPhotometer. RNA of high quality should have an A260/A280 ratio of 2.0. The 
integrity of RNA was also examined by running 500 ng of RNA samples on a 1% 
(w/v) non-denaturing agarose gel. 
 
2.1.10 DNA constructs and plasmids 
Typically, 30-100 ng/µL in 20 µL (sufficient for 8 reactions) of purified plasmid 
DNA samples were sent to GATC Biotech for sequencing. The obtained sequence 
was compared to the reference sequence from the National Centre for 
Biotechnology Information (NCBI) database using NCBI Basic Local Alignment 
Search Tool (BLAST). BLAST allows for alignment of two sequences and 
provides statistical analysis of the sequence similarity. 
 
 
 
 
 
 
 
 
 
	   89	  
Table 2.1.10.1: List of plasmids used in this study. 
Plasmid Description Source 
pCR2.1 A TA-Cloning vector for cloning amplified 
PCR products. It contains the lacZ gene which 
encodes for β-galactosidase, allowing for 
blue/white colony screening of transformants. 
Invitrogen 
pUC19 Control plasmid Invitrogen 
pβ-gal An expression vector encoding β-galactosidase 
(β-gal) under the regulation of an SV40 
promoter. 
Laboratory stock 
pGL4.11-p53RE-
luc2 
A p53 luciferase reporter construct. It drives 
firefly luciferase expression from a wt MDM2 
promoter cloned into pGL4.11 which contains 
Luc2. Luc2 is a mammalian codon optimised 
version of Luciferase for more efficient 
translation and expression in mammalian cells. 
Laboratory stock 
pRL-TK A luciferase reporter constructs that drives 
constitutive Renilla luciferase expression from 
an HSV thymidine kinase promoter. 
Kindly provided 
by Prof Mike 
White 
pEGFP-N1 An expression vector encoding red-shift variant 
of green fluorescent protein (GFP) suitable for 
N-fusions. 
Clontech 
pEYFP-N1 Encodes an enhanced yellow-green variant of 
GFP suitable for N-fusions. 
Clontech 
pEYFP-C1 Encodes an enhanced yellow-green variant of 
GFP suitable for C-fusions. 
Clontech 
pECFP-N1 Encodes an enhanced cyan variant of GFP 
suitable for N-fusions. 
Clontech 
pECFP-C1 Encodes an enhanced cyan variant of GFP 
suitable for C-fusions 
Clontech 
pCMV-HA A mammalian vector expressing hemagglutinin 
(HA) 
Clontech 
pFLAG-CMV-6b A FLAG expression vector in mammalian cells Sigma-Aldrich  
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pCEP4 A basic mammalian expression vector Invitrogen 
 
pcDNA3.1 A basic mammalian expression vector Invitrogen 
 
pCMVNeoBam An empty vector that contains two independent 
transcription units, a CMV promoter and a 
HSV thymidine kinase promoter. 
Kindly provided 
by Dr Bert 
Vogelstein 
pCMVNeoBam-
MDM2 
Encodes full length human MDM2, used for 
expression in mammalian cells 
Kindly provided 
by Dr Bert 
Vogelstein 
pCMVNeoBam-
MDM2C464A 
Encodes human MDM2 that harbours a single 
point mutation (C464A) at the zinc-
coordinating residue in the RING domain that 
is critical for its E3 ubiquitin ligase activity. 
Used for expression in mammalian cells. 
Kindly provided 
by Dr Dimitris 
Xirodimas  
pCEP4-p53 Encodes full length human p53 Kindly provided 
by Dr Dale 
Haines 
pHis6-Ub Encodes ubiquitin tagged with six consecutive 
histidines 
Kindly provided 
by Prof Mathias 
Treier 
pcDNA3.1-
NM23-LV 
Encodes full length NM23-LV Kindly provided 
by Dr Linda 
Valentijn 
pcDNA3.1-HA-
NM23-LV 
Encodes HA-tagged full length NM23-LV Kindly provided 
by Dr Linda 
Valentijn 
pCEP4-NME1 Encodes for full length NME1 of isoform b. Laboratory stock 
pCEP4-NME2 
 
Encodes for full length NME2 of isoform a. Laboratory stock 
pCEP4-HA-
NME2 
 
Encodes HA-tagged full length NME2 of 
isoform a. 
Laboratory stock 
pCEP4- Encodes for full length NME2 of isoform a Laboratory stock 
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NME2H118F 
 
with a point mutation (H118F) at the phospho-
acceptor residue critical for NDPK activity 
pCEP4-
NME1H118C 
 
Encodes for full length NME1 of isoform a 
with a point mutation (H118C) at the phospho-
acceptor residue critical for NDPK activity 
Laboratory stock 
 
 
2.1.10.1 Constructs expressing fluorescence-labelled NME fusion proteins 
In order to generate constructs that express fluorescence-labelled NME fusion 
proteins, NME1, NME2, NME2H118F and NM23-LV DNA fragments were 
cloned into pEYFP and pECFP vectors, to result in both C- and N- terminally 
fluorescent-tagged forms of NMEs, as illustrated in Figure 2.1.10.1.1. Based on 
DNA templates as listed in Appendix 1, primers for PCR reaction were designed 
to include two desired restriction sites (ECoRI and BamHI) compatible to the 
multiple cloning sites of the pEYFP/pECFP backbones, and in some cases, to 
delete STOP codon (dSTOP). Standard cloning procedures (Section 2.1) were 
followed. 
 
Briefly, NME DNA fragments were amplified by PCR according to DNA 
templates and primers, as well as PCR conditions listed in Appendix 1. PCR 
products were ligated into pCR2.1 vector for transformation into XL1-Blue 
bacteria cells. Extracted DNAs from positive colonies were digested with ECoRI 
and BamHI restriction enzymes to check for insertion and sent for sequencing. 
The correct NME fragments were subcloned into pEYFP and pECFP vectors at 
ECoRI and BamHI restriction sites.  
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Figure 2.1.10.1.1: Schematic diagram illustrating the cloning strategy for A. 
generating constructs expressing EYFP/CFP-labelled NME fusion proteins B. 
designing primers that include deleted STOP codon (dSTOP) and/or restriction 
sites. 
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2.2 Cell Culture 
Cell culture was performed in Class II safety cabinet using aseptic technique. All 
cells were grown at 37°C in a humidified incubator of 5% CO2 and all reagents 
were pre-warmed to 37°C. Cells were routinely passaged 1:10 at 90-100% 
confluence. Once cells reached the desired confluence, the old media was 
discarded and the cells were washed with Dulbecco’s Phosphate Buffered Saline 
(PBS, Sigma-Aldrich). PBS wash helps to remove any remaining traces of serum 
in the growing media which is capable of inhibiting Trypsin-EDTA activity. 
Trypsin-EDTA (Sigma-Aldrich) solution was then added to the cells and the flask 
was tilted gently to ensure even coverage. The cells were incubated, if required at 
37°C, for 2-5 min. The flask was gently tapped at the side for a few times. Once 
the cells started to detach from the flask, the trypsin was inactivated by adding at 
least 1x volume of growth medium. The cells were then pipetted vigorously to 
ensure single cell suspension and applied into fresh culture vessel at the desired 
cell density with fresh medium.  
 
To prepare cryostocks, cells were harvested by trypsinisation and pelleted by 
centrifugation at 300 x g for 5 min at RT. The media was aspirated and the pellets 
were gently re-suspended in 1 mL of freezing media (10% DMSO in FBS). The 
cell suspension was then transferred into cryovials (Nunc). To ensure slow 
freezing, the vials were placed into polystyrene containers and stored at -80°C 
overnight. After 24h, the cryovials were transferred to liquid nitrogen for storage. 
When recovering cells from liquid nitrogen, the stocks were defrosted as quickly 
as possible in a 37°C water-bath. The thawed cells were re-suspended in complete 
growth media in an appropriate tissue culture flask. The medium was changed 
when the cells adhered to the flask surface, usually on the following day. 
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Table 2.2.1: List of cell lines used in this study. 
Cell line Description and Maintenance Source 
H1299 H1299 (non-small cell lung carcinoma) cells were 
obtained from the American Type Culture Collection 
(Manassas, VA). H1299 cells are immortalised and p53-
null. They were largely used in this study because they 
are well characterised, easily maintained and are 
relatively easy to transfect. The cells were maintained in 
RPMI-1640 medium (Sigma-Aldrich) supplemented 
with 10% Fetal Bovine Serum (FBS, Sigma-Aldrich). 
 
American 
Type 
Culture 
Collection 
 
 
H1299 Clone 9 A derivative of H1299 that overexpresses MDM2. 
Clone 9 cells were maintained as described above for 
H1299. 
 
Laboratory 
stock 
RFM9  A RING-finger mutant derivative of H1299 that lacks 
E3 ubiquitin ligase activity of MDM2. RFM9 cells were 
maintained as described above for H1299. 
 
Laboratory 
stock 
HEK293 Human embryonic kidney 293 cells was maintained in 
DMEM HEPES modification medium supplemented 
with DMEM HEPES modification (Sigma-Aldrich), 
10% FBS and 2mM L-glutamine (Invitrogen).  
 
Laboratory 
stock 
U2OS 
 
 
 
A human osteosarcoma cell line. The cells were 
maintained in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10% Fetal Bovine Serum (FBS, 
Sigma-Aldrich). 
 
American 
Type 
Culture 
Collection 
Double null 
MEF 
Mouse embryonic fibroblast with null p53 and MDM2 
(p53-/-, Mdm2-/-). The cells were maintained in DMEM 
HEPES modification, 10% FBS and 2mM L-glutamine. 
 
Laboratory 
stock 
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2.3 Introducing exogenous DNA into mammalian cells 
2.3.1 GeneJuice transfection  
GeneJuice (Novagen) was used to transiently transfect mammalian cells with 
plasmid DNA, according to the manufacturer’s protocol. GeneJuice contains a 
non-toxic cellular protein and novel polyamine that allows for efficient entry of 
DNA into cells. Transfection was performed on 50-80% confluent cells, usually at 
3 µL of GeneJuice per µg of DNA (ratio 3:1), with empty vectors added to ensure 
equal DNA content of transfections. Prior to transfection, GeneJuice, serum-free 
medium and DNA were equilibrated to RT. Appropriate volume of serum-free 
medium was added in a sterile tube. For each condition, DNA was prepared and 
mixed together (if performing co-transfection) in a sterile 1.5 ml screw-cap 
centrifuge tube. Then, GeneJuice was added directly and dropwise to the serum-
free medium without touching the walls of the tube and mixed thoroughly by 
vortexing for a few seconds. The GeneJuice mixture was incubated for 5 min at 
RT then added to the DNA. The GeneJuice/DNA mixture was mixed by flicking 
the tube a few times and then incubated at RT for 15 min. The mixture was then 
added drop-wise to the cells in complete growth medium, covering the entire dish 
surface. The dish  was rocked gently to ensure even distribution of the transfection 
mixture. The cells were kept in a tissue culture incubator at 37°C, normally for at 
least 24h before harvested for analysis or downstream experiments.  
 
2.3.2 Lipofectamine transfection 
Lipofectamine transfection is a cationic lipid-mediated transfection used in this 
study for introducing plasmid DNA or siRNA into mammalian cells. 
Lipofectamine can form liposomes in an aqueous environment and entrap 
negatively charge nucleic acid molecules to mediate the transport of transfection 
materials into cells. Typically, transfection was performed on approximately 90-
95% confluent cells to enhance transfection efficiency and expression levels, and 
to minimise cytotoxicity. Before transfection, Opti-MEM Reduced Serum Medium 
(Invitrogen), Lipofectamine 2000 (Invitrogen) and DNA were equilibrated to RT. 
Lipofectamine was typically used at 2.5 µL per µg of DNA. For a 6-well plate, 
DNA and Lipofectamine were each diluted in 250 µL (1.5 ml for 10-cm dish) of 
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Opti-MEM medium in separate tubes and mixed well by a brief vortex. The 
mixtures were incubated at RT for 5 min. After incubation, the diluted 
Lipofectamine was added to the diluted DNA and the DNA/Lipofectamine 
mixture was mixed by flicking the tube several times. The DNA/Lipofectamine 
mixture was incubated for 20 min at RT. Then, all the transfection mixture was 
added drop-wise to cells in complete growth media, distributing the drops over the 
entire dish surface. The dish was gently rocked to ensure even distribution. The 
cells were incubated in a 37°C tissue culture incubator. Transfection mixture was 
removed 2-6h after incubation and replaced with complete growth medium to 
minimise cytotoxicity. Transfected cells were analysed at least 24h post-
transfection. 
 
2.3.3 siRNA transfection 
siRNA transfection was performed on 40% confluent H1299 cells using 
Lipofectamine 2000 transfection reagent. Prior to transfection, Lipofectamine 
2000 and Opti-MEM Reduced Serum Medium were equilibrated to RT. siRNA 
(Table 2.3.3.1) was defrosted just before transfection. Typically, cells were 
transfected with siRNA at a final concentration of 40 nM. For a 6-well plate, 80 
pmoles of siRNA and 4 µL of Lipofectamine 2000 was each diluted in 250 µL 
Opti-MEM medium in separate tubes. The mixtures were incubated at RT for 5 
min and then combined. The transfection mixture was mixed by flicking the tube 
for a few times and incubated for at RT for 20 min. The entire mixture was then 
added drop-wise to cells in complete growth media, distributing the drops evenly 
across the entire dish surface. The dish was rocked gently and then incubated at 
37°C in a tissue culture incubator. Transfection mixture was removed 6h after 
incubation and replaced with complete growth medium. Transfected cells were 
analysed at least 24h post-transfection. 
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Table 2.3.3.1: Target sequence of siRNA. All of the siRNAs used in this study 
were synthesised by Dharmacon. 
 
Name Target Sequence Accession Base No. 
Scrambled 5’- AAGGACGCAUCCUUCUUAAUU -3’ N/A N/A 
MDM2 oligo 1 5’- AAGCCACAAAUCUGAUAGUAU -3’ NM_002392 872-890 
NME1 oligo 6 5’- GAGAUCGGCUUGUGGUUUCUU -3’ NM_198175 713-731 
NME1 oligo 7 5’- CCGCCUUGUUGGUCUGAAAUU -3’ NM_198175 427-447 
NME1 oligo 8 5’- GAGCGUACCUUCAUUGCGAUU -3’ NM_000269 121-140 
NME1 oligo 9 5’- GAGAGAUUAUCAAGCGUUUUU -3’ NM_000269 173-192 
NME2 oligo 7 5’- GCGAGAUCAUCAAGCGCUU -3’ NM_002512 295-313 
NME2 oligo 8 5’- AAGGCGAGAUCAUCAAGCGCUU -3’ NM_001018137 315-334 
 
2.4 Protein extraction and quantification (Bradford assay) 
Bradford assay was performed to prepare and quantify protein samples [386]. 
Briefly, Cells were harvested by trypsinisation and pelleted by centrifugation at 
300 x g for 5 min. The supernatants were discarded and the pellets were washed 
with 1 ml of PBS followed by centrifugation as previous step. The pellets were 
stored at -80°C before being further processed [386].  
 
In order to extract protein, cell pellets were defrosted and then re-suspended on ice 
in lysis buffer supplemented with protease inhibitors (2 µg/mL aprotonin, 0.5 
µg/mL leupeptin, 100 µg/mL soy bean trypsin inhibitor (STI), 1 µg/mL pepstatin 
(Roche), 1 mM phenylmethylsulphonyl fluoride (PMSF, Fluka)). Either Standard 
Lysis and Immunoprecipitation (SLIP) (50 mM HEPES, pH 7.5 (Calbiochem), 
150 mM NaCl (VWR), 0.5 mg/mL bovine serum albumin (BSA, Fluka), 10% 
(v/v) glycerol, 0.1% (v/v) Triton X-100 (Sigma-Aldrich)) or 
radioimmunoprecipitation assay (RIPA), pH7.6 (50mM Tris. HCl (Calbiochem), 
0.5% Na deoxycholate, 1% NP-40 (Sigma-Aldrich), 150mM NaCl, 0.1% SDS 
(VWR)) buffers was used as lysis buffer in this study.  Following incubation on 
ice for 10 min, the lysates were centrifuged at 16,000 x g for 10 min at 4°C. The 
supernatants were then transferred to fresh pre-chilled 1.5-mL micro-centrifuge 
tubes and kept on ice.  
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To prepare protein standards, 20 mg of BSA was first dissolved in 1 mL of lysis 
buffer and then serial dilutions were generated to obtain the following 
concentrations: 10, 5, 2.5 1.25, 0.625, 0.3125 mg/ml. 2 µL of the standards (or 
samples) were then added to 1 mL of protein assay dye reagent (Bio-Rad) (diluted 
1:5 with H2O) mixed well by vortexing. 2 µL of the lysis buffer was also added to 
1 mL of protein assay dye reagent and used as a blank. The addition of protein to 
Bradford reagent causes a change in the dye colour, which can be measured by a 
shift in absorbance at 595 nm. The absorbance of the known protein standards was 
measured using a BioPhotometer (Eppendorf) to create a standard curve. Protein 
concentrations of samples of interest were then determined based on the calibrated 
spectrophotometer. Normally, 50 µg of total protein was made up in sample 
loading buffer (4x) (250 mM Tris, pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol, 4 
mg/mL bromophenol blue, 1% (v/v) β-mercaptoethanol (Sigma-Aldrich)) to a 
total volume of 20 µL, to achieve a final concentration of 1x buffer. 
 
A micro-Bradford assay was performed when low protein yields were expected. A 
micro-Bradford assay was essentially identical to the regular Bradford assay 
described earlier except the protein standards were created in Passive Lysis Buffer 
(PLB, Strategen) as follows: 5, 2.5, 1.25, 0.625, 0.3125, 0.156, 0.078 mg/mL. 5 
µL of standards (or samples) were added to 1 mL of protein assay dye reagent. 
The spectrophotometer was calibrated and protein concentrations of the samples 
were estimated as previously described. 
 
2.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using two-gel Mini-PROTEAN® Tetra cell (Bio-Rad) 
in an electrophoresis tank filled with running buffer (25 mM Tris, 220 mM 
glycine, 0.1% SDS). Protein samples and pre-stained protein markers (NEB) were 
denatured by boiling for 5-10 min, vortexed and centrifuged at 16,000 x g for 2 
min at 4 °C. The samples were kept on ice while being loaded into the wells of 
polyacrylamide gel. Typically, SDS-PAGE was run at 200 V for approximately 
1h. 
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2.6 Western blotting 
Western blotting is used to detect and quantify specific proteins in the studied 
sample using specific antibodies. Proteins are first separated based on their 
molecular size using SDS-PAGE (Section 2.5) and then transferred to a Hybond 
ECL nitrocellulose membrane (GE Healthcare) using Mino Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad). Briefly, the gel was placed on the 
nitrocellulose membrane in the cassette between sponges and Whatman paper. The 
cassette was placed in the tank filled with transfer buffer (25 mM Tris, 192 mM 
glycine, 20% methanol) along with an ice pack (to prevent overheating during the 
transfer). The transfer was run for 1h at 100 V. Following the transfer, the 
membrane was briefly stained with Ponceau S (0.1% (w/v) in 5% acetic acid 
(Sigma-Aldrich)) followed by several rinses with water. Stained membrane was 
cut according to the size of the proteins of interest by referencing the protein 
marker. After that, the membrane was destained with PBS/Tween (0.075 M NaCl, 
0.065 M Na2HPO4, 0.015 M NaH2PO4xH2O, 0.1% Tween 20 (Sigma-Aldrich)) 
and blocked in 5% (w/v) non-fat dried milk in PBS/Tween solution at 4°C 
overnight to prevent nonspecific antibody binding to the membrane. After 
blocking, the membrane was incubated with primary antibodies (in 5% 
milk/PBS/Tween solution) for 1h at RT with agitation (Table 2.6.1). The 
membrane was washed for at least 3 times for 15 min in PBS/Tween. The 
horseradish peroxidase (HRP)-conjugated secondary antibodies (in 5% 
milk/PBS/Tween solution) were applied and the membrane was incubated for 1h 
at RT with agitation. The membrane was again washed at least 3 times for 15 min 
in PBS/Tween. After the final wash, the membrane was incubated with Western 
Lightning Chemiluminescence Plus ECL reagent (Perkin Elmer) for 1 min. After 
the supply of Western Lightning Chemiluminescence Plus ECL reagent had been 
discontinued, ECL Prime (or Select for enhanced signal) Western blotting 
detection (Amersham) was used as replacement.  The signal was detected by 
chemiluminescence using a Kodak IM4000 image station.  
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Table 2.6.1:  A. Primary and B. secondary antibodies for Western blotting. 
 
A 
Primary antibodies 
Antibody Source Raised in  Working 
concentration 
Anti-β-Actin (AC-15) Santa-Cruz Mouse monoclonal 1:10,000 
Anti-α-tubulin (DM1A) Sigma-Aldrich Mouse monoclonal 1:2,000 
*Anti-β-gal (OB02) Merck Mouse monoclonal 3 µg/mL 
Anti-β-gal (AB986) Milipore Rabbit polyclonal 1:1,000 
Anti-GFP (Clone 7.1 and 
13.1) 
Roche Mouse monoclonal 0.4 µg/mL 
Anti-p53 (DO-1/Ab-6)  Calbiochem Mouse monoclonal 3 µg/mL 
Anti-MDM2 (IF2/Ab-1)  Calbiochem Mouse monoclonal 3 µg/mL 
Anti-NME1 (NM301) Santa-Cruz Mouse monoclonal 3 µg/mL 
Anti-NME2 (L15) Santa-Cruz Goat polyclonal 3 µg/mL 
*Anti-NME1/2 (ab31019) abcam Rabbit polyclonal 6 µg/mL 
Anti-NME1/2 (C1C3) GeneTex Rabbit polyclonal 1:1,000 
Anti-HA (12CA5) abcam Mouse monoclonal 3 µg/mL 
Anti-HA (16B12) abcam Mouse monoclonal 3 µg/mL 
Anti-Histone H3 (ab1791) Santa-Cruz Mouse monoclonal 3 µg/mL 
Anti-Lamin A/C (636) Santa-Cruz Mouse monoclonal 1:200 
Anti-B23 (NA24) Santa-Cruz Mouse monoclonal 1:200 
 
* Supply discontinued and replaced with alternatives  
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B 
Secondary antibodies (HRP-conjugated) 
Antibody Source Working concentration 
Sheep anti-mouse IgG Amersham 1:2,500 
Donkey anti-rabbit IgG Amersham 1:5,000 
Rabbit anti-goat IgG Jackson 
ImmunoResearch 
Laboratories 
1:20,000 
 
 
2.7 Densitometry 
When necessary, densitometry was performed to quantitatively measure 
chemiluminescence signal intensity using the Kodak Molecular Imaging Software. 
The areas for analysis were defined by manually creating regions of interest 
(ROIs) on the image using the software tools. Volumes of the ROIs selected were 
calculated by the software according to the recorded pixel information.  A blank 
area of the blot was selected as background ROI. The signal intensity for each 
sample was calculated by deducting the sum intensity of the background ROI from 
the sum intensity of each of the sample ROIs. 
 
2.8 Dual-luciferase reporter assays 
Luciferase reporter assay is commonly used to study eukaryotic gene expression. 
The Dual-Luciferase® Reporter Assay System (Promega) was used to 
simultaneously detect the expression of firefly and Renilla luciferase constructs 
which had been transfected into mammalian cells. Briefly, the luciferase assay was 
performed on a 48-well plate which had been co-transfected with luciferase 
constructs, pGL4.11-p53RE-luc2 (firefly luciferase) and pRL-TK (Renilla 
luciferase). At least 24h post-transfection, the old medium was aspirated and cells 
were washed twice with 300 µL of PBS. 150 µL of Passive Lysis Buffer (diluted 1 
in 5 in H2O before use) was then added to each well and incubated with agitation 
for 10 min at RT. The cell lysates were re-suspended and transferred into 1.5-mL 
micro-centrifuge tubes and centrifuged at 16,000 x g for 1 min. The supernatants 
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were transferred into fresh 1.5-mL micro-centrifuge tubes and examined for firefly 
luciferase activity. 30 µL of LAR II (Luciferase Assay Reagent II) was added in a 
fresh tube. 6 µL of the sample was added and vortexed for 1 sec. Immediately, 
luminescence was measured at 560 nm in a Glomax 20/20 luminometer (Turner 
BioSystems). The reaction was then quenched and the Renilla luciferase reaction 
was initiated by adding 30 µL of Stop & Glo® Buffer (supplemented with 50x 
Stop & Glo® Substrate). The tube was vortexed for 5 sec and the luminescence 
generated by Renilla luciferase was measured with an integration period of 10 sec. 
The results were normalised to protein concentrations in the samples, which had 
been determined using a micro-Bradford assay (Section 2.4). 
 
2.9 In situ β-galactosidase (β-gal) assay 
In situ β-gal assay was performed in this study to examine transfection efficiency. 
Cells were transfected with pβ-gal containing the lacZ gene. LacZ gene encodes 
for β-gal that cleaves the glycosidic linkage in X-Gal into galactose and 5-bromo-
4-chloro-3-hydroxyindole, which upon dimerisation and oxidation generates an 
insoluble blue product. The dimerisation and oxidation reactions require the 
transfer of an electron facilitated by ferric and ferrous ions.  
 
Briefly, 24-72h post-transfection, tissue culture medium was aspirated off the 
cells. Transfected cells were washed gently with 2 mL of PBS. Then, 2 ml of 
fixation solution (0.5% (v/v) glutaraldehyde (BDH) in PBS) was added to each 
well and incubated at RT for 15 min. In the meantime, substrate buffer (3 mM 
potassium ferrocyanide, 3 mM potassium ferricyanide, 2% (w/v) X-Gal (BDH), 1 
mM MgCl2) was made up in PBS. After incubation, the fixation buffer was 
aspirated and cells were washed with PBS. Then, 1 mL of substrate buffer was 
added to each well and incubated in a tissue culture incubator at 37°C for 8-10h. 
After that, substrate buffer was removed and cells were rinsed twice with H2O 
before allowed to air-dry.  Cells were then examined using light microscopy. 
Typically, untransfected cells were also assayed to determine baseline levels of 
endogenously expressed β-gal. 
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2.10 Live cell imaging  
The live cell imaging system used in this study was developed and maintained by 
Dr Carlos Rubbi (University of Liverpool) (Figure 2.10.1). The imaging system 
was designed in a way that throughout the imaging process, cell culture vessel was 
kept in a microscope chamber, which was maintained at 37°C and supplied with a 
humidified CO2-filled atmosphere.  
 
Typically, cells were cultured to about 40-50% confluence on the day of 
experiment to allow sufficient room for cell migration, taking cell proliferation 
rate into account. 5 mL of fresh complete growth medium was added into each 
well and 2 mL of H2O was applied in the gap between the wells to maintain 
humidity in the chamber. The cell culture plate was placed and secured inside the 
microscope with the temperature probe submerged in the water-filled gap between 
the wells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10.1: Microscope chamber for live cell imaging.  
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To examine cell migration using the live cell imaging system, at least 2 positions 
were selected per well and imaged with a time-lapse of 3-5 min for 24h (unless 
otherwise stated) using Simple PCI software (Hamamatsu Corporation). The 
recorded images were then combined to create movies and analysed using ImageJ 
software (National Institutes of Health). Plugins enabling tracking and analysis of 
cell motility of individual cells were written by Dr Carlos Rubbi. Whenever 
possible, 20 cells were selected and tracked for each condition. The following 
parameters were determined and compared: -­‐ Total distance travelled – the length of the entire track of each cell -­‐ Net distance travelled – distance in straight line between the first and last 
position of each cell -­‐ Speed – total distance travelled divided by the duration of experiment in 
min -­‐ Persistence – net distance travelled divided by total distance travelled 
 
2.11 Boyden chamber migration assay 
Boyden chamber migration assay was performed to measure the migratory 
potential of cells by examining their ability to migrate from one medium-filled 
compartment to another through a microporous membrane. BD FalconTM Cell 
Culture Inserts for 24-well plates with a polyethylene terephthalate (PET) 
membrane containing 8.0 µm at a density of 6 ± 2 x 104 /cm2 (BD Biosciences) 
were used for migration assays. 600 µL of complete growth medium was added to 
the wells of a 24-well Companion Plate (BD Biosciences). The cell culture inserts 
were placed in the companion plate and then pre-gassed in the tissue culture 
incubator for at least 30 min before seeding. Meanwhile, cells were harvested in 
complete growth media and counted. Typically, 15,000 cells in 300 µL of medium 
were seeded into the insert and the plate was incubated at 37°C, 5% CO2 for 18h. 
After incubation, the inner side of the insert was cleaned rigorously with a cotton 
bud to remove cells that did not migrate through the porous membrane. The insert 
was soaked in PBS and its inner side was further cleaned with a fresh cotton bud. 
Using the REASTAIN Quick-Diff Kit (Reagena), cells successfully migrated 
through the porous membrane were fixed with 1 mL of REASTAIN Quick-Diff 
Fix solution for 10 min. The membrane was then stained with 500 µL of 
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REASTAIN Quick-Diff Red solution for 2 min, followed by 500 µL of 
REASTAIN Quick-Diff Blue solution for 2 min. The insert was rinsed with plenty 
of H2O and left upside down to air-dry. The dried membrane was then carefully 
cut off the insert using a sharp scalpel blade and mounted on a microscope glass 
slide under a cover slip using DPX Mountant (Sigma-Aldrich). Once the slide was 
dry, cells that migrated through the membrane were counted on a microscope.  
 
2.12 Expression microarrays 
 DNA microarray is a useful tool for measuring the expression levels of large 
numbers of genes simultaneously. In this study, the expression profiles of Clone 9 
(over-expressing MDM2) and RFM9 (RING-finger mutant Clone 9) were 
compared with their parental H1299. The RNA samples for each cell line were 
prepared in triplicate on three separate occasions by previous members of our lab 
(Dr Anna Behrendt and Hubert Pakula). Microarray hybridisation of biotinylated 
cDNA was performed using an Affymetrix GeneChip® Human Exon 1.0 ST 
Array by members of the Applied Biology team (led by Prof. Ross Sibsons, 
University of Liverpool). Data analysis was performed by Dr Bryony Lloyd 
(University of Liverpool). Quality control analysis was performed on the raw array 
data using Expression Console software (Affymetrix). Normalisation was 
performed to minimise systemic errors so that the majority of observed differences 
originate from biological variation. The data was then analysed to identify 
differentially expressed genes and validated by quantitative real-time PCR 
(Section 2.13). All of the experimental work and analysis for microarray (except 
validation of expression using quantitative real-time PCR) were performed before 
I joined the lab. 
 
2.13 Quantitative real-time PCR 
2.13.1 Reverse transcription (RT) 
RNA samples were reverse-transcribed to generate complementary DNA (cDNA) 
using the RNA-directed DNA polymerase Moloney Murine Leukemia Virus 
Reverse Transcriptase (M-MuLV RT, NEB). To reverse transcribe RNA, the 
initial reaction components (0.5-2 µg RNA solution, 40 µM Primer: oligo dT 
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(MWG Eurofins), 2.5 mM of each dNTPs (GE Healthcare), nuclease-free H2O) 
were mixed together in a sterile, nuclease free, 0.2-mL PCR tube. The initial 
reaction mixture were heat-denatured at 80°C for 5 min and placed immediately 
onto ice. The remaining components (x10 RT buffer, 10 U/ µL RNase inhibitor, 
M-MuLV RT (NEB)) were then added to the tube and the reverse transcription 
reaction was performed at 42°C for 1h. A reaction without adding the reverse 
transcriptase was also included for each sample as negative control. After 1h, the 
reaction was terminated by heat-inactivating the enzyme at 90°C for 10 min. 
cDNA samples were stored at -20°C for future use. 
 
2.13.2 Standard preparation 
A standard curve can be calculated from external standard samples of known 
amounts and is used to determine the concentration of the target molecule in the 
unknown. Genes of interest selected from the expression microarray analysis were 
amplified by PCR from the cDNA using the primers listed in Appendix 2, after 
performing a gradient PCR to determine their optimum annealing temperatures. 
The PCR products were cloned into pCR2.1 vector using standard cloning 
protocols as described in Section 2.1. Once the identity of the PCR products were 
confirmed by sequencing, plasmids were purified using QIAPrep Spin Miniprep 
Kit (QIAGEN). The DNAs were quantified using NanoDrop ND-1000 (Thermo 
Scientific). Typically 7 standard amounts of each plasmid were prepared by 1:10 
serial dilution on the day of experiment as follows: 5, 5 x 10-1, 5 x 10-2, 5 x 10-3, 5 
x 10-4, 5 x 10-5 and 5 x 10-6 ng per reaction.  
 
2.13.3 qRT-PCR 
Quantitative Real-Time PCR (qRT-PCR) was performed on cDNA samples using 
the iQTM SYBR® Green Supermix and iQ5 multicolor real time PCR detection 
system (Bio-Rad). qRT-PCR was performed for the genes of interest selected from 
the expression microarray analysis and a housekeeping gene (HPRT1) to 
standardise the data. The reactions were set up in clear 96-well PCR microplates 
by combining the reaction components (2x iQTM SYBR® Green Supermix, 
forward primer (0.1 µg/µL), reverse primer (0.1 µg/µL), H2O) except for the 
template cDNA. 50 ng in 5 µL of test cDNA samples, as well as the prepared 
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standards (Section 2.13.2) were pipetted into designated wells of the PCR 
microplate. qRT-PCR was performed in triplicate for each reverse transcription, 
including for minus RT and only H2O negative controls. Following the addition of 
cDNA, the reaction plate was sealed with a Microseal® ‘B’ film (Bio-Rad). The 
plate was briefly centrifuged and then placed into the iQ5 multicolor real time 
PCR detection system to begin the qRT-PCR reaction. The thermal cycling 
parameters and primers used for each gene are shown in Table 2.13.3.1 and 
Appendix 2, respectively. 
 
 
Table 2.13.3.1: Standard cycling parameters for qRT-PCR. 
 
Initial denaturisation 95°C 3 min 
40 cycles 
Denaturisation 
Anneal 
 
94°C 
64°C 
 
30 sec 
30 sec 
Melt curve 95°C to 55°C 1°C per 10 sec 
 
 
2.13.4 Data analysis 
Data analysis was performed using the CFX ManagerTM Software (Bio-Rad). 
Briefly, the cycle number (CT) at which the fluorescence passes a certain threshold 
was determined and reflects the quantity of the sample. To generate a standard 
curve, CT for the 7 standards were determined and plotted against the log of the 
standard amounts, producing a regression line. Using this standard curve, the 
amount of product in the unknown samples within the same real-time PCR run 
was determined. 
 
Melting curve analysis was also performed to determine whether the desired PCR 
product is free from non-specific by-products such as primer-dimer. PCR products 
can be characterised by melting curve analysis because each double-stranded DNA 
molecule has a characteristic melting temperature (Tm), at which 50% of the DNA 
is double-stranded and 50% is melted (i.e. single stranded). A sharp decrease in 
SYBR Green I fluorescence occurs when the temperature reaches the Tm of a 
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PCR product. If the PCR generated only one amplicon, melting curve analysis will 
show only one melting peak (Figure 2.13.4.1). If primer-dimers or other non-
specific products are present, additional melting peaks (normally at a lower 
temperature due to shorter product) will be shown and the corresponding data will 
be eliminated from analysis. 
 
 
 
 
 
Figure 2.13.4.1: Melting curve graphs for real-time PCR. A. Melting curve 
showing a sharp drop in fluorescence signal when the temperature reaches the Tm 
of a PCR product. B. Melting curve peak chart will show only one melting peak if 
only one amplicon was generated by PCR. 
 
 
For each transcription reaction, the average values were determined and 
normalised by dividing the average gene expression value by the expression value 
of the reference gene (HPRT) for the corresponding reverse transcription reaction. 
The normalised relative value was then averaged between the three transcription 
reactions. Since the RNA samples were also present in triplicate, the normalised 
relative values for each gene were averaged between the triplicates and the 
standard deviation was calculated. The relative gene expression was obtained by 
dividing the gene expression level in the test sample by the gene expression level 
in the control sample. 
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2.14 Nucleoside diphosphate kinase (NDPK) assay 
NDPK assay was performed based on the protocol described by Agarwal et al. 
1978 with minor modifications [279]. Accordingly, NDPK activity was 
determined by a coupled pyruvate-lactate dehydrogenase system, with ATP as the 
phosphate donor and thymidine diphosphate (dTDP) as phosphate acceptor 
nucleotides (Figure 2.14.1). The oxidation rate of nicotinamide adenine 
dinucleotide (NADH) was determined by spectrophotometrically measuring the 
decrease in absorbance at 334 nm over time. The consumption of NADH can thus 
act as a surrogate indicator of NDPK activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14.1: NDPK assay principle. NDPK activity was determined by 
measuring the rate of oxidation of NADH spectrophotometrically following the 
formation of ADP from ATP in a coupled pyruvate-lactate dehydrogenase system. 
The consumption of NADH reflects the ADP formation by NDPK. dTDP, 
thymidine diphosphate; dTTP, thymidine triphosphate; PEP, phosphoenol 
pyruvate; ATP, adenosine triphosphate; ADP adenosine diphosphate; LDH, lactate 
dehydrogenase; PK, pyruvate kinase; NADH, reduced nicotinamide adenine 
dinucleotide; NAD+, oxidised nicotinamide adenine dinucleotide. 
 
 
Briefly, 250,000 cells were harvested and centrifuged at 16,000 x g for 5 min at 
4°C. The supernatant was discarded and the cell pellet was washed with 1 ml of 
PBS, followed by centrifugation at 16,000 x g for 5 min at 4°C. The PBS was 
discarded and the cell pellet was lysed with 100 µL of RIPA buffer (Section 2.4), 
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followed by centrifugation at 16,000 x g for 5 min at 4°C. The lysate was then 
transferred to a fresh micro-centrifuge tube and kept on ice. For each reaction, 200 
µL of 5x buffer reagent (250 mM HEPES, 25 mM MgCl2, 375 mM KCl, 5 mg/mL 
BSA), 10 µL of each 100 mM ATP (Sigma-Aldrich), 10 mM NADH (Santa Cruz), 
100 mM phosphoenol pyruvate (PEP, Santa Cruz) and 40 mM dTDP (Sigma-
Aldrich), and 750 µL of H2O (pH7) were mixed and equilibrated at RT. To avoid 
contamination from adenylate kinase activity, 100 µM of adenylate kinase 
inhibitor, P1,P5-Di(adenosine-5’)pentaphosphate (Ap5A, Sigma-Aldrich), was 
added to the reaction mixture. Next, 12.5 U/ml of each pyruvate kinase (Sigma-
Aldrich) and 22.5 U/mL of L-lactate dehydrogenase (Sigma-Aldrich) were added 
to the mixture. Typically 3-5 µL of the lysate was used per 1 mL reaction. The 
reaction mixture was vortexed and then transferred to a UV compatible cuvette. 
The decrease in absorbance (or O.D.) was measured using a Biochrom Libra S32 
spectrophotometer at 334 nm every 12 sec for 2 min. The reaction should be 
linear. If not, the extract was diluted or prepared in a more concentrated form. To 
measure the basal activity, the same amount of RIPA solution was added instead 
of the lysed sample. All measurements were performed in triplicate. The change in 
O.D. per minute was calculated by subtracting the basal activity and then 
converted to enzyme activity, considering the O.D. of a 1 mM NADH solution is 
6.29. A unit of activity is defined as the amount required to convert 1 µmol of 
NADH to NAD+ per minute. 
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2.15 In vivo ubiquitination assay  
In vivo ubiquitination assay was performed to identify target substrates subjected 
to ubiquitination in the cell. Essentially, the assay utilises Ni-NTA agarose beads 
(QIAGEN) to purify 6xHis-tagged ubiquitin (His6-Ub) covalently bound to its 
protein substrates. Histidine residues in the His6-Ub bind to the vacant positions in 
the coordination sphere of the immobilised nickel ions with high specificity and 
affinity. When cell lysates are loaded onto the matrix, His6-ubiquitinated proteins 
are bound whereas other proteins pass through the matrix. Proteins subjected to 
His6-ubiquitination can then be eluted in buffer under denaturing conditions. 
 
The protocol used was adapted from [117]. Briefly, H1299 cells were transfected 
with 15 µg of His6-Ub expression plasmid per 15-cm dish in addition to other 
expression constructs using GeneJuice transfection reagent. 24h post-transfection, 
cells were split 1:2 and further grown for an additional 24h. Cells were then 
harvested into two aliquots: 10% for Western blotting to confirm expression and 
possible degradation of transfected proteins; and the remaining 90% was used in 
the assay for purification with Ni-NTA agarose beads. 
 
To perform the purification assay, cell pellet (90%) was lysed in 2 mL of Buffer 
A, pH8.0 (1 mL per 15-cm dish) (6 M guanidinium-HCl (Fluka), 0.1 M NaH2PO4, 
0.01 M Tris-Cl, 10 mM β-mercaptoethanol, 5 mM imidazole (BDH)) 
supplemented with 10 mM N-ethylmaleimide (NEM, Sigma-Aldrich) to avoid 
deubiquitination. 100 µL/mL of Ni-NTA agarose beads was added to the lysate 
and incubated for 4h on the rotator at RT. Following incubation, Ni-NTA beads 
were washed with 1 mL of each Buffer A, Buffer B, pH8.0 (8 M urea (Fluka), 0.1 
M NaH2PO4, 0.01 M Tris-Cl, 10 mM β-mercaptoethanol), and Buffer C (same 
composition as Buffer B, except at pH6.3), successively. These buffers contain 
strongly denaturing buffers, such as 8 M urea or 6 M guanidinium hydrochloride, 
to prevent co-purification of non-covalently bound proteins. After the washes, 
proteins bound to the beads were eluted into 80-120 µL of 1x sample buffer 
supplemented with 200 mM imidazole and analysed by SDS-PAGE and Western 
blotting. 
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2.16 Immunoprecipitation 
Briefly, H1299 cells in 15-cm dishes were transfected with plasmids of interest 
using GeneJuice transfection reagent. 48h post-transfection, cells were harvested 
and the pellets were frozen at -80°C for at least 1h. The pellets were thawed and 
lysed using SLIP buffer supplemented with protease inhibitors for at least 10 min 
on ice. The lysates were clarified by centrifugation at 16,000 x g for 10 min at 
4°C. The supernatant was immediately transferred into a fresh pre-chilled micro-
centrifuge tube. Bradford assay was performed to determine the protein 
concentration of the samples. A small proportion of the lysate, usually just 
sufficient for conventional Western blot, was used to confirm expression of 
transfected plasmids. The remaining lysates, typically about 4 mg of total protein, 
were used for each point of immunoprecipitation. For immunoprecipitation, the 
lysate volume was made up to 500 µL with SLIP buffer. Protein G Sepharose 
beads (100 µL of 50% slurry per sample) were washed 3 times with 1 mL of SLIP 
buffer and collected by centrifugation at 16,000 x g for 30 sec at 4°C. After the 
last wash, the beads were re-suspended in SLIP buffer to obtain 50% slurry. 50 µL 
of the 50% slurry of washed Protein G Sepharose beads were added to each 
protein sample. The samples were incubated for 1h at 4°C on the rotator to remove 
non-specific proteins bound to the beads. After incubation, the samples were 
centrifuged for 30 sec at 4°C at 16,000 x g and the supernatants were transferred 
to pre-chilled fresh tubes. 2 µg of antibody was added to each of the samples and 
incubated for 1h on rotator at 4°C to allow the antibody to bind to its antigen. 
After that, 50 µL of the 50% slurry of Protein G Sepharose beads was added to 
each of the samples and incubated for 2h at 4°C on a rotator to capture the 
antibody/antigen complex on the beads. The samples were then centrifuged for 30 
sec at 16,000 x g. The supernatants were discarded and the beads were washed 3 
times with 500 µL of SLIP buffer. Following the last wash, the collected beads 
were re-suspended in 40-80 µL of 1x protein sample buffer and stored at -80°C for 
conventional SDS-PAGE and Western blotting analysis. For NDPK assay, 80-100 
µL of RIPA buffer was added to the collected beads containing the 
immunoprecipitated proteins and was immediately used for the assay. 
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2.17 Flow cytometry 
Typically, approximately 1 x 106 cells were harvested in a 15-mL Falcon and 
washed twice with cold PBS by centrifugation at 150 x g for 5 min. Following the 
final wash, PBS was aspirated carefully leaving about 100 µL above the pellet. 
The tube was flicked vigorously for several times to dislodge the cells and to 
create a single cell suspension. In order to allow propidium iodide (PI), a 
fluorochrome, to pass through the cell membrane and intercalate with DNA, cell 
membranes were permeabilised by fixation. For fixation, cells were gently 
vortexed while slowly adding drop-wise 5 mL of 70% ice-cold ethanol. The 
samples were left on ice for at least 1h (or up to two weeks at 4°C) before being 
further processed. Fixed cells were pelleted by centrifugation at 150 x g at 4°C and 
washed twice in cold PBS/0.1% Tween (Sigma-Aldrich) to remove residual 
ethanol.  
 
As PI is also able to bind non-specifically to RNA, specific staining of DNA 
requires RNase A treatment. A solution of RNase A was prepared in advance as 
follows. 10 mg/mL of RNase A (Sigma-Aldrich) was made up in 0.01 M sodium 
acetate (pH 7.4), followed by boiling at 100°C for 15 min to inactivate DNase 
contaminants. The solution was cooled and 1/10th volume of 1 M Tris HCl (pH7.4) 
was added. The RNase A solution was aliquoted and stored at -20°C.  
 
After the last wash, PBS/Tween was removed and the cell pellets were re-
suspended in 100 µL of 10 mg/mL RNase A and left on ice for 5 min. Staining 
solution containing 850 µL of PBS and 50 µL of 1 mg/mL PI (Sigma-Aldrich) in 
PBS was added to each sample and left on ice in the dark for 30 min. Flow 
cytometry was performed on the samples using the Becton Dickinson 
FACSCaliburTM flow cytometer. Typically, 20,000 events were recorded for each 
run. Analysis was performed using FlowJo Analysis Software. The flow cytometry 
parameters used for analysis in this study were as follows: FL2 linear to detect PI, 
FL1-Height (EYFP Log), FL2-Width linear, FL2-Area linear, FS linear and SS 
linear. 
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2.18. Hypotonic lysis and sub-cellular fractionation 
The hypotonic lysis and sub-cellular fractionation methods were performed based 
on the nucleolar isolation protocol described by Lam and Lamond 2006 [387]. 
Briefly, cells were harvested by trypsinisation and collected in a 50-mL Falcon 
tubes. The cells were washed three times with ice-cold PBS at 218 x g at 4°C. 
After the final wash, the cells were re-suspended in 5 mL of Buffer A (10 mM 
HEPES (pH7.9), 10 mM KCl, 1.5 mM MgCl2, 0.5 mM Dithiothreitol (DTT, 
Sigma-Aldrich)), supplemented with protease inhibitors (Section 2.4), and 
incubated on ice for 5 min. A small drop of the cell suspension was put on a glass 
slide and checked under a phase-contrast microscope, using a 20x objective. The 
cells should be swollen, but not burst. The cells were maintained in this hypotonic 
condition by being incubated at 4°C. The cell suspension was transferred to a pre-
cooled 7-mL Potter homogeniser and homogenized on ice for 10 times using a 
tight pestle. The homogenised cells were checked under a phase-contrast 
microscope after every 10 strokes. Homogenisation was stopped when more than 
90% of the cells were burst, leaving intact nuclei with various amounts of 
cytoplasmic material attached. In most cases, the presence of this cytoplasmic 
contamination does not affect the final purity of the isolated nucleoli. The 
homogenised cells were centrifuged at 218 x g at 4°C for 5 min. For NDPK assay, 
the supernatant was kept on ice and used immediately as a hypotonic lysed cell 
sample. 
 
For preparation of different sub-cellular fractions, the supernatant was retained as 
cytoplasmic fraction and stored at -80°C. The pellet contains enriched, but not 
highly pure, nuclei. The pellet was re-suspended with 3 mL of S1 solution (0.25 M 
sucrose (Sigma-Aldrich), 0.5 mM MgCl2, supplemented with protease inhibitors 
(Section 2.4)). The re-suspended pellet was carefully layered over with 3 mL of S2 
solution (0.35 M sucrose, 0.5 mM MgCl2, supplemented with protease inhibitors 
(Section 2.4)), making sure the two layers were cleanly separated. The sample was 
then centrifuged at 1,430 x g for 5 min at 4°C to obtain a cleaner nuclear pellet. 
The pellet was re-suspended with 3 mL of the S2 solution. The nuclear suspension 
was sonicated with 6 burst, with 10-sec intervals between each burst, using a 
sonicator. The sonicated nuclei were checked under a phase-contrast microscope. 
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They should be virtually no intact cells and nucleoli should be readily observed as 
dense, refractile bodies. The sonicated sample was then layered over 3 mL of the 
S3 solution (0.88 M sucrose, 0.5 mM MgCl2, supplemented with protease 
inhibitors (Section 2.4)) and centrifuged at 3,000 x g for 10 min at 4°C. The pellet 
contains nucleoli, whereas the supernatant was retained as nucleoplasmic fraction 
and stored at -80°C. The nucleoli were re-suspended with 0.5 mL of S2 solution, 
followed by centrifugation at 1,430 x g for 5 min at 4°C, to obtain a pellet 
containing highly purified nucleoli. The nucleoli was re-suspended in 0.5 mL of 
the S2 solution and stored at -80°C.  
 
The cytoplasmic, nucleoplasmic and nucleoli fractions of U2OS cells used in this 
study were kindly provided by Dr Carlos Rubbi. A Bradford assay (Section 2.4) 
was performed for the U2OS cell fractions to quantify their protein levels. The 
samples were added with appropriate amounts of sample buffer for SDS-PAGE 
and Western blotting analysis.  
 
2.19 MTT assay 
MTT assay was used as a measure of cell viability/growth. Typically, cells were 
harvested by trypsinisation and re-suspended in complete growth medium. Either a 
haemocytometer or Beckman coulter counter (Z2 Coulter® Particle Count and 
Size Analyser) was used to count the concentration of cells. 2,000 cells in 200 µL 
of growth media were seeded into each well of a 96-well plate. Typically, cell 
proliferation was monitored over 7 days. Accordingly, cells were seeded into 7 
plates and let proliferate with medium changing every day. After 24h (Day 0), 20 
µL of 5 mg/mL sterilised MTT (Molekula) in PBS was added to each well, in 
addition to the existing medium. The plate was incubated for 3h at 37°C in a tissue 
culture incubator. After incubation, 190 µL of solution was aspirated off each well 
and discarded. 100 µL of DMSO was added to each well. The plate was then 
incubated for a further 30 min at 37°C. The absorbance was measured at an OD of 
595 nm using a plate reader. The procedure was repeated for plates Day 1 to Day 6 
in order to generate a growth curve. 
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3.1 Microarray analysis of the effects of MDM2 on gene expression 
Following the findings that MDM2 promotes cell motility in a RING-finger-
independent manner [384], gene expression profiles were studied using exon array 
analysis to identify the differences and overlaps in the expression changes induced 
by wt MDM2 (Clone 9) and a RING-mutant (RFM) of MDM2 (C464A) in 
parental H1299 cells. It was hypothesised that there is a possibility that genes that 
are mutually regulated in both Clone 9 and RFM9 represent genes that are 
involved in the same pathways to promote cell motility. RNAs were extracted 
from these cells (by Mr Hubert Pakula, a former member of the laboratory) for 
expression analysis by Dr Bryony Llyod. Two attempts at the microarray analysis 
experiment were made. In the initial experiment, 32 genes were found to be 
mutually regulated for more than 2.25-fold in Clone 9 and RFM compared to 
H1299 cells. A complete list of differentially regulated genes is shown in 
Appendix 3. However, since there was a high variability in the control H1299 
RNA samples (Batch 1), the microarray experiment was repeated using freshly 
extracted H1299 RNA (by Dr Anna Behrendt, a former member of the laboratory) 
(Batch 2) as a control. In the second microarray analysis experiment, 151 genes 
were identified to be mutually regulated in Clone 9 and RFM. The list of 
differentially regulated genes identified in the second attempt is represented in 
Appendix 4. All of the experimental work and analysis for microarray (except 
validation of expression using quantitative real-time PCR) were performed before 
I joined the laboratory. 
 
3.1.1 Validation of exon array analysis 
Following the identification of two lists of genes that are mutually regulated in 
Clone 9 and RFM9, validation for the expression differences obtained from 
microarray analysis was performed. For this purpose, four genes were selected 
from these lists based on the relative mRNA expression level (normalised to the 
expression level in the parental H1299 cells) and a literature review that suggested 
a role in regulating motility/invasion/metastasis and that therefore they could be 
involved in the observed migratory phenotype of MDM2 overexpressing cells. 
The selected genes are TUBA1B, RPS24, ADAMTS1, and PCDHB2. A brief 
summary of the functions of the selected genes is presented in Table 3.1.1.1 
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Table 3.1.1.1: The list of genes selected for validation by qRT-PCR based on 
the expression differences identified by microarray analysis. 
 
Fold change  Gene 
symbol 
 
 
Full name 
 
 
 
Clone 9 
vs 
H1299 
RFM9 
vs 
H1299 
Function 
 
 
 
 
TUBA1B 
 
Tubulin alpha 1b 
 
 
 
 
 
 
 
22.29 
 
 
 
 
 
 
 
32.34 
 
 
 
 
 
 
 
-­‐ Major constituent of 
microtubules 
-­‐ Essential in cell 
division 
-­‐ Increased expression is 
associated with poor 
prognosis in HCC 
[388] 
 
 
RPS24 
 
Ribosomal 
protein S24 
 
 
 
 
 
 
8.69 
 
 
 
 
 
 
 
8.89 
 
 
 
 
 
 
 
 
-­‐ A component of the 
40S ribosomal subunit 
-­‐ Upregulated in HCC 
[389] 
-­‐ Important in rRNA 
processing and 
proliferation [390] 
 
 
ADAMTS1 
 
A disintegrin and 
metallopeptidase 
with 
thrombospondin 
type 1  
 
 
 
 
 
6.43 
 
 
 
 
 
 
 
 
 
3.34 
 
 
 
 
 
 
 
 
 
 
-­‐ Member of the matrix 
metalloproteinase 
family  
-­‐ Impairs angiogenesis, 
tumour growth, and 
metastasis [391, 392] 
-­‐ May contribute to the 
metastatic program 
[393] 
 
 
PCDHB2 Protocadherin 
beta 2 
 
 
 
6.82 
 
 
 
 
4.41 
 
 
 
 
 
-­‐ Roles in tissue 
morphogenesis and 
formation of neuronal 
circuits [394] 
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In order to validate the expression differences observed in the selected targets 
presented in Table 3.1.1.1, qRT-PCR was performed using RNA extracted from 
H1299, Clone 9, RFM9 and EV Cl.1 of H1299 (as a negative clonal control). RNA 
extraction was performed in triplicates and the quality of RNA was examined 
before proceeding to qRT-PCR analysis. Whilst it is difficult to detect mRNA 
since it comprises only 1-3% of total RNA, main components of the ribosomal 
RNA (rRNA)  28S and 18S are easily detectable because they comprise more than 
80% of total RNA. 28S and 18S rRNAs can be visualised as two clear separate 
bands on agarose gel stained with ethidium bromide. Since 28S and 18S rRNAs 
are derived from the same precursor rRNA, both molecules have the same number 
of copies. Thus the ratio of 28S:18S rRNA depends only on their size, which is 
approximately 5 kb and 1.9 kb (in mammals), respectively. Theoretically, the ratio 
of 28S:18S is estimated at 2.7:1 but a ratio of 2.1 is indicative of good quality, 
intact RNA. The ratio of the intensity of these bands can be used as a measure of 
the integrity of the extracted RNA since these two rRNA species have different 
degradation rates, in which 28S rRNA is more susceptible to degradation than 18S 
rRNA [395]. The ratio of the 28S:18S rRNA in the analysed RNA samples was 
approximately 2:1 (Figure 3.1.1.1) suggesting that the RNAs were not degraded.  
 
An OD 260/280 ratio is used to estimate the nucleic acid purity and an ideal value 
for RNA is 2.0. The ratios obtained for the extracted samples (Table 3.1.1.2) are 
slightly lower (above 1.83), which could be due to the presence of protein 
contaminants. The OD 260/230 ratio is an alternative indicator of nucleic acid 
purity. The ratio should be higher than 2.0 and lower ratios may indicate the 
presence of inorganic contaminants that absorb at 230 nm (such as guanidinium 
thiocynate and EDTA). As shown in (Table 3.1.1.2), most of the obtained OD 
260/230 ratios are mostly above 2.0, suggesting that the samples are essentially 
free of inorganic contaminants. Overall, the RNAs extracted were suitable for 
qRT-PCR analysis. 
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Table 3.1.1.2: Spectrophotometrical quantification of the RNA used for qRT-
PCR. RNA was extracted from the indicated cell lines on three separate occasions 
(I-III). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples OD 260/280 OD 260/230 
H1299 I 1.88 2.35 
H1299 II 1.90 2.28 
H1299 III 1.91 2.35 
Clone 9 I 1.92 1.79 
Clone 9 II 1.90 2.13 
Clone 9 III 1.88 2.29 
RFM9 I 1.89 2.20 
RFM9 II 1.84 2.40 
RFM9 III 1.83 2.34 
EV I 1.86 2.28 
EV II 1.88 2.34 
EV III 1.89 2.14 
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Figure 3.1.1.1: Analysis of the integrity of RNA used for qRT-PCR. RNA was 
extracted from H1299, Clone 9, RFM9 and EV Cl.1 (derived from H1299) on 
three separate occasions. A. Western blot of the lysate samples of the indicated 
cells used for RNA extraction. Primary antibodies used were anti-MDM2 (IF2) 
and anti-β-actin (AC-15). B. The RNA integrity was examined by running 500 ng 
of total RNA on a 1.2% (w/v) agarose gel stained with EtBr and visualized using 
UV light. The 28S and 18S RNA bands are indicated. 
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qRT-PCR was performed as described in Materials and Methods Sections 2.13.3 
and 2.13.3. The relative expression levels (normalised to HPRT) of the four 
selected targets in H1299, Clone 9, RFM9 and EV Cl.1 are represented in Figure 
3.1.1.2. Most of the determined relative gene expression levels of the four selected 
genes in the indicated cells did not validate gene expression obtained from the 
exon array analysis. No difference in mRNA expression of TUBA1B was detected 
in Clone 9 or RFM9, even though exon array indicates a 22- and 32-fold change in 
expression, respectively, compared to H1299. Only ADAMTS1 expression in 
Clone 9 was significantly higher than in parental H1299 (p=0.012). However, no 
difference in ADAMTS1 expression level was observed in RFM9. 
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Figure 3.1.1.2: Relative expression levels of the ADAMTS1, PCDHB2, RPS24, 
and TUBA1B in the indicated cell lines. qRT-PCR was performed on RNA 
extracted from H1299, Clone 9, RFM9 and EV Cl.1. The histograms show mean 
of the average expression levels (normalised to HPRT expression) in three 
replicate RNA samples. Error bars indicate standard errors of mean. 
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3.1.2 Validation of gene expression changes in transiently transfected cells 
To exclude the possibility of clonal variation affecting ADAMTS1 gene 
expression observed in Clone 9, qRT-PCR was repeated in transiently transfected 
H1299 cells. H1299 cells were transfected with plasmids expressing wt MDM2, 
RFM and EV, using both GeneJuice and Lipofectamine 2000, as described in 
Figure 3.1.2.1B. A small aliquot of cells from each condition was used for western 
blot analysis. Figure 3.1.2.1A shows the expected expression of MDM2 in 
transfected cells. Higher levels of MDM2 were detected in cells transfected with 
RFM compared to wt MDM2. This is because RFM lacks an E3-ligase activity for 
targeting MDM2 for proteasomal degradation. In addition, in comparison to 
GeneJuice, transfection using Lipofectamine 2000 also leads to a marginally 
higher expression of the plasmids. RNA was extracted from the transfected 
samples and the RNA quality was tested as described previously in Section 3.1.1. 
Based on the 28S:18S rRNA, OD 260/280 and OD 260/230 ratios of the analysed 
samples (Figure 3.1.2.1B and Table 3.1.2.1), the extracted RNA was suitable for 
qRT-PCR analysis. The relative expression levels (normalised to HPRT) of the 
four selected targets in transfected H1229 cells are represented in Figure 3.1.2.2. 
No difference in expression of the selected genes was observed in all the 
transfected cells, regardless of the transfection reagents used (Figure 3.1.2.2). This 
observation is in accordance with analysis of RNA extracted from stable clones, 
but in contradiction to the exon array analysis. 
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Table 3.1.2.1: Spectrophotometrical quantification of the RNA extracted 
from transfected cells used for qRT-PCR. RNA was extracted from transiently 
transfected H1299 for qRT-PCR analysis. GJ, GeneJuice; Lipo, Lipofectamine 
2000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples OD 260/280 OD 260/230 
EV-GJ 2.10 1.38 
MDM2-GJ 2.02 2.23 
RFM-GJ 2.06 2.16 
EV-Lipo 2.05 2.11 
MDM2-Lipo 2.05 2.21 
RFM-Lipo 2.04 2.23 
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Figure 3.1.2.1: Analysis of the integrity of RNA extracted from transiently 
transfected cells. H1299 cells were transfected with either 10 µg of wt MDM2, 
RFM, or EV in 10-cm dishes, using GeneJuice (GJ) or Lipofectamine 2000 (Lipo), 
as indicated. A. Western blot of the lysate samples of the indicated cells used for 
RNA extraction. Primary antibodies used were anti-MDM2 (IF2) and anti-β-actin 
(AC-15). B. RNA integrity of RNA extracted from transfected cells was examined 
by running 500 ng of total RNA on a 1.2% (w/v) agarose gel stained with EtBr 
and visualized using UV light. The 28S and 18S RNA bands are indicated. 
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Figure 3.1.2.2: Relative expression levels of the ADAMTS1, PCDHB2, RPS24, 
and TUBA1B in transiently transfected H1299 cells. qRT-PCR was performed 
on RNA extracted from H1299 transfected with wt MDM2, RFM, or EV, using 
GeneJuice (GJ) or Lipofectamine 2000 (Lipo). The histograms show mean of the 
average expression levels (normalised to HPRT expression) in RNA samples. 
Error bars indicate standard error of mean. 
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3.1.3 Validation of gene expression changes in transient transfected cells 
qRT-PCR analysis presented in Section 3.1.1 suggests that mRNA expression of 
ADAMTS1 in Clone 9 is more than 40-fold greater than H1299 and EV Cl.1 
controls. However, concerns were raised as this result was not reproducible in 
H1299 transfected with wt MDM2 (Section 3.1.2). In order to eliminate the 
possibility of this result being an effect of clonal selection, qRT-PCR was repeated 
for ADAMTS1 using two additional clones that express high levels of MDM2 
(MDM2 Cl.1 and Cl.3). EV Cl.2 was also included as an additional negative 
control. RNA extraction was performed in triplicates for H1299, EV C1.1 and 
Cl.2, Clone 9, and MDM2 Cl.1 and Cl.3. The quality of RNA was examined, as 
described in Section 3.1.1, before proceeding to qRT-PCR analysis. Based on the 
28S:18S rRNA, OD 260/280 and OD 260/230 ratios of the analysed samples 
(Table 3.1.3.1 and Figure 3.1.3.1), the extracted RNA was suitable for qRT-PCR 
analysis. The relative expression levels (normalised to HPRT) of ADAMTS1 in 
indicated clones are represented in Figure 3.1.3.2. Only Clone 9 shows higher 
mRNA expression compared to H1299 and H1299 clonal derivatives EV Cl.1 and 
Cl.2 (about 150-fold). No difference in ADAMTS1 expression was observed in 
the other two high MDM2 expressing clones (Figure 3.1.3.2). This observation 
indicates that the expression changes of ADAMTS1 observed in Clone 9 were 
most likely a result of chance differences selected through cell cloning. An 
alternative explanation might be related to the difference in dynamic range 
between microarray platforms and qRT-PCR. The dynamic range represents the 
range of the initial mRNA concentrations, over which accurate expression levels 
can be determined. Most commercially available microarray platforms have a 
dynamic range that is lower by several orders of magnitude than that achievable 
by qRT-PCR. Therefore, it is unlikely that the larger dynamic range of qRT-PCR 
assays, which provides a more sensitive detection of expression changes, would 
have under-represented the differences in expression observed through microarray 
analysis. Instead, we question the reliability of the microarray analysis, 
considering we had issues with control variability in the first instance (Section 
3.1).  As we were unable to validate the expression differences obtained from 
microarray analysis, we decided to terminate this particular line of investigation. 
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Table 3.1.3.1: Spectrophotometrical quantification of the RNA used for qRT-
PCR. RNA was extracted from the indicated cell lines on three separate occasions 
(I-III). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples OD 260/280 OD 260/230 
H1299 I 1.81 2.37 
H1299 II 1.76 2.39 
H1299 III 1.74 2.38 
EV Cl.1 I 1.82 2.42 
EV Cl.1 II 1.85 2.34 
EV Cl.1 III 1.79 2.23 
EV Cl.2 I 1.87 2.39 
EV Cl.2 II 1.82 2.3 
EV Cl.2 III 1.77 2.33 
Clone 9 I 1.86 2.39 
Clone 9 II 1.82 2.31 
Clone 9 III 1.84 2.38 
MDM2 Cl.1 I 1.87 2.39 
MDM2 Cl.1 II 1.8 2.32 
MDM2 Cl.1 III 1.8 2.37 
MDM2 Cl.3 I 1.8 2.32 
MDM2 Cl.3 II 1.79 2.37 
MDM2 Cl.3 III 1.82 2.35 
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Figure 3.1.3.1: RNA integrity of RNA extracted from clonal cells for qRT-
PCR. RNA was extracted from H1299, EV Cl.1 and Cl.2, Clone 9, MDM2 Cl.1 
and Cl.3 on three separate occasions (I-III). A. Western blot of the lysate samples 
of the indicated cells used for RNA extraction. Primary antibodies used were anti-
MDM2 (IF2) and anti-β-actin (AC-15). B. The RNA integrity was examined by 
running 500 ng of total RNA on a 1.2% (w/v) agarose gel stained with EtBr and 
visualized using UV light. The 28S and 18S RNA bands are indicated. 
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Figure 3.1.3.2: Relative expression levels of the ADAMTS1 in clonal cells. 
qRT-PCR was performed on RNA extracted from H1299, EV Cl.1 and Cl.2, Clone 
9, MDM2 Cl.1 and Cl.3. The histograms show mean of the average expression 
levels (normalised to HPRT expression) in three replicate RNA samples. Error 
bars indicate standard errors of mean. 
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3.2 Investigation of the mechanisms of action of MDM2 in antagonising 
NME2 motility suppressive effect 
3.2.1 RCC 117 cells are refractory to transfection using GeneJuice 
In order to study the effect of high levels of MDM2 in promoting cell motility in 
RCC, cells had to be engineered to overexpress exogeneously introduced MDM2 
or other genes of interest. This could be achieved through transient transfection of 
the cells. To establish the optimal conditions for transfection using GeneJuice, 
RCC cell line 117 (p53 wild-type) and non-small cell lung carcinoma cell line 
H1299 (positive control, since we know that these cells transfect well) were 
transfected with 1 µg of pβ-gal per well of a 6-well plate using different ratios of 
DNA:GeneJuice. Following transfection, the transfection efficiency was estimated 
based on in situ β-gal staining. Consistent with previous observations by past 
members from our laboratory, 117 cells were refractory to transfection, regardless 
of the DNA:GeneJuice ratios used (Figure 3.2.1.1). On the other hand, H1299 
cells are easy to transfect and maintain. They possess a homozygous partial 
deletion of TP53 gene and are therefore p53 null, which makes them an excellent 
system for studying p53-independent processes. Since they are also easy to 
transfect, this makes them a good cell line for transient transfection experiment to 
examine the effects of protein of interest on cell motility. A decent transfection 
efficiency can aid the elucidation of the effect of cell population expressing 
exogenous proteins of interest.   
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Figure 3.2.1.1: In situ β-gal staining on RCC 117 and H1299 cells 24h post-
transfection using GeneJuice. 117 cells were refractory to transfection, 
regardless of the DNA:GeneJuice ratios used whereas H1299 cells were easily 
transfectable, with transfection efficiency of about 30% in this case.  
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3.2.2 Optimisation of co-transfection efficiency for live cell imaging motility 
assay 
Investigation of the effect of a protein on cell motility using live cell imaging often 
involves co-transfection of plasmid of interest with a fluorescent plasmid, based 
on the assumption that transfected cells that express fluorescent protein also 
express the protein of interest. Hence it was important to estimate the proportion 
of plasmid of interest co-transfected with fluorescent plasmid. We also aimed to 
examine whether the percentage of co-transfection was dependent upon (a) the 
ratio of the plasmid of interest to fluorescent plasmid used and; (b) the duration for 
which transfected cells were incubated before imaging. For this purpose, a co-
transfection experiment was performed using pEGFP-N1 as a surrogate indicator 
for the plasmid of interest and pCEP4-mCherry as the fluorescent plasmid for cell 
tracking. Using GeneJuice transfection reagent, 1.75 µg or 3 µg of pEGFP-N1 
were co-transfected with a constant amount of pCEP4-mCherry (0.25 µg) in 
H1299 cells. Transfected cells were imaged at 24h, 36h and 48h post transfection, 
as shown in Figure 3.2.2.1A. Transfected cells were split from a mother plate  
(P1), which was used for 24h and 36h post-transfection imaging, into a new plate 
(P2) for 36h and 48h post-transfection imaging.  
 
As shown in Figure 3.2.2.1B, of all the transfected cells, more than 70% of cells 
expressed both EGFP and mCherry (Average = 82.9% +/- (S.E.M.) 2.43). The co-
transfection efficiency does not seem to depend upon the amount of EGFP used 
and the duration of incubation after transfection. Since only cells that are 
fluorescent with mCherry will be tracked, it is reasonable to only take mCherry 
transfected cells into account to calculate the percentage of cells co-transfected 
with EGFP. More than 85% of the cells transfected with mCherry were also 
transfected with EGFP, with an average co-transfection efficiency of 
approximately 93.6 +/- 1.39 (S.E.M)%. This suggests that there is more than 9 out 
of 10 chance that, when selecting a cell amongst cells expressing mCherry, the 
selected cell will also express the protein of interest. This is useful for the 
experimental design of our live cell imaging system since it is important to ensure 
that cells selected for tracking represented cells that have also uptaken the gene of 
interest. 
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Figure 3.2.2.1: Co-expression of mCherry and EGFP. Using GeneJuice 
transfection reagent, H1299 cells were transfected with either 1.75 µg or 3 µg of 
pEGFP-N1 and 0.25 µg pCEP4-mCherry as indicated. Transfected cells were 
imaged at 24h, 36h and 48h post-transfection. Transfected cells were split from a 
mother plate  (P1), which was used for 24h and 36h post-transfection imaging, 
into a new plate (P2) for 36h and 48h post-transfection imaging. A. Image of the 
same transfected cells expressing mCherry and EGFP, viewed with individual and 
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combined fluorescence and/or phase contrast (PC). B. Percentage of EGFP only, 
mCherry only and both EGFP and mCherry transfected cells. C. Percentage of 
EGFP expressing cells over total mCherry expressing cells. P-values were derived 
from statistical analyses by Student’s t-test. Error bars indicate standard error. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   138	  
3.2.3 Live cell imaging of cell motility 
3.2.3.1 Analysis of the effects of NME2, NME2 kinase dead mutant 
NME2H118F, MDM2 and MDM2 RING finger mutant on cell motility  
MDM2 has been shown to promote cell motility independently of its E3 ligase 
activity [384]. MDM2 has also been shown to promote cell motility through 
antagonising NME2 motility suppressive effect [183]. Both studies utilised 
Boyden chamber motility assay method to examine cell motility. In the light of 
these studies, we aimed to examine the effects of MDM2 and NME2 on cell 
motility using live cell imaging system to see whether live cell imaging system 
would be a reliable method for such investigation in the future. Accordingly, the 
effects of NME2, NME2H118F (kinase dead mutant), MDM2 and MDM2 RING-
finger mutant (RFM) that lacks E3 ligase activity on motility were examined. In a 
6-well plate, H1299 cells were co-transfected with 1.75 µg of plasmids encoding 
the aforementioned proteins and 0.25 µg of pCEP4-mCherry, which serves as an 
indicator of transfected cells for cell tracking. Live cell imaging was performed (as 
described in Materials and Methods Section 2.10) on transfected cells 30h post-
transfection for a duration of 20h (Please see Appendix 5 for movies). Two 
positions were selected from each well for imaging. About 10-20 of each mCherry 
expressing and non-mCherry expressing cells were tracked for each position 
selected and then analysed in terms of total distance travelled, average speed, and 
net distance travelled (Figure 3.2.3.1.1A, B and C). Transfected cells were also 
harvested for western blot analysis 30h after transfection to confirm proteins 
expression as shown in Figure 3.2.3.1.1D. Non-mCherry expressing cells 
(indicated in grey) were also tracked in each well for motility analysis to ensure 
that any difference detected in mCherry expressing cells was not due to mCherry 
itself but to the ectopically introduced NME2 or MDM2. However, no obvious 
difference was observed in terms of total distance, average speed, net distance 
travelled, and persistence (net distance/ total distance) of cells transfected with 
NME2 or MDM2, in comparison to their corresponding empty vectors. Persistence 
can be used as an indicator of the directionality of cell migration, in which 
persistence is positively correlated with directionality. However, it is difficult to 
interpret the motility data obtained here, since there appears to be great variability, 
especially in terms of net distance travelled (Figure 3.2.3.1.1C).  
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Figure 3.2.3.1.1: Analysis of the effects of NME2, NME2 kinase dead mutant 
NME2H118F, MDM2 and MDM2 RING finger mutant on cell motility. 
H1299 cells were co-transfected with 1.75 µg plasmids of interest and 0.25 µg 
pCEP4-mCherry, which serves as an indicator of transfected cells for cell tracking 
purpose. Live cell imaging was performed on the transfected cells 30h post-
transfection for a duration of 20h. mCherry expressing cells were tracked for 
motility analysis in terms of A.  total distance, B. average speed, C. net distance 
travelled, and D. persistence (net distance/ total distance) for mCherry expressing 
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cells. Non-mCherry expressing cells (indicated in grey) were also tracked in each 
well for motility analysis to ensure that any difference detected in mCherry 
expressing cells were not due to mCherry itself but the ectopically introduced 
NME2 or MDM2.  E. Western blot analysis for transfected cells 30h post-
transfection. Anti-MDM2 (IF2), anti-β-actin (AC-15) and anti-NME2 (L15) 
primary antibodies were used. Error bars indicate standard error. 
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3.2.3.2 Analysis of the effects of MDM2 overexpression on cell motility  
Since the motility results generated using live cell imaging system (Section 
3.2.3.1) were not consistent with those obtained using the more widely used 
Boyden chamber motility assay, it was questionable whether the live cell imaging 
system used in this study was a reasonable method for measuring cell motility.  
Since high levels of MDM2 have been shown to promote cell motility using 
Boyden chamber motility assay in a published paper by Polański et al. [384], we 
aimed to use the effect of MDM2 on cell motility as a control to examine whether 
the co-transfection method described in Section 3.2.2 can be used for examining 
cell motility using the live cell imaging system.  
 
H1299 cells were transfected, as described in Figure 3.2.3.2.1, with an increasing 
amount of MDM2 and 0.25 µg of mCherry using GeneJuice to examine whether 
increased MDM2 levels would result in a positive correlative change in cell 
motility as measured using live cell imaging. Motility assay was performed using 
live cell imaging 30h post-transfection for a duration of 12h (Please see Appendix 
6 for movies). Cell motility was analysed in terms of total distance travelled, 
average speed, net distance travelled, and persistence (net distance/ total distance) 
(Figure 3.2.3.2.1A, B, C and D). Contrary to the cell motility promoting effect of 
MDM2 observed when Boyden chamber motility assay was used, no difference in 
cell motility was observed with increasing amount of MDM2, using the co-
transfection coupled with live cell imaging system (Figure 3.2.3.2.1). Cells 
expressing mCherry were also tracked in their phase contrast mode (indicated in 
green), as concerns were raised as to whether mCherry saturation could affect cell 
tracking and therefore motility. However, when mCherry expressing cells were 
tracked using phase contrast mode, the levels of different cell motility parameters 
examined here were comparable to those seen in the presence of mCherry 
fluorescence, indicating that mCherry saturation does not affect cell motility. 
Overall, we failed to confirm the effect of MDM2 on cell motility using live cell 
imaging system. 
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Figure 3.2.3.2.1: Analysis of the effects of increasing level of MDM2 on cell 
motility using live cell imaging. Motility assay was performed using live cell 
imaging on transfected H1299 cells with an increasing amount of MDM2 and 0.25 
µg of pCEP4-mCherry using GeneJuice 30h post-transfection for 12h. Non-
mCherry expressing cells (indicated in grey) were also tracked in each well for 
motility analysis to ensure that any difference detected in mCherry expressing 
cells were not due to mCherry itself but the ectopically introduced MDM2. Two 
positions were selected from each well for imaging. About 10-20 of each mCherry 
expressing and non-mCherry expressing cells were tracked for each position 
selected and then analysed in terms of total A. distance travelled, B. average 
speed, C. net distance travelled, and D. persistence (net distance/ total distance).  
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In an independent experiment, the effect of high levels of MDM2 on cell motility 
was examined using Boyden chamber motility assay as described in Materials and 
Methods (Section 2.11). Essentially, H1299 cells were transfected in triplicates 
with MDM2, RFM or an EV control followed by Boyden chamber motility assay 
and western blot analysis 30h after transfection. As shown in Figure 3.2.3.2.2, 
cells expressing high levels of MDM2 demonstrate increase in cell motility and 
this effect was independent of MDM2 RING-finger. This result is consistent with 
the published data in Polański et al. (2010) which showed that MDM2 promotes 
cell motility and invasiveness in a RING-finger independent manner [384]. This 
result also suggests that Boyden chamber is a more reliable method compared to 
live cell imaging for assessing cell motility in our study. 
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Figure 3.2.3.2.2: Analysis of the effects of increasing level of MDM2 on cell 
motility using Boyden chamber. A. H1299 cells were transfected in triplicates 
with MDM2, RFM or an empty vector (EV) control followed by Boyden chamber 
motility assay 30h after transfection. P-values were derived from statistical 
analyses by Student’s t-test (n=3). Error bars indicate standard error. B. Western 
blot showing the levels of MDM2 and RFM protein expression after transfection. 
Actin was used as a loading control.  Anti-MDM2 (IF2) and anti-β-actin (AC-15) 
primary antibodies were used. 
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3.2.4 Analysis of the effects of a stable NME2 knockdown on cell motility and 
NDPK activity 
Since we were unable to establish a reliable live cell imaging system to assay cell 
motility, a more widely used Boyden chamber motility assay was used instead to 
examine the effects of NME2 on cell motility. Stable knockdown clones 
expressing short hairpin (sh)RNA NME2 in H1299 and Clone 9 (H1299 over-
expressing MDM2) cell lines (generated by Dr Maria Maguire, a past member of 
our laboratory) were used for this purpose. Clones generated using H1299 as 
parental cell line were named with a preceding ‘H’ whereas clones generated using 
Clone 9 with ‘9’.  Together with Scrambled (Scr) clones as negative controls, the 
NME2 knockdown clones were examined for NME2 expression by Western blot 
using a primary antibody specific for NME2 (L15) (Figure 3.2.4.1A). Western blot 
analysis shows substantial down-regulation of NME2 in the knockdown clones, as 
well as high expression of MDM2 in Clone 9 and its derivatives, as expected. 
These clones were further characterised by examining the levels of NDPK activity. 
NDPK activity assay was performed as described in Materials and Methods 
(Section 2.15) for each cell lines using 250,000 cells per sample (n=3).  As 
expected, all the NME2 knockdown clones show considerably lower NDPK 
activity levels compared to NDPK activity observed for their respective parental 
cell line and Scrambled controls (Figure 3.2.4.1B). Interestingly, NDPK activity 
for Clone 9 is lower compared to NDPK activity observed for H1299 cells. 
 
Boyden chamber motility assay was performed using each cell line with n≥4. In 
the absence of NME2, both HNME2:Cl.2 and Cl.7 cells are significantly more 
motile compared to H1299 and Scrambled controls (Figure 3.2.4.1C), consistent 
with the role of NME2 as a tumour suppressor. On the other hand, all of the Clone 
9 cell lines demonstrate significantly higher motility than that of their parental 
H1299. This is expected since overexpression of MDM2 has been shown to 
promote cell motility [103, 384]. However, knockdown of NME2 in Clone 9 cells 
did not further promote cell motility, with motility levels comparable to Clone 9. 
One possible explanation for this could be that there is no real difference in 
motility in these cell lines. Alternatively, it is possible that, upon MDM2 
transfection, the cells reach as high mobility as possible and are not capable of 
being more motile even when NME2 was down-regulated.  
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In order to ensure that the cell motility results obtained above were not affected by 
the rate of cell proliferation, which might be caused by the absence of NME2 and 
overexpression of MDM2, MTT cell proliferation assay (Section 2.25) was 
performed for NME2 knockdown clones. Growth curves in Figure 3.2.4.1 show 
that all cell lines used in the motility assay have comparable proliferation profiles. 
Cell proliferation rates were particularly similar from Day 0 to Day 2, i.e. the time 
frame during which Boyden chamber motility assay took place, suggesting that 
cell proliferation rate is unlikely a determinant for the increase in motility 
observed in NME2 knockdown clones. In summary, knockdown of NME2 
promotes increased cell motility and abrogates most of the endogenous NDPK 
activity in cells, supporting the role of NME2 as a metastasis suppressor and that 
this function may be NDPK activity-dependent. 
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Figure 3.2.4.1: Analysis of the effects of a stable NME2 knockdown on cell 
motility and NDPK activity. A. Western blot analysis for stable knockdown 
clones expressing shRNA NME2 showing decent knockdown of NME2. Anti-
MDM2 (IF2), anti-β-actin (AC-15) and anti-NME2 (L15) primary antibodies were 
used. HE, high exposure. B. NDPK activity assay for the NME2 knockdown 
clones. 250,000 cells per sample were used for each NDPK activity assay (n=3). 
Blue, H1299 parental cell line; Green, Clone 9 (H1299 overexpressing MDM2) as 
parental cell line. C. Boyden chamber assay for the clones (n≥4).  D. Growth 
curves, examined using MTT assay, showing similar proliferation profile for the 
clones. In other words, the increase in motility seen in the knockdown clones is 
unlikely due to a difference in proliferation rate. P-values were derived from 
statistical analyses by Student’s t-test. Error bars indicate standard error.  
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3.2.5 Analysis of the NDPK activity in MDM2 overexpressing cells 
Since results presented in Section 3.2.4 indicated that NDPK activity is lower in 
cells expressing high levels of MDM2 (Clone 9) and also that the effect of NME2 
on cell motility is NDPK activity-dependent, we hypothesised that overexpression 
of MDM2 might lower cellular NDPK activity to promote cell motility. Therefore, 
the effect of MDM2 levels on NDPK activity was investigated. Accordingly, 
additional clones (MDM2 Cl.1 and Cl.3) that express high levels of MDM2 were 
included in the study to ensure that the result seen in Clone 9 has not occured by 
chance. Furthermore, RFM Cl.9, Cl.8 and Cl.6 were included as well, to examine 
whether the effect of MDM2 on NDPK activity is RING-finger-dependent. Empty 
vector (EV) clones were used as control. All of these clones used for this assay are 
derivatives of H1299. As shown in Figure 3.2.5.1, NDPK activity of Clone 9 
appears lower than that of H1299, which is consistent with result represented in 
Figure 3.2.4.1B, even though the decrease was not statistically significant in this 
experiment (p=0.1228). However, since the levels of NDPK activity in all other 
MDM2 and RFM clones are on a par with H1299 and EV clones, the result seen in 
Clone 9 may be due to clonal selection. Therefore, the results presented here fail to 
demonstrate that high levels of MDM2 reduce NDPK activity in cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   149	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5.1: Analysis of the effects of high levels of MDM2 on NDPK 
activity. NDPK assay was performed for clones that express high levels of MDM2 
(MDM2 Cl.1, Cl.3 and Cl.9) and RFM Cl.9, Cl.8 and Cl.6. Empty vector (EV) 
clones were used as control. HNME2:Cl.7 was also included as negative control. 
All of these clones were derivatives of H1299. Error bars indicate standard error. 
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3.2.6 Analysis of the effects of NME2H118F, MDM2 and RFM on NME2 
protein levels and NDPK activity 
NME2 is a relatively small protein (152 aa) with active sites responsible for 
NDPK activity spanning almost the entire protein, and this leads us to hypothesise 
that NME2 might exert its motility suppressive effect through NDPK activity. In 
addition, a preliminary study performed by a past member of our laboratory  (Dr 
Radoslaw Polański) has demonstrated that NME2H118F kinase mutant does not 
inhibit cell motility, suggesting that the effect of NME2 on motiltiy is NDPK 
activity-dependent. Since high levels of MDM2 have been shown to promote cell 
motility independently of its RING-finger [384], we aimed to examine the effect 
of MDM2 on cellular NDPK activity. H1299 cells were transfected with 1 µg of 
each pCEP4-NME2, pCEP4-NME2H118F, pCMVNeoBam-MDM2 and 
pCMVNeoBam-MDM2C464A (RFM) using GeneJuice. Transfected cells were 
harvested 24h post-transfection for NDPK activity assay and Western blotting. 
Western blot analysis presented in Figure 3.2.6.1A shows higher expression of 
MDM2 in RFM transfected cells compared to wild-type MDM2 transfected cells, 
as expected, since RFM is unable to target MDM2 for degradation, resulting in 
accumulation of MDM2 in the cells. Furthermore MDM2 does not appear to have 
any effect on NME protein levels. As shown in Figure 3.2.6.1B, NDPK activity of 
NME2 transfected cells was significantly higher compared to that of EV 
transfected cells, indicating that the NME2 plasmid used was functionally active. 
However, NDPK activity of NME2H118F kinase mutant is on par with EV 
control, suggesting that it is unlikely that kinase mutant promotes cell motility 
through the loss of kinase activity. It is also possible that the change in activity 
could not be detected in this assay since NME2 proteins were abundantly 
expressed in the cells.  
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Figure 3.2.6.1: Investigation of the effects of NME2H118F, MDM2 and RFM 
on NME2 protein levels and NDPK activity. H1299 cells were transfected with 
1 µg of pEV, pCEP4-NME2, pCEP4-NME2H118F, pCMVNeoBam-MDM2 and 
pCMVNeoBam-MDM2C464A (RFM) using GeneJuice. 0.2 µg of β-gal was used 
as a transfection efficiency control. Transfected cells were harvested 24 hours post 
transfection for NDPK assay (n=3) and western blot analysis. P-values correspond 
to statistical analyses by Student’s t-test (n=3). Error bars indicate standard error. 
A. NDPK actity B. Western blotting using anti-MDM2 (IF2), anti-β-actin (AC-
15), anti-NME1/2 (ab31019) and anti-β-gal (OB02) primary antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!"
#
$%
!&
#
'(
%
#
$%
!&
)*
*+
(#
%
,%
&#
-./01#
-.2345#
6-./017#
$%!&#6189:;#<05=7#
$%!*#6>??:;#<05=7#
%,%&#
@.2345#
6%,%&#A#$%!7#
2# B#
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
EV NME2 H118F MDM2 RFM 
U
/ m
l  
NDPK Activity 
p=0.0324 
	   152	  
3.2.7 Analysis of the in trans effect of NME2H118F on cellular NDPK activity 
Since NME2 can form homo- or hetero-hexamers comprised of individual active 
subenzymes, we wanted to investigate whether the NME2 kinase dead mutant has 
any in trans effect on the NDPK activity of the wt NME2. For example, the kinase 
mutant may exert an allosteric, possibly dominant negative effect and suppress wt 
NME2 NDPK activity by oligomerisation with wt NME2. To address this 
question, H1299 cells were transfected with 0.5 µg of pCEP4-NME2, pCEP4-
NME2H118F or both using GeneJuice, followed by NDPK activity assay 24h, 48h 
and 72h after transfection (n=3). EV was used as a control. As expected, 
NME2H118F does not induce any NDPK activity due to the lack of a crucial 
phospho-acceptor histidine 118 residue required for NDPK activity (Figure 
3.2.7.1). On the contrary, NDPK activity levels of NME2 transfected cells increase 
dramatically over time, proportionally to its protein expression levels. When co-
expressed with wild-type NME2, the kinase mutant does not seem to affect NDPK 
activity induced by wild-type NME2 (p=0.1222, p=0.0865 and p=0.2429 for 24h, 
48h and 72h post-transfection, respectively). This indicates that kinase dead 
mutant NME2H118F has no effect in trans on cellular NDPK activity.  
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Figure 3.2.7.1: Analysis of the in trans effect of NME2H118F on cellular 
NDPK activity. A. NDPK activity assay for H1299 cells transfected with 
indicated plasmids followed by NDPK activity assay 24h, 48h and 72h after 
transfection (n=3). EV and NME2H118F were used as negative controls. As 
expected kinase dead mutant NME2H118F does not induce any NDPK activity 
due to the lack of a crucial phospho-acceptor histidine 118 residue for NDPK 
activity. When co-expressed with wild-type NME2, the kinase mutant does not 
seem to affect NDPK activity induced by the wild-type. 0.2 µg of β-gal was used 
as a transfection efficiency control. P-values correspond to statistical analyses by 
Student’s t-test (n=3). Error bar indicates standard error. B. Western blot analysis 
of samples from panel A, with actin as a loading control.  Primary antibodies used 
were anti-β-actin (AC-15), anti-NME1/2 (ab31019) and anti-β-gal (OB02).  
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3.2.8 Analysis of the effect of denaturing- or detergent-based lysis method on 
NDPK activity 
The majority of the cellular NDPK activity is contributed by NME in oligomeric 
forms [290, 293]. The NDPK assay used in our study measures the overall NDPK 
activity in cells and is not able to determine the relative contributions of different 
NME forms In other words, the assay does not distinguish whether monomer or 
oligomer contributes more to the overall activity. In previous experiments 
presented in this thesis, RIPA buffer, both detergent-based and denaturing, was 
used for cell lysis when preparing samples for NDPK assay. There is a concern 
that this lysis method may disrupt the interactions between NME2 subunits and 
thus the NDPK activity measured might not be a true representation of the actual 
NDPK activity in the cells. 
 
To address this question, H1299 cells were lysed using different lysis buffers 
varying in denaturing strength to compare their effects on observed cellular NDPK 
activity. Hypotonic extraction assay method is designed to minimise disruption of 
protein-protein interaction to preserve the protein oligomeric structure. It is both 
non-denaturing and non-detergent-based. SLIP lysis buffer is detergent-based but 
non-denaturing.  
 
As shown in Figure 3.2.8.1, no difference in NDPK activity was observed between 
using a denaturing (RIPA) or non-denaturing (SLIP) lysis buffers. Although the 
laborious hypotonic lysis method gives a statistically higher NDPK activity in 
comparison to that of the detergent-based lysis methods, the difference is not 
dramatic enough to give us concern about our previous interpretation of NDPK 
activity in the cells. For result consistency and assay simplicity, RIPA buffer was 
used for cell lysis in all NDPK assays presented in this thesis. 
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Figure 3.2.8.1: Analysis of the effect of denaturing- or detergent-based lysis 
method on NDPK activity. A. Hypotonic lysis of H1299 cells. Cells were 
incubated in a hypotonic buffer until swollen. After 20 strokes of homogenisation 
the cells were burst, leaving intact nuclei with various amounts of cytoplasmic 
material attached. After 30 strokes, a more homogenised solution was obtained, 
leaving cleaner nuclei.  B. No difference in NDPK activity was observed between 
using a denaturing (RIPA) or non-denaturing (SLIP) lysis buffers. The NDPK 
activity resulted from hypotonic method is slightly but statistically higher that of 
the denaturing lysis methods. P-values correspond to statistical analyses by 
Student’s t-test (n=3). Error bar indicates standard error. 
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3.2.9 Analysis of the effect of MDM2 overexpression on cellular NDPK 
activity level 
It has been demonstrated that up-regulation of MDM2 in RCC opposes the 
motility suppressive effect of NME2 [183]. However, it is unclear whether this 
was an NDPK activity-dependent phenomenon. Therefore, we wanted to examine 
the effect of MDM2 overexpression on cellular NDPK activity level. In order to 
determine the time point post-transfection when MDM2 is expressed at the highest 
level, different time-points were studied. In addition, considering that different 
transfection reagents may vary in their transfection efficiency, both GeneJuice and 
Lipofectamine 2000 were used and compared. Accordingly, H1299 cells were 
transfected with 1.5 µg MDM2 using GeneJuice or Lipofectamine 2000 followed 
by NDPK activity assay 30h and 48h after transfection (n=3). As demonstrated in 
Figure 3.2.9.1B, when cells were transfected with GeneJuice, the highest 
expression of MDM2 was detected at 48h post-transfection, whilst with the 
Lipofectamine, the expressions seems to decrease at 48h. However, no difference 
in NDPK activity level was observed when MDM2 was overexpressed, regardless 
of the transfection reagents used Figure 3.2.9.1A.  
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Figure 3.2.9.1: Analysis of the effect of MDM2 overexpression on cellular 
NDPK activity level. A. NDPK activity assay for H1299 cells transfected with 1.5 
µg MDM2 using GeneJuice or Lipofectamine 2000 as transfection reagents. 
NDPK activity assay was performed 30h and 48h after transfection (n=3). EV was 
used as a control. P-values correspond to statistical analyses by Student’s t-test 
(n=3). Error bar indicates standard error. B. Western blot analysis of samples from 
panel A. Primary antibodies used were anti-MDM2 (IF2), anti-β-actin (AC-15) 
and anti-NME1/2 (ab31019). 
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3.2.10 Examining whether MDM2 opposes the motility suppressive effect of 
NME2 through inhibition of NDPK activity 
Considering that NMEs are very small proteins, it is hard to believe that NMEs 
have any other biochemical activity other than their defining NDPK activity. In 
order to investigate whether NME2 suppressive effect on motility is ascribed to its 
NDPK activity and whether MDM2 oppose NME2 motility suppressive effect 
through suppression of the NDPK activity, NME2 was transfected with or without 
MDM2 into NME2 knockdown clones from both H1299 and Clone 9 parental 
lines, followed by NDPK assay. Two previous experiments (performed in 
9NME2:Cl.6 and HNME2:Cl.2) show that NDPK activity was significantly 
reduced in the presence of MDM2, suggesting a role of MDM2 in modulating 
NME2 kinase activity. However, these experiments were performed as part of 
pilot studies without clear evidence from Western blots that the expression of 
NME2 protein in all conditions was equal. In other words, the reduction in NDPK 
activity may not simply be explained by the presence of MDM2 since fluctuation 
in NME2 protein levels is a major determinant of NDPK activity. In light of these 
results, the experiment was repeated in wild-type H1299, Clone 9, and the NME2 
KD clones from the two parental lines (HNME2:Cl.2, HNME2:Cl.7, 9NME2:Cl.1 
and 9NME2:Cl.6). NME2 knockdown clones were used because as NME2 is 
abundantly expressed in cells, it may be easier to detect changes in NDPK activity 
in a system that has minimal NME2 expression. 
 
The main goal was to examine whether MDM2 opposes the suppressive effect of 
NME2 on motility through suppressing NDPK activity. 1 µg of pCEP4-NME2 
was co-transfected with either 1.5 µg pCMVNeoBam-MDM2 or 0.75 µg 
pCMVNeoBam-MDM2C464A (RFM) into the afore-mentioned cell lines. EV and 
NME2H118F were included as controls. The reason for using RFM is to examine 
whether RF, crucial for E3 ubiquitin ligase activity, is required for MDM2 effects 
on NDPK activity, if there are any. Please note that the amount of RFM plasmid 
used was half of the wt MDM2 plasmid to compensate for increased stability of 
RFM protein because of the absence of auto-ubiquitination. Transfected cells were 
harvested 24h post-transfection for NDPK assay and western blot analysis.  
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In H1299 cells (Figure 3.2.10.1A), the NDPK activity level of NME2 was lower in 
the presence of wt MDM2 compared to that of NME2 alone (p=0.0182). On the 
other hand, an increase in NDPK activity was observed in the presence of RFM 
(p=0.0274), which suggests that MDM2 may suppress NDPK activity in an E3 
ligase-dependent manner. The results in Clone 9 mimic that of H1299 (Figure 
3.2.10.1D), although no significant difference in NDPK activity was observed in 
the presence of MDM2 (p=0.2156) and RFM (p=0.0635). As shown in Figure 
3.2.10.1, the levels of NDPK activity were dramatically reduced when NME2 is 
downregulated in NME2 stable knockdown clones. In comparison to their parental 
cell lines, only about 20-30% of NDPK activity remains in the knockdown clones 
suggesting that the majority of cellular NDPK activity is atributed to NME2 either 
in the forms of monomer, homo-oligomer or hetero-oligomer with other isoforms. 
Unfortunately, we were unable to analyse the results obtained from the 
knockdown clones since it was rather difficult to detect the expression of 
transfected NME2, as shown in the western blots. This is not surprising 
considering the cells already contain short hairpin RNA (shRNA) for NME2. 
Nevertheless, we have observed some potential inhibitory effect of MDM2 on 
NDPK activity in 9NME2Cl.1 and Cl.6 (p=0.04988 and p=0.0367, respectively). 
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Figure 3.2.10.1 (To be continued) 
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Figure 3.2.10.1 (To be continued) 
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Figure 3.2.10.1: Examining whether MDM2 opposes the motility suppressive 
effect of NME2 through inhibition of NDPK activity. 1 µg of pCEP4-NME2 
was co-transfected with either 1.5 µg pCMVNeoBam-MDM2 or 0.75 µg 
pCMVNeoBam-MDM2C464A (RFM) into NME2 knockdown clones from both 
H1299 and Clone 9 parental lines using GeneJuice. EV and NME2H118F were 
included as negative controls. 0.2 µg of β-gal was used as a transfection efficiency 
control. Transfected cells were harvested 24h post-transfection for NDPK assay 
(n=3) and Western blot analysis. P-values correspond to statistical analyses by 
Student’s t-test (n=3). Error bars indicate standard error. For Western blotting, 
samples were separated on 12% and 15% gels and actin was used as a loading 
control. Primary antibodies used were anti-MDM2 (IF2), anti-β-actin (AC-15), 
anti-NME1/2 (ab31019) and anti-β-gal (OB02). Results are shown in A. H1299 B. 
HNME2:Cl.2 C. HNME2:Cl.7 D. Clone 9 E. 9NME2:Cl.1 F. HNME2:Cl.6. 
Downward arrow indicates low to high exposures. 
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3.2.11 Optimisation of the NDPK activity assay 
3.2.11.1 Optimisation 1: Time-points 
Previous results presented in this thesis (Figure 3.2.7.1A) have demonstrated that 
the levels of transiently transfected NME2 expression and NDPK activity increase 
over time, up to 72h post-transfection. As the MDM2 protein levels seem to peak 
at 30-48h post-transfection with pCMVNeoBam-MDM2 (Figure 3.2.9.1), it is 
therefore interesting to see whether the effect of MDM2 on NDPK activity may 
also gradually increase over time. The hypothesis was that with higher NDPK 
activity more effect of MDM2 could be detected.  
 
H1299 were transfected with 1 µg of NME2 and either 1.5 µg of MDM2 or 0.75 
µg of RFM using GeneJuice, followed by NDPK assay (n=3) and western blotting 
24, 48 and 72h post-transfection. In situ β-gal staining was performed 24h after 
transfection for determination of transfection efficiency. As expected, the NDPK 
activity (Figure 3.2.11.1.1A) and NME2 protein expression (Figure 3.2.11.1.1B) 
levels in wt NME2 transfected cells increase with incubation time. Down-
regulation of NME2 by MDM2 was also observed at 48h and the effect seems to 
be RING finger-dependent. No suppressive effect on NDPK activity was observed 
at 24h when cells were co-transfected with wild-type MDM2 (Figure 3.2.11.1A). 
However, MDM2 seems to have a subtle suppressive effect on NDPK activity at 
48h and this effect gradually increases over time. A similar trend was observed in 
the presence of RFM. Nevertheless the inhibitory effects observed were not 
statistically significant. 
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Figure 3.2.11.1.1 (To be continued) 
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Figure 3.2.11.1.1: Optimisation of NDPK activity assay: Time-points. A. 
NDPK activity assay for H1299 cells transfected with 1 µg of NME2 and either 
1.5 µg of MDM2 or 0.75 µg of RFM 24h, 48h and 72h after transfection. EV and 
NME2H118F were included as controls. 0.2 µg of β-gal was used as a transfection 
efficiency control. When co-expressed with wild-type MDM2, no difference in 
NDPK activity was observed at 24h but there seem to be a suppressive effect on 
NDPK activity that gradually increases over time from 48h onwards. A similar 
trend was observed in the presence of RFM. P-values correspond to statistical 
analyses by Student’s t-test (n=3). Error bars indicate standard error. B. Western 
blot analysis of samples from panel A separated on 12% and 15% gels, with actin 
as a loading control. Primary antibodies used were anti-β-actin (AC-15), anti-
MDM2 (IF2), anti-NME1/2 (ab31019) and anti-β-gal (OB02).  Downward arrow 
indicates low to high exposures. C. In situ β-gal staining (24h post-transfection) 
for determination of overall transfection efficiency.   
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3.2.11.2 Optimisation 2: NME2 to MDM2 ratios   
So far, results presented in this thesis indicate that the suppressive effect of 
MDM2 on NDPK activity is not a consistent phenomenon.  It was thought that the 
amount of MDM2 used for the assay was not sufficient for inducing a significant 
suppressive effect. In previous experiments performed in this thesis, 
NME2:MDM2 plasmid ratio  (in µg) used for transfection was 1:1.5. Here, we 
aimed to use up to 1:6 of NME2 to MDM2 ratio for optimisation. NDPK activity 
assay was performed for H1299 cells transfected with 0.5 µg of NME2 and either 
3 µg of MDM2 or 1.5 µg of RFM 24h, 48h and 72h after transfection, as described 
in Figure 3.2.11.2.1. As shown in Figure 3.2.11.2.1A, the suppressive effects of 
MDM2 on NDPK activity increase from 24h to 72h post-transfection. In 
particular, at 48h and 72h, the effect is statistically significant compared to NME2 
alone, with (p=0.0446) and (p=0.0280), respectively. MDM2 expression level was 
observed to peak at 48h but diminished considerably at 72h (Figure 3.2.11.2.1B). 
This suggests that the effect of MDM2 may accumulate over time after 
transfection. Interestingly western blots also show that there is a hint of NME2 
down-regulation in the presence of MDM2, particularly at 72h time point. Similar 
results were obtained (Figure 3.2.11.2.2) when the experiment was repeated using 
1:3 ratio of NME2 to MDM2 for 48h and 72h (since these are the time points at 
which reaction effect seem to occur more noticeably). 
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Figure 3.2.11.2.1: Optimisation: NME2 to MDM2 ratios. Experiment was 
performed as described in Section 3.2.11.1 but using 1:6 of NME2 to MDM2 
plasmids for transfection. A. NDPK activity assay for H1299 cells transfected with 
0.5 µg of NME2 and either 3 µg of MDM2 or 1.5 µg of RFM 24h, 48h and 72h 
after transfection. EV and NME2H118F were included as controls. 0.2 µg of β-gal 
was used as a transfection efficiency control. P-values correspond to statistical 
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analyses by Student’s t-test (n=3). Error bars indicate standard error. B. Western 
blot analysis of samples from panel A separated on 12% and 15% gels, with actin 
as a loading control. Primary antibodies used were anti-β-actin (AC-15), anti-
MDM2 (IF2), anti-NME1/2 (ab31019) and anti-β-gal (OB02). Downward arrow 
indicates low to high exposures. C. In situ β-gal staining (24h post-transfection) 
for determination of overall transfection efficiency. Magnification: x5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   169	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.11.2.2: Optimisation: NME2 to MDM2 ratios. Experiment was 
performed exactly as described in Section 3.2.11.1 except using 1:3 of NME2 to 
MDM2 plasmids for transfection. A. NDPK activity assay for H1299 cells 
transfected with 1 µg of NME2 and either 3 µg of MDM2 or 1.5 µg of RFM 24h, 
48h and 72h after transfection. EV and NME2H118F were included as controls. 
0.2 µg of β-gal was used as a transfection efficiency control. P-values correspond 
to statistical analyses by Student’s t-test (n=3). Error bar indicates standard error. 
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B. Western blot analysis of samples from panel A separated on 12% and 15% gels, 
with actin as a loading control. Primary antibodies used were anti-β-actin (AC-
15), anti-MDM2 (IF2) anti-NME1/2 (ab31019) and anti-β-gal (OB02). Downward 
arrow indicates low to high exposures. C. In situ β-gal staining (24h post-
transfection) for determination of overall transfection efficiency. PC, phase 
contrast; BF, bright field. Magnification: x10. 
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3.2.11.3 Optimisation 3: Transfection efficiency. 
Transfection experiments for examining the effect of MDM2 on NDPK activity 
were thus far performed using GeneJuice, with transfection efficiency typically 
being between 15-40%. The low transfection efficiency could mean that only a 
small proportion of the cells assayed for NDPK activity were actually transfected 
with our plasmids of interest. In other words, the effect of MDM2 on NDPK 
activity could be underestimated due to low transfection efficiency. As a result, we 
wanted to examine whether higher transfection efficiency that can be obtained 
using  Lipofectamine 2000 as a transfection reagent would have any effect on 
results obtained. In the first instance, we examined whether transfection incubation 
time before medium changing has any effect on cellular cytotoxicity and 
transfection efficiency when Lipofectamine 2000 is used. Accordingly, H1299 
cells were transfected with 1 µg of pβ-gal. Medium containing transfection 
reagent was replaced at 2h, 4h and 6h post-transfection. β-gal assay was 
performed 24h post-transfection to determine the transfection efficiency. As 
shown in Figure 3.2.11.3.1, transfection efficiency increases with longer 
incubation time before medium changing. More than 90% of cells were expressing 
β-gal with medium changing after 6h of transfection. Although the transfection 
(6h) was also accompanied with a slightly higher number of cell deaths (result not 
shown), it was decided that medium would be changed 6h after transfection, in the 
interest of higher transfection efficiency. 
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Figure 3.2.11.3.1: Optimisation: Transfection efficiency. H1299 cells were 
transfected with 1 µg of pβ-gal. Medium containing transfection reagent was 
replaced at 2h, 4h and 6h post-transfection. In situ β-gal assay was performed 24h 
post-transfection to determine the transfection efficiency. PC, phase contrast; BF, 
bright field. Magnification: x10.  
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3.2.12 MDM2 down-regulates NME2 in a dose-dependent manner 
Following a series of optimisation experiments, the effect of MDM2 on NME2 
level and NDPK activity was further investigated using the optimised conditions. 
It was assumed that if MDM2 has a suppressive effect on NDPK level and/or 
activity, the effect would, to some extent, be relative to the amount of MDM2 
used. For this purpose, experiment was repeated as described in Section 3.2.11.1, 
except that H1299 were co-transfected with an increasing amount of MDM2 and a 
constant amount of NME2 (0.25 µg) using Lipofectamine 2000. Transfection 
medium was changed 6h post-transfection and cells were harvested 48h after 
transfection for NDPK assay (n=3). 
 
As shown in Figure 3.2.12.1A, MDM2 seems to have negligible suppressive effect 
on NDPK activity even when the transfection efficiency was high (about 90%). 
There is a marginal but statistically significant difference in the NDPK activity 
when cells were transfected with 1.5 µg of MDM2 (p=0.0356).  However, 
Western blot and densitometry analyses (Figure 3.2.12.1B&C) suggest that 
MDM2 down-regulates NME2 in a dose-dependent manner, since NME2 protein 
levels decrease in the presence of increasing amount of MDM2. This effect does 
not seem to be a consequence of uneven transfection efficiency. Interestingly, 
when co-expressed with the same amount of RFM (1.5 µg), some degree of NME2 
down-regulation was observed, but the extent was much lower than that incurred 
by wild-type MDM2. 
 
In a reverse manner, when MDM2 was down-regulated using siRNA (MDM2 
oligo 1) followed by NDPK activity assay 48h post-transfection (n=3), a marginal 
but statistically significant increase in NDPK activity was observed (p=0.0203) 
(Figure 3.2.12.2A). Western blot also demonstrates an increase in NME2 level 
upon down-regulation of MDM2 (Figure 3.2.12.2B). These results suggest that 
MDM2 has an ability to down-regulate NME2 protein level and, perhaps by doing 
so, inhibit the NDPK activity of NME2.  
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Figure 3.2.12.1 (To be continued) 
C 
A 
B 
D 
!"
#!!"
$!!"
%!!"
&!!"
'!!!"
'#!!"
'$!!"
'%!!"
'&!!"
#!!!"
()
"
*+
(#
"
*+
(#
,'
'&
-"
*+
(#
"."
!/0
"12
"+
3+
#"
*+
(#
"."
'/!
"12
"+
3+
#"
*+
(#
"."
'/0
"12
"+
3+
#"
*+
(#
."'
/0"
12
"4-
+
"
!
"#
$
%##
&'()#*+,-./0#
56!/#770"
56!/%8#$"
56!/!70%"
56!/!&&&"
()
"
*+
(#
"
*+
(#
",
''
&-
"
*+
(#
"."
!/
0"µ
2"+
3+
#"
*+
(#
"."
'/
!"µ
2"+
3+
#"
*+
(#
"."
'/
0"µ
2"+
3+
#"
*+
(#
"."
'/
0"µ
2"4
-+
"
+3+#"
'#9"
'09"
:;2<="
:;>?@A"B:;2<=C""
+3+#"
:;>?@A"B*+("D"+3+#C""
*+(#"B=EFGH"I<AJC"
KEF"LE"MN2M"GO5"
*+('"BP55GH"I<AJC"
'123./4$1/50#
QH<ARSG?LGJ"TALH<ARSG?LGJ"
UV"
W-"
6789%#*3390#
!"
#"
$"
%"
&"
'!"
'#"
'$"
()
"
*+
(#
"
*+
(#
,'
'&
-"
*+
(#
"."
!/0
"12
"+
3+
#"
*+
(#
"."
'/!
"12
"+
3+
#"
*+
(#
"."
'/0
"12
"+
3+
#"
*+
(#
"."
'/0
"12
"4-
+
"
#:
.8
29
%#;
2/
12
3.
/0
#<=
>?
@ A
#
>?@A""
:;2<="
!"
#!"
$!"
%!"
&!"
'!!"
()
"
*+
(#
"
*+
(#
,'
'&
-"
*+
(#
"."
!/0
"12
"+
3+
#"
*+
(#
"."
'/!
"12
"+
3+
#"
*+
(#
"."
'/0
"12
"+
3+
#"
*+
(#
"."
'/0
"12
"4-
+
"
#:
.8
29
%#;
2/
12
3.
/0
#<=
>?
@ A
#
>?@A"
*+(#"
	   175	  
Figure 3.2.12.1: MDM2 down-regulates NME2 in a dose-dependent manner. 
To examine the effect of MDM2 on NME2 level and NDPK, H1299 were co-
transfected with 0.25 µg of NME2 and an increasing amount of MDM2 or 1.5 µg 
RFM using Lipofectamine 2000. EV and NME2H118F were included as controls. 
0.2 µg of β-gal was used as a transfection efficiency control. Transfection media 
was changed 6h post-transfection. A. NDPK activity assay for transfected cells 
48h post-transfection (n=3). P-values correspond to statistical analyses by 
Student’s t-test. Error bar indicates standard error. B. Western blot analysis of 
samples from panel A separated on 12% and 15% gels, with actin as a loading 
control. Primary antibodies used were anti-β-actin (AC-15), anti-MDM2 (IF2), 
anti-NME1/2 (ab31019) and anti-β-gal (OB02). Downward arrow indicates low to 
high exposures. C. Densitometry analysis was performed on Western blot in panel 
B to estimate the signal intensities of β-gal and NME2 relative to their 
corresponding actin controls.   D. In situ β-gal staining (24h post-transfection) for 
determination of overall transfection efficiency. PC, phase contrast; BF, bright 
field. Magnification: x10. 
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Figure 3.2.12.2: Down-regulation of MDM2 leads to an increase in NDPK 
activity supporting the potential role of MDM2 in suppressing NDPK activity. 
A. Down-regulation of MDM2 in H1299 cells using siRNA (MDM2 oligo 1, used 
at 80 pmol per well of a 6-well plate) followed by NDPK activity assay 48h post-
transfection (n=3). Mock (transfection reagent only) and Scrambled siRNA were 
used as negative controls. P-values correspond to statistical analyses by Student’s 
t-test. Error bar indicates standard error.  B. Western blot analysis of samples from 
panel A showing decent down-regulation of MDM2 expression and a rise in 
NME2 level upon MDM2 down-regulation. Downward arrows indicating low to 
high exposures. Primary antibodies used were anti-β-actin (AC-15), anti-MDM2 
(IF2) and anti-NME1/2 (ab31019). 
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3.2.13 Analysis of the effect of MDM2 on NME2 level and NDPK activity in 
siRNA NME1 knockdown cells 
Both NME1 and NME2 are abundantly expressed in cells and can contribute to 
cellular NDPK activity through homo- and/or hetero-oligomerisation. 
Furthermore, since our assay does not discriminate between NDPK activity 
contributed by NME1 or NME2, it was questioned whether the effect of MDM2 
measured was the effect on NDPK activity contributed by NME2 alone. To 
examine this, NME1 was down-regulated using transiently transfected siRNA 
NME1 oligo 9 (80 pmol for each well of a 6-well plate) in H1299 cells. Mock 
(only transfection reagent) and Scrambled siRNA were used as negative controls. 
24h later, the NME1 down-regulated cells were transfected with 0.25 µg of 
pCEP4-NME2 and 1.5 µg of MDM2 or 1.5 µg of RFM using Lipofectamine 2000. 
The transfected cells were harvested 48h after the second transfection (72h post 
siNME1 KD) for NDPK activity assay (n=3). Western blot in Figure 3.2.13.1A 
and β-gal assay in Figure 3.2.13.1C show that NME1 knockdown followed by 
subsequent transient transfections have worked quite well. In the event of 
bypassing NDPK activity from endogenous NME1, both wt MDM2 and RFM 
seem to down-regulate NME2 protein expression, an observation supported by 
densitometry analysis (Figure 3.2.13.1B). However, unlike previous observation in 
Figure 3.2.11.2.1, no significant difference in NDPK activity was observed in the 
presence of either wt MDM2 or RFM. This suggests that even though MDM2 does 
not seem to inhibit NME2 NDPK activity in the absence of NME1, MDM2 still 
has an effect on NME2 protein levels. 
 
It is worth mentioning that when NME1 is down-regulated, not much difference 
was observed in NDPK activity (mean activity for EV = ~380 U/ml), which is on 
par with the activity of EV transfected H1299 (mean activity = 350-500 U/ml). 
This is consistent with our previous NDPK activity results in which there was a 
massive reduction in NDPK activity in NME2 KD clones (Figure 3.2.11.1B and 
C). This suggests that the endogenous NME1 contributes relatively little to the 
cellular NDPK activity measured in our assay and that the majority of the NDPK 
activity comes from NME2 or at least that NME2 is required for the 
hexamerisation with NME1 that contributes to the overall NDPK activity. 
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Figure 3.2.13.1: Analysis of the effect of MDM2 on NME2 level and NDPK 
activity in siRNA NME1 knockdown cells. A. NME1 was first down-regulated 
using siRNA NME1 oligo 9 (80 pmol for each well of a 6-well plate) in H1299 
cells. Mock (only transfection reagent) and Scrambled siRNA were used as 
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negative controls. 24h later, the NME1 down-regulated cells were transfected with 
0.25 µg of pCEP4-NME2 and 1.5 µg of MDM2 or 1.5 µg of RFM using 
Lipofectamine 2000. 0.2 µg of β-gal was used as a transfection efficiency control. 
Transfected cells were harvested 48h after the second transfection (72h post 
siNME1 KD) for NDPK activity assay (n=3). A. Western blot analysis of samples 
separated on 12% and 15% gels, with actin as a loading control. Primary 
antibodies used were anti-β-actin (AC-15), anti-MDM2 (IF2), anti-NME1/2 
(ab31019) and anti-β-gal (OB02). Downward arrow indicates low to high 
exposures. B. Densitometry analysis was performed on western blot in panel A to 
estimate the signal intensities of β-gal and NME2 relative to their corresponding 
actin controls. C. NDPK activity assay. P-values correspond to statistical analyses 
by Student’s t-test. Error bar indicates standard error.  D. In situ β-gal staining 
(24h post-transfection) for determination of overall transfection efficiency. PC, 
phase contrast; BF, bright field. Magnification: x10. 
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3.2.14 Analysis of the effect of MDM2 on NME1 level and NDPK activity 
Results presented in Section 3.2.13 suggest that NDPK activity of NME2 was 
unaffected by MDM2 in the absence of NME1. This raises the question of whether 
the effect of MDM2 on NDPK activity seen intermittently in previous sections 
was actually dependent and/or is a direct effect on NME1. Therefore the effect of 
MDM2 on NME1 protein level and NDPK activity was examined. Accordingly, 
H1299 were transfected with 0.25 µg pCEP4-NME1 and 1.5 µg of MDM2 or 
RFM using Lipofectamine 2000. EV and NME2H118C (kinase mutant) were used 
as negative controls. Transfected cells were harvested for NDPK activity assay 
48h post-transfection (n=3).  
 
Apart from kinase mutant, the expression of ectopically introduced NME1 could 
be detected, as shown in Figure 3.2.14.1A. Since the transfected NME1 plasmid 
encodes a longer form of NME1 (isoform a), its corresponding protein band on 
western blot can be easily separated and distinguished from endogenous NME1. In 
the presence of wt MDM2, NME1 expression levels decrease, with the most 
prominent effect at 72h post transfection. However, the effect was not seen in the 
presence of RFM, suggesting that MDM2 down-regulates NME1 in a RING-
finger-dependent manner. Similarly, Figure 3.2.14.1B suggests that wt MDM2 has 
a suppressive effect on NME1 NDPK activity (p=0.0211), although the effect 
from RFM was less prominent (p=0.0780). 
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Figure 3.2.14.1: Analysis of the effect of MDM2 on NME1 level and NDPK 
activity. H1299 cells were transfected with 0.25 µg pCEP4-NME1 and 1.5 µg of 
MDM2 or RFM using Lipofectamine 2000. EV and NME2H118C (kinase mutant) 
were used as negative controls. A. Western blot analysis of samples separated on 
10% and 15% gels, with actin as a loading control. Primary antibodies used were 
anti-β-actin (AC-15), anti-MDM2 (IF2), anti-NME1/2 (ab31019) and anti-β-gal 
(OB02). Downward arrow indicates low to high exposures. B. Transfected cells 
were harvested for NDPK activity assay 48h post-transfection (n=3). P-values 
correspond to statistical analyses by Student’s t-test (n=3). Error bar indicates 
standard error. C. In situ β-gal staining (24h post-transfection) for determination 
of overall transfection efficiency. PC, phase contrast; BF, bright field. 
Magnification: x10.  
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3.2.15 Analysis of the contribution of NME1 and NME2 towards NDPK 
activity through siRNA down-regulation 
As mentioned before, our method of measuring NDPK activity is not selective and 
does not discriminate between isoforms of NME. However, we wanted to examine 
the relative contribution of NME1, NME2 and both in combination to cellular 
NDPK activity. For this purpose, NME1 and NME2 were down-regulated, 
individually or in combination, in H1299 cells using siRNAs NME1 oligo 9 and 
NME2 oligo 8 (40 pmol for each well of a 6-well plate, i.e. a total of 80 pmol of 
siRNA/well), respectively. Mock (only transfection reagent) and Scrambled 
siRNA were used as negative controls. Transfected cells were harvested 48h and 
72h post-transfection for NDPK activity assay (n=3) and western blot purpose.  
 
As demonstrated on Western blot in Figure 3.2.15.1A, down-regulation of NME1, 
at both 48h and 72h, does not seem to affect NME2 expression level. Similarly, no 
difference was observed on NME1 expression level when NME2 was down-
regulated. In terms of NDPK activity level, there was a decline of about 50 U/ml 
compared to that of Scrambled control when NME1 alone was down-regulated 
(Figure 3.2.15.1B). On the other hand, down-regulation of NME2 alone leads to a 
greater decrease in activity, of about 150 U/ml. Interestingly, the largest decrease 
in cellular NDPK activity was observed when both NME1 and NME2 were down-
regulated, indicating that whilst NME2 may play a greater role in contributing to 
NDPK activity compared to NME1, it is the combination of both NME1 and 
NME2 that provides the majority of cellular NDPK activity. Similar results for 
NDPK activity were obtained for both 48h and 72h post-transfection. 
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Figure 3.2.15.1: Analysis of the contribution of NME1 and NME2 towards 
NDPK activity through siRNA downregulation. NME1 and NME2 were down-
regulated, individually or in combination, in H1299 cells using siRNAs NME1 
oligo 9 and NME2 oligo 8 (40 pmol for each well of a 6-well plate, i.e. a total of 
80 pmol of siRNA/well), respectively. Mock (transfection reagent only) and 
Scrambled siRNA were used as negative controls. Transfected cells were 
harvested 48h and 72h post-transfection for NDPK activity assay and western blot 
purpose. A. Western blot analysis of samples separated on 15% gels, with actin as 
a loading control. Primary antibodies used were anti-β-actin (AC-15) and anti-
NME1/2 (ab31019). Downward arrow indicates low to high exposures. B. NDPK 
activity assay (n=3). P-values correspond to statistical analyses by Student’s t-test 
(n=3). Error bar indicates standard error. 
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3.3 Investigation of whether NME proteins are substrates for MDM2-
mediated ubiquitination 
3.3.1 Sub-cellular localisation of NME proteins  
Results presented in Section 3.2 have suggested that overexpression of MDM2 
may negatively regulate NME1 and NME2 expression levels, although the 
suppressive effects of MDM2 on NDPK activity were inconsistent. This has led us 
to question whether the suppressive effect of MDM2 was localised to a specific 
cellular compartment, which could be missed by the assay used for measuring 
NDPK activity in this study. Therefore, cellular localisation of MDM2 and NME 
proteins was examined in order to gain more information on the mechanisms of 
interaction between MDM2 and NME2. U2OS cells were fractionated (by Dr 
Carlos Rubbi) into cytoplasmic, nucleoplasmic, and nucleolar fractions according 
to the protocol of Lam and Lamond [387].  
 
Figure 3.3.1.1 shows the MDM2 levels in all of the fractions from untreated and 
proteasome inhibitor MG132-treated U2OS cells. 90-kDa MDM2 was abundant in 
the cytoplasm even without the stabilising effect of MG132. As expected, the 90-
kDa band was highly enriched after stabilisation by MG132, particularly in the 
nucleolar fraction. Furthermore, it appears that the 60-kDa MDM2 was more 
abundant in the nucleoplasmic fraction compared to cytoplasmic and nucleolar 
fractions under normal conditions. Interestingly, sub-cellular distribution of the 
60-kDa isoform changes after treatment with MG132. Upon treatment with 
MG132, more of the 60-kDa MDM2 was detected in the cytoplasm and 
particularly in the nucleoli, but less in the nucleoplasm. Treatment with MG132 
was also accompanied by stabilisation of a ladder of what appear to be unknown 
MDM2 isoforms in the nucleoli. These MDM2 isoforms have molecular weight 
typically lower than 60 kDa. 
 
The fractionation samples were also probed with three different anti-NME 
antibodies specific for either NME1 or NME2, or both (Figure 3.3.1.1), in order to 
increase our confidence that the bands detected were genuine. As the supply of 
anti-NME1/2 (ab31019), which recognises both NME1 and NME2, had been 
discontinued, a replacement antibody (C1C3) was used instead after testing has 
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demonstrated that this antibody also recognises both NME1 and NME2 (Appendix 
7). 
 
Figure 3.3.1.1 shows that the 17-kDa NME1 and NME2 forms were found almost 
exclusively in the cytoplasm. Unexpectedly, both NME1 and NME2 levels were 
considerably lower in the cytoplasmic fraction upon treatment with MG132. This 
suggests that NME1 and NME2 are not likely to be subjected to proteasomal 
degradation in cytoplasm. Interestingly, when the three different NME antibodies 
mentioned earlier were used, a common banding pattern was observed at 
molecular weight above 17 kDa. Two distinctive bands, one at ~50 kDa (indicated 
with ) and the other at ~30 kDa (indicated with ), were found abundant in 
both nucleoplasmic and nucleolar fractions in both treated and untreated samples.  
In particular, when membranes were probed with anti-NME1 and anti-NME1/2 
antibodies, the ~30 kDa band is more abundant in the nucleolar fractions (Figure 
3.3.1.1C, E). More interestingly, a ladder of bands was detected in the nucleolar 
fractions, indicating that some post-translational events modifying NME2 may 
take place in the nucleoli. The ladder was particularly visible when membranes 
were probed with anti-NME1 and anti-NME1/2 antibodies and appeared to be 
slightly more abundant after treatment with MG132 (Figure 3.3.1.1C, E). The 
fractionation data therefore suggest that some unknown isoforms of NME could be 
ubiquitinated in nucleoli and that this might be mediated by MDM2. 
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Figure 3.3.1.1: Sub-cellular fractionation of U2OS cells. Western blots of 
fractions of U2OS cells untreated and treated with 10 µM MG132 for 4h probed 
with anti-MDM2 (IF2) (A); fraction markers for nucleolus: B23 (sc-53175), 
cytoplasm: α-tubulin (DM1A) and lamin A/C (sc-7297), and nucleus: histone H3 
(ab1791) (B). C. Western blots as in panel A probed with anti-NME1 (SC-465). 
D. Western blots as in panel A probed with anti-NME2 (L15). E. Western blots as 
in panel A probed with anti-NME1/2 (C1C3). Except for histone H3, 30 µg of 
fractionation samples were loaded in each well. Whole-cell extracts (WCE) of 
H1299, Clone 9 and H1299 transfected with 1 µg pCEP4-NME2 (H+N) were used 
as controls, with their loading amounts adjusted for visualisation purpose.  WCE 
of H1299 and Clone 9 were loaded at 3 µg/well, whereas H+N was loaded at 5 
µg/well. For histone H3, fractionation samples were loaded at 6 µg/well, and 
WCE at 15 µg/well. Western blot samples were separated on different gels for 
each primary antibody. Downward arrow indicates low to high exposures. Red 
area represents saturation of signal as a result of overexposure. Cyt, cytoplasmic; 
Npl, nucleoplasmic; Nol, nucleolar; H, H1299; Cl.9, Clone 9. 
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Figure 3.3.1.1 (Continued): Sub-cellular fractionation of U2OS cells. Western 
blots of fractions of U2OS cells untreated and treated with 10 µM MG132 for 4 
hours probed with anti-MDM2 (IF2) (A); fraction markers for nucleolus: B23 (sc-
53175), cytoplasm: α-tubulin (DM1A) and lamin A/C (sc-7297), and nucleus: 
histone H3 (ab1791) (B). C. Western blots as in panel A probed with anti-NME1 
(SC-465). D. Western blots as in panel A probed with anti-NME2 (L15). E. 
Western blots as in panel A probed with anti-NME1/2 (C1C3). Except for histone 
H3, 30 µg of fractionation samples were loaded in each well. Whole-cell extracts 
(WCE) of H1299, Clone 9 and H1299 transfected with 1 µg pCEP4-NME2 (H+N) 
were used as controls, with their loading amounts adjusted for visualisation 
purpose.  WCE of H1299 and Clone 9 were loaded at 3 µg/well, whereas H+N 
was loaded at 5 µg/well. For histone H3, fractionation samples were loaded at 6 
µg/well, and WCE at 15 µg/well. Western blot samples were separated on 
different gels for each primary antibody. Downward arrow indicates low to high 
exposures. Red area represents saturation of signal as a result of overexposure. 
Cyt, cytoplasmic; Npl, nucleoplasmic; Nol, nucleolar; H, H1299; Cl.9, Clone 9. 
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Figure 3.3.1.1 (Continued): Sub-cellular fractionation of U2OS cells. Western 
blots of fractions of U2OS cells untreated and treated with 10 µM MG132 for 4 
hours probed with anti-MDM2 (IF2) (A); fraction markers for nucleolus: B23 (sc-
53175), cytoplasm: α-tubulin (DM1A) and lamin A/C (sc-7297), and nucleus: 
histone H3 (ab1791) (B). C. Western blots as in panel A probed with anti-NME1 
(SC-465). D. Western blots as in panel A probed with anti-NME2 (L15). E. 
Western blots as in panel A probed with anti-NME1/2 (C1C3). Except for histone 
H3, 30 µg of fractionation samples were loaded in each well. Whole-cell extracts 
(WCE) of H1299, Clone 9 and H1299 transfected with 1 µg pCEP4-NME2 (H+N) 
were used as controls, with their loading amounts adjusted for visualisation 
purpose. WCE of H1299 and Clone 9 were loaded at 3 µg/well, whereas H+N was 
loaded at 5 µg/well. For histone H3, fractionation samples were loaded at 6 
µg/well, and WCE at 15 µg/well. Western blot samples were separated on 
different gels for each primary antibody. Downward arrow indicates low to high 
exposures. Red area represents saturation of signal as a result of overexposure. 
Cyt, cytoplasmic; Npl, nucleoplasmic; Nol, nucleolar, WCE, whole-cell extract; 
H, H1299; Cl.9, Clone 9. 
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3.3.2 In vivo His-ubiquitination assay 
Fractionation analyses of MDM2 and NME sub-cellular distribution suggest that 
NME1 and NME2 proteins could be targets for MDM2-mediated ubiquitination 
taking place in nucleoli. Since down-regulation of NME proteins in the presence 
of MDM2 was consistently observed in experiments presented earlier in this thesis 
(Figure 3.2.12.1), it is possible that MDM2 mono-/poly-ubiquitinate NMEs and 
then targets the modified NME for protein shuttling or degradation. Furthermore, a 
publication by David Meierhofer et al. listed NME1 as one of the potential 
substrate for ubiquitination in Hela cells using a strategy that utilises stable cell 
lines expressing 6xHis-biotin-tagged ubiquitin for purification of the ubiquitinated 
proteome [385]. In the same study, peptide (VMLGETNPADSKPGTIR) 
containing potential ubiquitination site (K100), found in both NME1 and NME2 
amino acid sequence was identified using mass spectrometry [385]. These data 
have led us to hypothesise that NME proteins could be subjected to MDM2-
mediated ubiquitination. Therefore, we aimed to utilise an in vivo ubiquitination 
assay to examine whether MDM2 plays a role in mediating modification of NME 
proteins. 
 
The in vivo ubiquitination assay is based upon purification of ubiquitin-conjugates 
by affinity chromatography. The in vivo ubiquitination assay utilised in this study 
allows for identification of substrates that are covalently modified by addition of 
6xHis-tagged ubiquitin (His6-Ub) moieties expressed in the cell. Ubiquitin 
conjugates can be purified by using Ni-NTA agarose beads due to high affinity 
binding of His residues to Ni ions (Please see Materials and Methods Section 
2.15). 
 
In order to test the validity of in vivo ubiquitination assay, a simplified control 
experiment was performed initially using a known target of MDM2 ubiquitination, 
i.e. p53. H1299 cells were transfected with constructs expressing His6-Ub, MDM2 
and/or p53, as described in Figure 3.3.2.1. Transfected cells were processed as 
described in Materials and Methods (Section 2.15), and harvested cells were 
processed for western blot analysis. A second aliquot consisting 90% of the 
sample was processed for the in vivo ubiquitination assay. In order to purify 
proteins conjugated to His6-Ub, lysates were incubated with Ni-NTA beads for 4 
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hours, washed and eluted with sample buffer supplemented with 200 mM 
imidazole. Eluted samples along with cell lysates were subjected to SDS-PAGE 
followed by Western blot analysis with antibodies against p53 (DO-1) and MDM2 
(IF2) as indicated in Figure 3.3.2.1. 
 
As expected, Western blot analysis of the experiment lysate shows that p53 was 
markedly down-regulated upon MDM2 overexpression (Figure 3.3.2.1A). Western 
blot with anti-MDM2 for Ni-NTA pulled down (i.e. affinity purified) samples 
reveals a ladder of slowly migrating high molecular weight bands  (Figure 
3.3.2.1B, Lane 3). These bands indicate the presence of ubiquitinated MDM2, 
which is consistent with the ability of MDM2 to self-ubiquitinate.  The presence of 
ubiquitinated p53 was also confirmed, especially when MDM2 is overexpressed, 
as indicated by the ladder of bands above 58 kDa (Figure 3.3.2.1C, Lane 3).  The 
low level of ubiquitinated p53 observed in Figure 3.3.2.1C, Lane 2 is most likely 
due to ubiquitination by endogenous MDM2 in H1299 cells. These results show 
that the in vivo ubiquitination assay performed is applicable for future 
experiments.  
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Figure 3.3.2.1: In vivo ubiquitination assay with His6-Ub, p53 and MDM2. 
H1299 cells were transfected with 0.5 µg of pCEP4-wt p53, 5 µg pHis6-Ub and 5 
µg pCMVNeoBam-MDM2 in 10-cm dishes using GeneJuice in several 
combinations, as indicated. Transfected cells were harvested 32h post-transfection. 
A. Western blot for lysate samples of the transfected cells, illustrating the steady-
state levels of the indicated proteins. Primary antibodies used were anti-β-actin 
(AC-15), anti-MDM2 (IF2), anti-p53 (DO-1). B. Western blot probed with anti-
MDM2 (IF2) for proteins purified with His6-Ub on Ni-NTA agarose beads. C. 
Same as panel B except that the blot was probed with anti-p53 (DO-1). Downward 
arrow indicates low to high exposures. 
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3.3.2.1 Examining whether MDM2 has a role in the ubiquitination of NME2 
MDM2 has been shown to mediate ubiquitination of many of its interacting 
proteins, such as p53, MDMX, pRB and DHFR, just to name a few [80, 109, 110, 
117]. Since NME2 has also been identified as an MDM2-interacting protein [183], 
it was examined whether NME2 was also ubiquitinated by MDM2. 
 
H1299 cells were transfected with plasmids expressing His6-Ub, MDM2 and/or 
NME2, as described in Figure 3.3.2.1.1B, to examine whether NME2 could be 
pulled down along with His6-Ub, in either the absence or presence of transiently 
transfected MDM2 (Figure 3.3.2.1.1, Lanes 4 and 5/6 respectively). An increase in 
affinity purified NME2 levels in the presence of transfected MDM2 would suggest 
MDM2 involvement in NME2 ubiquitination. Furthermore, cells transfected only 
with His6-Ub show the endogenous ubiquitination levels of the proteins of interest 
(Figure 3.3.2.1.1). Lanes 1 and 3 represent specificity controls for the assay, since 
His6-Ub was not transfected and any proteins pulled down would be the 
consequence of non-specific interactions of these proteins with Ni-NTA agarose 
beads. In addition, the samples in Lanes 5 and 6 from cells transfected with 
MDM2 and His6-Ub which should display detectable MDM2 E3 ligase activity, 
and therefore serve as a positive control for the assay (Figure 3.3.2.1.1).  
 
As expected, MDM2 is detected in ubiquitinated forms in the presence of His6-Ub 
(Figure 3.3.2.1.1B, Lanes 5 and 6). It is unclear why less MDM2 ubiquitination 
was detected when a higher amount of MDM2 plasmid (24 µg) was used for 
transfection. Considering that the total amount of DNA used for transfection in 
Lane 6 is higher than in the other conditions, one possibility might be that the 
chances of cells up-taking His6-Ub plasmid are lower in the presence of such high 
amount of MDM2, resulting in less self-ubiquitination. Using antibody specific for 
NME2 (L15), bands at molecular weight of approximately 50 kDa were also 
detected under all conditions (Figure 3.3.2.1.1C). However, signal detected for 
NME in the presence of MDM2 (Lanes 5 and 6) seems to be stronger and seems to 
increase with the increasing amounts of MDM2. It is difficult to assess whether 
this is an indication of NME ubiquitination since the bands observed at 50 kDa 
would be too high a molecular weight for a ubiquitinated form of 17-kDa NME. 
Moreover, relatively weak bands were also present in Lanes 1, 2, 3 and 4, 
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suggesting that NME can bind non-specifically to the Ni-NTA beads which makes 
this data difficult to interpret. It is possible that these bands are heavy chains of the 
secondary antibodies used in western blotting.  It is also known that NME2 is 
capable to binding to metal ions such as Mg2+, Mn2+ and Ca2+to facilitate the 
catalysis process and this may provide an alternative explanation for the observed 
result [396]. Furthermore, when antibody that can detect both NME1 and NME2 
(C1C3) was used to probe the Ni-NTA purified proteins, only bands with 
relatively even intensity were observed at about 50 kDa. 
 
To examine whether the observed bands at 50 kDa were due to non-specific 
binding of secondary antibody, the corresponding secondary antibodies for L15 
and C1C3 were used alone (i.e. without applying primary antibody) for probing 
western blot for the Ni-NTA purified proteins. Both types of antibodies display a 
band at about 50 kDa in all the lanes (Figure 3.3.2.1.1D), suggesting that the bands 
observed when developed with anti-NME antibodies were due to non-specific 
binding of secondary antibody used in western blotting. Interestingly, when only 
goat polyclonal secondary antibody was used, the band intensity in the presence of 
MDM2 was not greater Figure 3.3.2.1.1C, Lanes 5 and 6, in contrast to that 
observed using anti-NME2 (L15) primary antibody. This suggests that despite the 
presence of non-specific bands resulting from secondary antibodies used, our 
result does not eliminate the possibility of some unknown isoforms of NME being 
ubiquitinated by MDM2. Therefore, it was decided that it is worth studying the 
involvement of MDM2 in NME1 ubiquitination, to examine whether more 
information could be obtained by comparing the ubiquitination profiles of NME1 
and NME2. 
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Figure 3.3.2.1.1: In vivo ubiquitination assay with His6-Ub, NME2 and 
MDM2. H1299 cells were transfected with 8 µg of pCEP4-NME2, 13 µg pHis6-
Ub and indicated amount of pCMVNeoBam-MDM2 in 15-cm dishes using 
GeneJuice in several combinations, as indicated. All transfected samples included 
a plasmid that expresses β-gal (2 µg) to enable comparison of transfection 
efficiency and also actin to act as loading control. Transfected cells were harvested 
48h post-transfection. A. Western blot for lysate samples of the transfected cells, 
illustrating the steady-state levels of the indicated proteins. Primary antibodies 
used were anti-β-actin (AC-15), anti-MDM2 (IF2), anti-NME2 (L15) and anti-β-
gal (AB986). Red area represents saturation of signal as a result of overexposure. 
B, C and D represent proteins purified with His6-Ub on Ni-NTA agarose beads. B. 
Western blot using anti-MDM2 (IF2) antibody C. Western blot probed with anti-
NME2 (L15) and anti-NME1/2 (C1C3) primary antibodies. D. Western blot 
probed with solely secondary antibody (without incubation with primary 
antibody). Goat polyclonal (GP) was used for comparison with anti-NME (L15) 
and rabbit polyclonal (RP) for anti-NME1/2 (C1C3). This experiment was 
performed twice and results from both experiments were consistent. 
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Figure 3.3.2.1.1 (Continued): In vivo ubiquitination assay with His6-Ub, 
NME2 and MDM2. H1299 cells were transfected with 8 µg of pCEP4-NME2, 13 
µg pHis6-Ub and indicated amount of pCMVNeoBam-MDM2 in 15-cm dishes 
using GeneJuice in several combinations, as indicated. All transfected samples 
included a plasmid that expresses β-gal (2 µg) to enable comparison of 
transfection efficiency and also actin to act as loading control. Transfected cells 
were harvested 48h post-transfection. A. Western blot for lysate samples of the 
transfected cells, illustrating the steady-state levels of the indicated proteins. 
Primary antibodies used were anti-β-actin (AC-15), anti-MDM2 (IF2), anti-NME2 
(L15) and anti-β-gal (AB986). Red area represents saturation of signal as a result 
of overexposure. B, C and D represent proteins purified with His6-Ub on Ni-NTA 
agarose beads. B. Western blot using anti-MDM2 (IF2) antibody C. Western blot 
probed with anti-NME2 (L15) and anti-NME1/2 (C1C3) primary antibodies. D. 
Western blot probed with solely secondary antibody (without incubation with 
primary antibody). Goat polyclonal (GP) was used for comparison with anti-NME 
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(L15) and rabbit polyclonal (RP) for anti-NME1/2 (C1C3). Downward arrows 
indicate low to high exposures. This experiment was performed twice and results 
from both experiments were consistent. 
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3.3.2.2 Examining whether MDM2 has a role in the ubiquitination of NME1  
Since NME1 shares a high degree of homology with NME2, we have also 
examined whether NME1 is a target for MDM2 ubiquitination. For this purpose, 
in vivo ubiquitination assay similar to Section 3.3.2.1 was performed to study 
whether MDM2 might modify NME1 by ubiquitination, along with NME2 for 
comparison. H1299 cells were transfected with constructs expressing His6-Ub, 
MDM2, NME1 or NME2 in different combinations, as described in Figure 
3.3.2.2.1A, to examine whether NME1 could be pulled down along with His6-Ub, 
in either the absence or presence of transiently transfected MDM2. 
 
Based on the western blot analysis of the transfected cell lysate (Figure 3.3.2.2.1B 
and C), both NME1 and NME2 appear to be down-regulated when co-transfected 
with His6-Ub alone (Lane 3), and the down-regulation was more prominent in the 
presence of both ubiquitin and MDM2 (Lane 5). MDM2 has been demonstrated in 
this study to play a role in NME2 down-regulation, and thus it is not surprising 
that MDM2 also has the same effect on NME1. As expected, western blot analysis 
(Figure 3.3.2.2.1D) shows two distinctive ladders of slowly migrating bands in the 
presence of MDM2 (Lanes 5 and 8), suggesting that ubiquitinated MDM2 has 
been pulled down on Ni-NTA agarose beads and that MDM2 E3 ligase activity 
was present. However, western blot analyses of Ni-NTA purified proteins using 
anti-NME1 antibody does not seem to show any signs of NME1 ubiquitination by 
MDM2, as only what seems to be non-specific bands were observed (Figure 
3.3.2.2.1E). Similarly, Figure 3.3.2.2.1F clearly shows that NME2 is also not 
ubiquitinated by MDM2. However, consistent with previous observation in this 
thesis (Figure 3.3.2.1.1C), the non-specific bands at 50 kDa seems to have greater 
intensity in the presence of His6-Ub and MDM2. 
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Figure 3.3.2.2.1 (To be continued) 
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Figure 3.3.2.2.1 (To be continued) 
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Figure 3.3.2.2.1: In vivo ubiquitination assay with His6-Ub, NME1 and 
MDM2. H1299 cells were transfected with 8 µg of pCEP4-NME1, 8 µg of 
pCEP4-NME2, 13 µg pHis6-Ub and indicated amounts of pCMVNeoBam-MDM2 
in 15-cm dishes using GeneJuice in several combinations, as indicated. All 
transfected samples included a plasmid that expresses β-gal (2 µg) to enable 
comparison of transfection efficiency and actin serves as loading control. 
Transfected cells were harvested 48h post-transfection. A, B and C Western blot 
for lysate samples of the transfected cells, illustrating the steady-state levels of the 
indicated proteins. Primary antibodies used were anti-β-actin (AC-15), anti-
MDM2 (IF2), anti-NME1 (SC465), anti-NME2 (L15) and anti-β-gal (AB986).  D, 
E and F represent western blots of proteins purified with His6-Ub on Ni-NTA 
agarose beads using anti-MDM2 (IF2), anti-NME1 (SC465), and anti-NME2 
(L15) antibodies, respectively. Downward arrows indicate low to high exposures. 
Red area represents saturation of signals as a result of overexposure. 
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3.3.2.3 Examining whether MDM2 has a role in the ubiquitination and NDPK 
activity regulation of NM23-LV 
Results presented in this thesis have thus far shown no evidence for MDM2-
mediated ubiquitination of NME1 or NME2. However, it remains unexplained as 
to why a 30 kDa band has been consistently detected in the nucleolar fractions, 
when Western blot of a fractionation study was probed with three different NME 
antibodies (Figure 3.3.1.1C, D and E). In addition, the fractionation data also 
suggest the possibility that some unknown NME isoforms might be ubiquitinated 
in the nucleoli (Figure 3.3.1.1C, E). Coincidently, in vivo ubiquitination assay 
described in Section 3.3.2.1 also implies that there is a possibility that an unknown 
isoform of NME is being ubiquitinated by MDM2 (Figure 3.3.2.1.1C). In the light 
of a study by Valentijn et al., which described a novel protein of 33-kDa that was 
named NM23-LV and which is a product of a read-through transcript of NME1 
and NME2 neighbouring genes [250], we hypothesised that the unknown band at 
30 kDa might represent NM23-LV, and that this long variant may be subjected to 
MDM2 ubiquitination.   
 
To examine whether NM23-LV is a target for MDM2 ubiquitination, H1299 cells 
were transfected with constructs expressing His6-Ub, NM23-LV, wt MDM2 or 
RFM, as described in Figure 3.3.2.3.1. RFM was included to examine whether 
protein ubiquitination, if any, was dependent on MDM2 E3 ligase activity. Note 
that RFM was used at half of the amount of wt MDM2 in order to adjust for 
stabilisation effect of RFM, to achieve a similar expression level with wt MDM2 
for comparison purpose. Along with the in vivo ubiquitination assay, transfected 
cells were also harvested 48h post transfection for NDPK activity, in order to 
examine the effect MDM2 on NM23-LV activity (Figure 3.3.2.3.2). 
 
As shown in western blot in Figure 3.3.2.3.1A, NM23-LV was detected at about 
28 kDa, unlike the published result by Valentijn et al. [250] suggesting that 
NM23-LV gives rise to a 33 kDa band on western blot. Prior to performing the in 
vivo ubiquitination assay, we have sequenced the plasmids kindly donated by Dr 
Linda Valentijn (Appendix 8) and also performed western blot analysis of cells 
transfected with these plasmids (Appendix 9). Based on these, we concluded that 
the 28-kDa band genuinely represents NM23-LV and that the observed difference 
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in the size of the band could be due to a number of factors, for example, the way 
the gels were run. Perhaps different percentages of gels and molecular weight 
markers were used, which may result in the differences observed. Co-transfection 
with His6-Ub seems to stabilise NM23-LV (Figure 3.3.2.3.1A Lanes 3 and 5) 
considering β-gal and β-actin levels were similar for these two conditions. A small 
degree of stabilisation of NM23-LV was also observed with the addition of wt 
MDM2 (Figure 3.3.2.3.1A Lanes 5, 6 and 7). However, this does not seem to be 
the case when NM23-LV was co-transfected with RFM (Lane 8). As shown in 
western blot with anti-MDM2 on Ni-NTA pulled down proteins (Figure 
3.3.2.3.1B), ubiquitination of MDM2 in a dose-dependent manner was clearly 
demonstrated in the presence of transiently transfected MDM2 (Lanes 6 and 7). As 
expected, only a low level of MDM2 ubiquitination was detected in the presence 
of RFM (Figure 3.3.2.3.1B, Lane 8), since E3 ligase activity is crucial for auto-
ubiquitination of MDM2. 
 
Interestingly, when the affinity purified samples were analysed by western blot 
using anti-NME1/2 antibody (Figure 3.3.2.3.1B), two distinctive bands of 
estimated molecular weights of 36 kDa (as indicated with ) and 40 kDa ( ) 
were observed in Lane 6 and Lane 7 on the lower exposure blot. Since unmodified 
NM23-LV is normally detected at 28 kDa on western blot, it is likely that the 
doublet of bands described earlier were mono-ubiquitinated forms of NM23-LV, 
considering each ubiquitin moiety weighs about 8.5 kDa. It is also likely that the 
monoubiquitination occurred at different sites on NM23-LV, leading to the slight 
shift in molecular weight, resulting in the doublet formation. Followed behind 
these two bands was a ladder of slowly migrating bands (high exposure blot, Lane 
6 and 7), indicating polyubiquitination of NM23-LV. The level of ubiquitination 
increases with the amount of wt MDM2 transfected, suggesting that NM23-LV is 
ubiquitinated by MDM2 in a dose-dependent manner. More interestingly, only a 
negligible amount of these bands was detected in RFM (Figure 3.3.2.3.1B, Lane 
8), even at a higher exposure, suggesting that ubiquitination of NM23-LV is E3 
ligase-dependent. Certain degree of NM23-LV ubiquitination was also detected in 
Lane 5 (high exposure blot), which is likely to be mediated by endogenous 
MDM2. 
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Figure 3.3.2.3.1: In vivo ubiquitination assay with His6-Ub, NM23-LV and 
MDM2. H1299 cells were transfected with indicated amounts (µg) of pcDNA3.1-
NM23-LV, pCMVNeoBam-MDM2, pCMVNeoBam-MDM2C464A and 13 µg 
pHis6-Ub in 15-cm dishes using GeneJuice in several combinations, as indicated. 
Note that RFM was used at half amount of wt MDM2 in order to achieve a similar 
level of expression for comparison purposes. All transfected samples included a 
plasmid that expresses β-gal (2 µg) to enable comparison of transfection efficiency 
and also actin to act as loading control. Transfected cells were harvested 48h post-
transfection. A. Western blot for lysate samples of the transfected cells, illustrating 
the steady-state levels of the indicated proteins. Primary antibodies used were anti-
β-actin (AC-15), anti-MDM2 (IF2), anti-NME1/2 (C1C3), and anti-β-gal 
(AB986).  B. Western blots of proteins purified with His6-Ub on Ni-NTA agarose 
beads using anti-MDM2 (IF2) and anti-NME1/2 (C1C3) antibodies, as indicated. 
Downward arrows indicate low to high exposures.  
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In terms of NDPK activity, no difference was observed in the activity of NM23-
LV when the levels were compared between cells transfected with NM23-LV 
alone or in combination with MDM2, and cells transfected with an empty vector 
control (Figure 3.3.2.3.2A). However, it is difficult to determine whether NM23-
LV possess NDPK activity based on this result, since NM23-LV expression levels 
were extremely low amidst the considerably higher abundance of endogenous 
NME1 and NME2 in the cells (Figure 3.3.2.3.2B). Thus it would be difficult, 
through this experiment, to detect any changes in NDPK activity caused by 
NM23-LV even if NM23-LV did possess NDPK activity. 
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Figure 3.3.2.3.2: Analysis of the NDPK activity with His6-Ub, NM23-LV and 
MDM2 transfection. Experimental design was the same as described in Figure 
3.3.2.3.1, NDPK activity assay was performed 48h after transfection. A. NDPK 
activity. Error bars indicate standard error (n=3). B. Western blot with anti-
NME1/2 (C1C3) and anti-β-actin (AC-15) showing the relative abundance of 
NM23-LV and NME1/2, as indicated by arrows. Red area represents saturation of 
signal as a result of overexposure.  
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In order to examine whether NM23-LV is a genuine target for MDM2-mediated 
ubiquitination, experiment described in Figure 3.3.2.3.1 was repeated, except for 
using HA-tagged NM23-LV plasmid (a kind gift from Dr Linda Valentijn). Since 
HA is not expressed endogenously, it can be used as an indicator for NM23-LV 
ubiquitination, if HA could be pulled down along with His6-Ub, in the presence of 
transfected MDM2. As shown on western blot in Figure 3.3.2.3.3, HA-NM23-LV 
was detected at approximately 28 kDa (Figure 3.3.2.3.3B), at a similar position as 
NM23-LV (Figure 3.3.2.3.3A). This is as expected since HA (9 aa) only has an 
estimated molecular mass of 1.1 kDa, which would be difficult to detect on a 
western blot. There seems to be some stabilisation of NM23-LV in the presence of 
His6-Ub and/or MDM2 (Figure 3.3.2.3.3B, Lanes 3, 4, 5 and 6) as observed in 
previous results presented in this thesis. However, this is more likely due to 
uneven transfection efficiency, as indicated by β-gal expression (Figure 
3.3.2.3.3A). As expected, MDM2 was ubiquitinated in the presence of His6-Ub 
and wt MDM2 (Figure 3.3.2.3.3D, Lane 5) but MDM2 ubiquitination was 
inhibited in cells transfected with RFM (Lane 6), indicative of polyubiquitination 
of MDM2 through E3 ligase activity. Consistent with observation in Figure 
3.3.2.3.1B (Lanes 5, 7 and 8), a thick band of approximately 36 kDa, indicating 
mono-ubiquitinated NM23-LV accompanied by a ladder of polyubiquitinated 
NM23-LV, was observed in the presence of His6-Ub and wt MDM2 (Figure 
3.3.2.3.3E, Lane 5), based on western blot probed with anti-NME1/2 (C1C3) for 
Ni-NTA purified proteins. Mono- and polyubiquitination of NM23-LV was clearly 
inhibited in the presence of RFM (Lane 6). There were also signs of NM23-LV 
ubiquitination, most probably mediated by endogenous MDM2. This result is 
supported by western blot using anti-HA (12CA5) antibody (Figure 3.3.2.3.3F), 
which demonstrates an NM23-LV ubiquitination profile identical to Figure 
3.3.2.3.3E. Overall, these results strongly suggest that NM23-LV is a substrate for 
MDM2-mediated ubiquitination and that this is E3 ligase- and dose-dependent 
phenomenon. 
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Figure 3.3.2.3.3 (To be continued) 
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Figure 3.3.2.3.3 (To be continued) 
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Figure 3.3.2.3.3: In vivo ubiquitination assay with His6-Ub, HA-NM23-LV 
and MDM2. H1299 cells were transfected with indicated amounts (µg) of 
pcDNA3.1-HA-NM23-LV, pCMVNeoBam-MDM2, pCMVNeoBam-
MDM2C464A and 13 µg pHis6-Ub in 15-cm dishes using GeneJuice in several 
combinations, as indicated. Note that RFM was used at half amount of wt MDM2 
to adjust for RFM stabilisation. All transfected samples included a plasmid that 
expresses β-gal (2 µg) to enable comparison of transfection efficiency and also 
actin to act as loading control. Transfected cells were harvested 48h post 
transfection. A, B and C. represent western blots for lysate samples of the 
transfected cells, illustrating the steady-state levels of the indicated proteins. A. 
Western blots probed with anti-MDM2 (IF2), anti-β-actin (AC-15), and anti-β-gal 
(AB986). B. Western blot probed with anti-NME1/2 (C1C3). The split bands in 
Lane 4 were caused by a crack across a complete membrane due to human error. 
Red areas correspond to signal saturation caused by overexposure. C. Western blot 
probed with anti-HA (12CA5). D, E, and F represent western blots of proteins 
purified with His6-Ub on Ni-NTA agarose beads using anti-MDM2 (IF2) antibody 
for D, anti-NME1/2 (C1C3) antibody for E, and anti-HA (16B12) antibody for F. 
This experiment was performed at least three times with consistent results. 
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3.3.2.4 Examining whether MDM2-mediated ubiquitination of NM23-LV 
results in proteasomal degradation 
The results previously presented in this thesis (Figures 3.3.2.3.2 and 3.3.2.3.3) 
have shown that NM23-LV can be ubiquitinated by MDM2 in a RING-finger-
dependent manner. We wanted to examine whether NM23-LV ubiquitinated by 
MDM2 is subjected to the proteasomal degradation, since one of the major roles of 
protein ubiquitination (particularly polyubiquitination) is to target proteins for 
proteasomal degradation. In order to examine whether NM23-LV ubiquitination 
by MDM2 follows the ubiquitin/proteasomal degradation pathway, in vivo 
ubiquitination assay was performed in the presence of proteasome inhibitor 
MG132. We expected to observe a shift in ubiquitination profiles upon inhibition 
of proteasome activity. 
 
H1299 cells were transfected with combinations of plasmids expressing NM23-
LV, MDM2 and pHis6-Ub, as described in Figure 3.3.2.4.1. Transfected cells were 
processed as described in Materials and Methods (Section 2.15), and harvested 
48h post-transfection. Transfected cells were treated with 100 µM of MG132 (in 
DMSO) 6h before harvesting in order to inhibit proteasome-dependent 
degradation and therefore increase the amount of cellular ubiquitinated proteins, or 
with DMSO as a negative control to test the effect of the drug vehicle on cells. 
 
As shown in Figure 3.3.2.4.1A, stabilisation of MDM2 was observed in cells 
treated with MG132 (Lane 7), but not with DMSO (Lane 5). This observation is 
expected, since ubiquitinated MDM2 could not be degraded through proteasome 
and therefore accumulated in the cells. Interestingly, NM23-LV was also stabilised 
in the presence of MG132 (Figure 3.3.2.4.1A, Lane 7), indicating that NM23-LV 
is subject to proteasome-mediated degradation in the cell. In addition, a slight 
increase in ubiquitinated protein was observed for both MDM2 (as expected) and 
NM23-LV when cells were treated with MG132 (Figure 3.3.2.4.1B, Lane 7) in 
comparison to when only DMSO was used (Lane 5). This increase of NM23-LV 
polyubiquitination is more noticeable in the high exposure blot probed with anti-
NME1/2 (C1C3).  Taken together, our in vivo ubiquitination data demonstrate that 
NM23-LV is a target for MDM2-mediated ubiquitination, that this occurs in a 
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dose- and E3 ligase-dependent manner, and that this modification by MDM2 
might also mark NM23-LV for proteasomal degradation.  
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Figure 3.3.2.4.1: In vivo ubiquitination assay with His6-Ub, HA-NM23-LV 
and MDM2 with addition of MG132. H1299 cells were transfected with 10 µg 
of pcDNA3.1-NM23-LV, 10 µg of pCMVNeoBam-MDM2, and 13 µg pHis6-Ub 
in 15-cm dishes using GeneJuice in several combinations, as indicated. All 
transfected samples included a plasmid that expresses β-gal (2 µg) to enable 
comparison of transfection efficiency and also actin to act as loading control. 100 
µM of MG132 was added to transfected cells 6h before harvest and DMSO was 
used as a control Transfected cells were harvested 48h post-transfection for in vivo 
ubiquitination assay. A. Western blots for lysate samples of the transfected cells, 
illustrating the steady-state levels of the indicated proteins. Primary antibodies 
used were anti-MDM2 (IF2), anti-β-actin (AC-15), anti-NME1/2 (C1C3), and 
anti-β-gal (AB986) B. Western blots of proteins purified with His6-Ub on Ni-NTA 
agarose beads using anti-MDM2 (IF2) and anti-NME1/2 (C1C3) antibodies. 
Downward arrow indicates low to high exposures.  
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Chapter 3.4 
 
Results 
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3.4 Functional consequences of NM23-LV and MDM2 interaction 
3.4.1 Investigation of whether NM23-LV interacts with MDM2 and/or 
possesses NDPK activity  
Results presented in Section 3.3 have demonstrated that NM23-LV, but not NME1 
or NME2, is subjected to ubiquitination by MDM2. In order to perform its 
function as an E3 ligase and catalyse the covalent attachment of a ubiquitin moiety 
to a substrate, MDM2 generally needs to interact with its substrate. Therefore, 
since MDM2 seems to be able to ubiquitinate NM23-LV, it is very likely that 
MDM2 is also able to interact with NM23-LV.  In addition, as reviewed in Section 
1.5.5, little is known about the function of NM23-LV. NM23-LV is a member of 
the NDPK family and it possesses a H118 site crucial for NDPK activity which 
makes it likely that the main function of NM23-LV is to act as a kinase. However, 
to our knowledge, the role of NM23-LV as a kinase and furthermore its interaction 
with MDM2 have not been studied. Results presented in Figure 3.4.2.3.2 have 
suggested that it is difficult to detect any NDPK activity contributed by NM23-LV 
when NM23-LV was transfected in cells that are already abundant with NME 
proteins. Therefore, it is necessary to isolate NM23-LV from cellular NMEs when 
performing NDPK activity assay, in order to specifically measure NDPK activity 
contributed by NM23-LV alone. In light of this, we aimed to examine whether 
NM23-LV possesses any NDPK activity and/or interacts with MDM2 using the 
immunoprecipitation approach through a single experiment. The effect of MDM2 
on NM23-LV NDPK activity was also investigated in this study. 
 
H1299 cells were transfected with 36 µg of pCMV-HA-EV, 36 µg of pcDNA3.1-
HA-NM23-LV, and 10 µg of pCMVNeoBam-MDM2 (as described in Figure 
3.4.1.1) using GeneJuice. Transfected cells were harvested 48h post-transfection 
and was processed for the immunoprecipitation assay, as described in Section 
2.16. As shown in Figure 3.4.1.1A, a striking MDM2 stabilisation was observed in 
cells co-transfected with HA-NM23-LV and MDM2 (Lane 4), despite having a 
lower transfection efficiency compared to that of in the absence of HA-NM23-LV 
(Lane 2), as illustrated by β-gal expression levels. Based on western blot of lysate 
samples shown in Figure 3.4.1.1C and E, HA-NM23-LV also appeared to be 
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stabilised by MDM2, particularly when anti-NME1/2 (C1C3) antibody was used. 
As expected, Western blot of the samples immunoprecipitated with HA antibody 
(16B12), displays an approximately 28-kDa band in cells transfected with HA-
NM23-LV (Figure 3.4.1.1D, Lanes 3 and 4) when probed with anti-HA (12CA5), 
indicating that NM23-LV has being immunoprecipitated. The presence of NM23-
LV has also been shown when western blots for the immunoprecipitated samples 
were probed with anti-NME1/2 (C1C3) and anti-NME2 antibody (Figure 3.4.1.1F 
and G, respectively). As shown in Figure 3.4.1.1B, MDM2 was clearly detected in 
the samples immunoprecipitated with HA antibody (16B12), upon co-transfection 
with HA-NM23-LV (Lane 4), but not in the absence of HA-NM23-LV (Lane 2). 
This indicates that MDM2 co-immunoprecipitates with NM23-LV, suggesting 
that, at least, these two proteins exist in a complex in the lysate. 
 
As shown in both Figure 3.4.1.1F and G, a noticeably greater amount of HA-
NM23-LV has been immunoprecipitated in the presence of MDM2 (Lane 4), 
suggesting that MDM2 might have a role in stabilising NM23-LV. Interestingly, 
an approximately 17-kDa NME protein (as indicated by ) has also been pulled 
down with HA-NM23-LV (Figure 3.4.1.1F and G, Lanes 3 and 4), and also in 
greater abundance when cells were co-transfected with MDM2 (Lane 4). The 17-
kDa band is most probably NME2 and not NME1, since a faint band at about 17 
kDa (as indicated with ) could be detected using NME2 specific antibody 
(Figure 3.4.1.1 G, Lane 4), but not using NME1 specific antibody (Figure 
3.4.1.1H, Lane 4).  The presence of NME2 in Figure 3.4.1.1F, Lanes 3 and 4 could 
be as a result of NM23-LV oligomerisation with NME2. It is likely that the greater 
amount of NME2 that has been pulled down in Lane 4 is due to the interaction 
between NME2 and MDM2, since NME2 has been shown to interact with MDM2 
[183]. 
 
The use of immunoprecipitation approach to isolate exogenous HA-NM23-LV for 
NDPK activity assay has demonstrated a negligible basal activity level in the 
absence of transfected HA-NM23-LV (Figure 3.4.1.1I). In the presence of both 
MDM2 and HA-NM23-LV, NDPK activity was significantly higher (93 U/ ml) in 
comparison to cells transfected with HA-NM23-LV alone (63 U/ ml). This 
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suggests that MDM2 may promote NDPK activity of NM23-LV, probably as a 
result of NM23-LV up-regulation. However, the increase in NDPK activity could 
also be attributed to NME2 present in the immunoprecipitated samples, as 
indicated by  in Figure 3.4.1.1F, Lanes 3 and 4.  
 
Overall, this study has demonstrated that NM23-LV can be co-
immunoprecipitated with MDM2 and is, at least, in the same complex with 
MDM2 within the cell lysate, suggesting that NM23-LV is likely to be an MDM2 
interacting protein. More intriguingly, NM23-LV has been shown to strikingly up-
regulate or stabilise MDM2. In addition, MDM2 seems to have an ability to up-
regulate NM23-LV levels. The analysis of NDPK activity also suggests that there 
is a possibility that NM23-LV possess NDPK activity and that MDM2 could 
promote NDPK activity of NM23-LV, although further studies are required to 
examine this. 
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Figure 3.4.1.1 (To be continued): 
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Figure 3.4.1.1 (To be continued): 
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Figure 3.4.1.1: NDPK activity assay for HA-NM23-LV following 
immunoprecipitation. H1299 cells were transfected with 6 µg of pCMV-HA-EV, 
36 µg of pcDNA3.1-HA-NM23-LV, and 10 µg of pCMVNeoBam-MDM2 in 
combinations in 15-cm dishes using GeneJuice. Transfected cells were harvested 
48h post-transfection and divided into two aliquots. The first aliquot consisting of 
10% of the samples was used for western blot analysis (Lysate), whereas the 
second aliquot containing the remaining samples was processed for the 
immunoprecipitation assay, as described in Section 2.16. 2 µg of anti-HA (16B12) 
antibody was added to the immunoprecipitation samples in order to allow antibody 
binding to HA-tagged NM23-LV (antigen) in the lysates. The samples were then 
incubated with Protein G Sepharose beads for 2h to capture the antibody/antigen 
complex on the beads. The washed beads were collected in two equal aliquots. 
One aliquot of the beads containing the immunoprecipitated proteins were re-
suspended in 1x protein sample buffer for Western blotting analysis (IP panel). 
The second aliquot was added with 80 µl of RIPA lysis buffer and was 
immediately used for NDPK activity assay. A, C, and E represent Western blot of 
the lysate samples of the transfected cells, using A. anti-MDM2 (IF2), anti-β-actin 
(AC-15), and anti-β-gal (AB986) antibodies; C. anti-HA (12CA5) and anti-β-actin 
(AC-15) antibodies; E. anti-NME1/2 (C1C3) and anti-β-actin (AC-15) antibodies. 
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B, D, F, G, and H represent proteins purified with anti-HA (16B12) antibody on 
Protein G Sepharose beads, followed by immunoblotting with B. anti-MDM2 
(IF2) antibody; D. anti-HA (12CA5) antibody; F. anti-NME1/2 (C1C3) antibody; 
G. anti-NME2 (L15); and H. anti-NME1 (SC465) antibodies. Note that only about 
half of Lane 4 (B) is shown due to human error. Downward arrows indicate low to 
high exposures. I. NDPK activity assay for the immunoprecipitated samples (n=3). 
P-values were derived from statistical analyses by Student’s t-test. Error bars 
indicate standard errors. IP, Immunoprecipitation; IB, Immunoblotting. 
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3.4.2 Examination of NDPK activity of immunoprecipitated HA-tagged 
NME2 and NM23-LV in HNME2:Cl.7  
Results presented in Section 3.4.1 suggest that it is likely that NM23-LV possesses 
NDPK activity and that MDM2 could promote NDPK activity of NM23-LV. 
However, we could not eliminate the possibility that the NDPK activity detected 
might be contributed, at least in part, by pulled down endogenous NME2, since 
NME2 can interact with both MDM2 and NM23-LV. Therefore, we aimed to 
perform an immunoprecipitation-NDPK activity assay experiment similar to one 
described in Section 3.4.1, except for using stable NME2 knockdown clones of 
H1299 parental cell line (HNME2:Cl.7). Characterisation of this cell line was 
described in Figure 3.2.4.1. We hypothesised that in the absence (or with 
negligible amount) of NME2 in the cells, the possibility of NME2 being pulled 
down with HA-tagged NM23-LV would be almost non-existent. Therefore, any 
NDPK activity detected from the immunoprecipitated samples would be solely 
contributed by NM23-LV.  
 
HNME2:Cl.7 cells were transfected with an increasing amount of pcDNA3.1-HA-
NM23-LV and 6 µg of pCEP4-HA-NME2, as described in Figure 3.4.2.1, using 
GeneJuice. pCMV-HA-EV was included as a negative control whereas HA-NME2 
served as a positive control. The amount of HA-NME2 used was adjusted for 
comparison with HA-NM23-LV. Transfected cells were harvested 48h post-
transfection and processed for immunoprecipitation and NDPK assay, as described 
in Figure 3.4.1.1. 
 
Western blot analyses of lysate samples in Figure 3.4.2.1A and B showed that the 
levels of HA-NM23-LV were considerably lower in comparison to HA-NME2 
levels, even though the amounts of HA-NM23-LV plasmids used for transfection 
were higher than HA-NME2 (Lanes 2, 3 and 4). When this experiment was 
designed, we wanted to minimise the amount of background NME2 and indeed, 
only a negligible amount of NME2 was present in the cells (Figure 3.4.2.1B). Note 
that there was a shift in HA-NME2 to approximately the same position as that of 
NME1 and this resulted in saturation of signal, as indicated by (*) in Figure 
3.4.2.1B, Lane 4. Furthermore, as expected, the level of NM23-LV and NME2 
proteins detected was consistent with their protein expression seen on western 
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blots of the HA-immunoprecipitated samples using either anti-HA (12CA5) or 
anti-NME1/2 (C1C3) antibodies (Figure 3.4.2.1C and D, respectively). A very 
faint band of what could be NME2 protein was detected both in cells transfected 
with HA-EV and HA-NM23-LV, and these bands seem to be at similar signal 
intensities. As shown in Figure 3.4.2.1G, NDPK activity increases with the 
amount of HA-NM23-LV transfected, with 8 U/ ml and 14 U/ ml for 12 µg and 36 
µg of HA-NM23-LV, respectively. On the contrary, NDPK activity for HA-NME2 
(6 µg) was recorded at 43 U/ ml, which is about 3.3-fold higher than that observed 
in cells transfected with 36 µg of HA-NM23-LV. However, when comparing the 
signal intensity of 6 µg of HA-NME2 and 36 µg of HA-NM23-LV using 
densitometry analysis (Figure 3.4.2.1C and D), the signal for HA-NME2 proteins 
detected was at least 6.9-fold higher in the presence of HA-NM23-LV, using anti-
NME1/2 antibodies for western blotting (Figure 3.4.2.1D, bands ‘g’ and ‘h’). 
Therefore, taking the protein expression levels of these immunoprecipitated HA-
tagged proteins into account, it is not unreasonable to conclude that NM23-LV 
could potentially contribute to NDPK activity at least two-fold higher than NME2, 
when an equal amount of NM23-LV and NME2 were used for NDPK activity 
assay. 
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Figure 3.4.2.1 (To be continued): 
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Figure 3.4.2.1: Examination of NDPK activity of immunoprecipitated HA-
tagged NME2 and NM23LV in HNME2:Cl.7. NME2 stable knockdown clone, 
HNME2:Cl.7, was transfected with 12 µg or 36 µg of pcDNA3.1-HA-NM23-LV 
and 6 µg of pCEP4-HA-NME2 in 10-cm dishes using GeneJuice. pCMV-HA-EV 
was included as a negative control whereas HA-NME2 serves as a positive 
control. The amount of HA-NME2 used was adjusted for comparison with HA-
NM23-LV. Transfected cells were harvested 48h post-transfection and processed 
for immunoprecipitation and NDPK assay, as described in Figure 3.4.1.1. A and B 
represent Western blot of the lysate samples of the transfected cells, using A. anti-
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HA (12CA5) and anti-β-actin (AC-15) antibodies; and B. anti-NME1/2 (C1C3) 
and anti-β-actin (AC-15) antibodies. (*) represents a shift in HA-NME2 to 
approximately the same position of NME1 and thus resulting in saturation of 
signal. C and D represent proteins purified with anti-HA (16B12) antibody on 
Protein G Sepharose beads, followed by immunoblotting with C. anti-HA 
(12CA5); and D. anti-NME1/2 (C1C3) antibodies; E and F correspond to 
densitometry analysis of the immunoprecipitated HA-tagged proteins as 
alphabeted in Western blots in C and D, respectively. Downward arrows indicate 
low to high exposures. G. NDPK activity for HA-immunoprecipitated samples 
(n=3). P-values were derived from statistical analyses by Student’s t-test. Error bar 
indicates standard error. IP, Immunoprecipitation; IB, Immunoblotting. 
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3.4.3 Analysis of the effect of MDM2 on NDPK activity of NM23-LV in 
NME2 knockdown clones 
Results presented in Sections 3.4.1 suggest that MDM2 is likely to promote 
NM23-LV NDPK activity. However, the experiment shown in Figure 3.4.1.1 was 
performed in H1299 cells, which contain a high level of endogenous NME2. The 
presence of this endogenous NME2 could contaminate immunoprecipitated HA-
tagged NM23-LV used for NDPK activity assay, making interpretation of NDPK 
activity measured difficult. Data described in Section 3.4.2 have demonstrated that 
stable NME2 knockdown clone HNME2:Cl.7 can be used in order to reduce 
cellular NME2 levels for immunoprecipitation-NDPK activity assay for HA-
NM23-LV. Therefore, we aimed to examine the effects of MDM2 on NM23-LV 
NDPK activity in HNME2:Cl.7. 
 
HNME2:Cl.7 cells were transfected with pCEP4-HA-EV, 12 µg of pcDNA3.1-
HA-NM23-LV, and 3.5 µg of pCMVNeoBam-MDM2, as described in Figure 
3.4.3.1, using GeneJuice. Transfected cells were harvested 48h post-transfection 
and processed for immunoprecipitation and NDPK assay, as described in Figure 
3.4.1.1. Based on western blot analyses of the lysates samples, MDM2 does not 
appear to have any effect on NM23-LV expression levels (Figure 3.4.3.1A, Lanes 
2 and 3), unlike previous results presented in Figure 3.4.1.1E. However, the up-
regulation effect of MDM2 on NM23-LV levels becomes more obvious when the 
levels of immunoprecipitated NM23-LV (Figure 3.4.3.1B, Lanes 2 and 3) were 
analysed. Consistent with our findings that MDM2 can co-immunoprecipitate with 
NM23-LV (Figure 3.4.1.1B), MDM2 was also pulled down with HA-NM23-LV 
(Figure 3.4.3.1B, Lane 3).  
 
NDPK activity was detected in the presence of NM23-LV even in the absence of 
endogenous NME2 in the immunoprecipitated samples, suggesting that the NDPK 
activity measured was genuinely contributed by NM23-LV. Furthermore, NDPK 
activity level increases in the presence of MDM2 (p=0.0446), suggesting a role of 
MDM2 in promoting NDPK activity of NM23-LV. It is therefore possible that the 
increase in NDPK activity is as a result of MDM2-mediated stabilisation of 
NM23-LV.  
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Figure 3.4.3.1: Examination of the effects of MDM2 on NM23-LV NDPK 
activity in NME2 knockdown clones. HNME2:Cl.7 cells were transfected in 
combinations with pCEP4-HA-EV, 12 µg of pcDNA3.1-HA-NM23-LV, and 3.5 
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µg of pCMVNeoBam-MDM2, in 10-cm dishes using GeneJuice. All transfected 
samples included a plasmid that expresses β-gal (1 µg) to enable comparison of 
transfection efficiency. Transfected cells were harvested 48h post-transfection and 
processed for immunoprecipitation and NDPK assay, as described in Figure 
3.4.1.1. A. Western blot for lysate samples of the transfected cells, illustrating the 
steady-state levels of the indicated proteins. Actin serves as loading control. 
Primary antibodies used were anti-β-actin (AC-15), anti-MDM2 (IF2), anti-NME2 
(L15) and anti-β-gal (AB986). B. Western blot for protein samples purified with 
anti-HA (16B12) antibody on Protein G Sepharose beads using anti-MDM2 (IF2) 
and anti-NME1/2 (C1C3) antibodies. Downward arrows indicate low to high 
exposures. C. NDPK activity for HA-immunoprecipitated samples (n=3). P-values 
were derived from statistical analyses by Student’s t-test. Error bar indicates 
standard error. 
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3.4.4 Investigation of the effect of NM23-LV on p53 protein levels in H1299 
and double null MEFs 
Results presented in Section 3.4.1 have indicated that NM23-LV is able to 
stabilise or up-regulate MDM2 levels. Since MDM2 is one of the main regulators 
of p53, we wanted to examine whether NM23-LV has any effect on p53 protein 
levels. Considering the stabilising effect NM23-LV has on MDM2, the 
expectation was that NM23-LV would down-regulate p53. 
 
To test this, p53-null H1299 cells were transfected with pCEP4-p53, 
pCMVNeoBam-MDM2 and pcDNA3.1-NM23-LV using GeneJuice, as described 
in Figure 3.4.4.1. 48h post transfection, cells were harvested and processed for 
SDS-PAGE and western blotting. Consistent with previous observations in this 
thesis (Figure 3.4.1.1A), co-transfection of MDM2 with NM23-LV leads to a 
marginal increase in NM23-LV levels and a dramatic increase in MDM2 levels 
(Figure 3.4.4.1A, Lane 4). As expected, MDM2 transfection leads to p53 down-
regulation in the cells, as observed in Figure 3.4.4.1A, Lane 2. In addition, p53 
levels decreased considerably more when both NM23-LV and MDM2 were 
transfected (Lane 4). This could be explained by the increase in the amount of 
MDM2 in the cells as a result of stabilisation by transfected NM23-LV. 
Interestingly, down-regulation of p53 by NM23-LV does not seem to be 
dependent upon MDM2 since a noticeable reduction in p53 levels has also been 
observed in cells transfected with NM23-LV (Figure 3.4.4.1A, Lane 3). However, 
it is possible that the observed reduction in p53 levels was due an increase in 
endogenous MDM2 level induced by transfected NM23-LV, even though the 
increase in MDM2 level could not be detected on western blot (Figure 3.4.4.1A, 
Lanes 1 and 3).  
 
To examine whether the inhibitory effect of NM23-LV on p53 level was indeed 
MDM2-independent, the experiment was repeated using mouse embryonic 
fibroblasts that are null for both p53 and MDM2 (p53-/-, Mdm2-/-), called double 
null MEFs. However, as shown in Figure 3.4.4.1B, the transfection efficiency for 
the transfection performed in double null MEFs was very low. It was difficult to 
detect the expression of transfected plasmids on western blots even when 80 µg of 
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protein samples (50 µg are normally used) were loaded into each lane for SDS-
PAGE. An exception to this was p53, as p53 was clearly detected in transfected 
cells, suggesting that transfection did occur. In addition, despite the poor 
transfection efficiency, the same effect of NM23-LV on p53 as demonstrated in 
H1299 (Figure 3.4.4.1A) has also been observed in double null MEFs. In addition, 
as shown in Figure 3.4.4.1A, Lane 3, NM23-LV seems to be able to down-regulate 
p53 levels in a MDM2-independent manner. Therefore, based on the results 
observed in H1299 and double null MEFs, it is likely that NM23-LV can down-
regulate p53 in a MDM2-independent manner. 
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Figure 3.4.4.1: Investigation of the effect of NM23-LV on p53 protein levels in 
H1299 and double null MEFs. H1299 or mouse embryonic fibroblasts double 
null MEFs (p53-/-, Mdm2-/-) cells were transfected with 0.2 µg of pCEP4-p53, 0.67 
µg pCMBNeoBam-MDM2 and 2.4 µg pcDNA3.1-NM23-LV in each well of a 6-
well plate using GeneJuice (for H1299) or Lipofectamine 2000 (for double null 
MEFs). All transfected samples included a plasmid that expresses β-gal (0.15 µg) 
to enable comparison of transfection efficiency. 48h post-transfection, cells were 
harvested and processed for SDS-PAGE and western blotting. A. Western blot for 
lysate samples of transfected H1299 cells (protein samples loaded at 50 µg/well) 
B. Western blot for lysate samples of transfected double null MEFs (protein 
samples loaded at 80 µg/well). Primary antibodies used were anti-β-actin (AC-15), 
anti-MDM2 (IF2), anti-p53 (DO-1), anti-NME1/2 (C1C3), and anti-β-gal 
(AB986). This experiment was performed twice with consistent results. 
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3.4.5 Examination of NM23-LV effects on p53 transcriptional activity  
Our data presented in in Section 3.4.4 suggest that NM23-LV may play a role in 
p53 down-regulation. To determine whether NM23-LV can exert an effect on p53 
transcription activity, luciferase assay was performed in p53-null H1299 and 
double null MEFs (p53-/-, Mdm2-/-) in triplicate wells of a 48-well plate. Cells 
were transfected with pGL4.11-p53RELuc-2, pRL-TK, pCEP4-p53, 
pCMVNeoBam-MDM2, pcDNA3.1-NM23-LV as described in Figure 3.4.5.1. 
Transfected cells were harvested 16h and 24h post-transfection and processed for 
luciferase assay, as described in Materials and Methods (Section 2.8). The activity 
of the Renilla luciferase serves as an internal control for the transfection 
efficiency. As wild-type p53 was reported to modulate the activity of some 
promoters [397], including HSV-TK used in this study for Renilla expression, it is 
necessary to analyse our results with caution. In experiments shown in Figure 
3.4.5.1A and B, although co-transfection of p53 and NM23-LV leads to a massive 
reduction in luminescence, it appears that Renilla activity also seems to decrease. 
Therefore, instead of normalising the firefly luciferase activity to Renilla activity 
as recommended by the manufacturer, the two luciferase activities were presented 
side by side for comparison. However, since the activity levels of Renilla activity 
were considerably lower than firefly luciferase activity, it is difficult to visualise 
Renilla activity on the graph, and thus a chart showing the amount of Renilla 
activity was also presented.  
 
The luciferase activity profiles for H1299 were similar at both 16h and 24h, except 
that Renilla activity at 24h was uneven (Figure 3.4.5.1A and B). As expected, the 
positive control plasmid p53-RE-luc2 was considerably induced following co-
transfection with p53 in both H1299 and double null MEFs at both 16h and 24h 
(Figure 3.4.5.1). Also, as expected, the presence of MDM2 results in a drop in 
luciferase luminescence. The presence of NM23-LV alone in H1299 at both 16h 
and 24h seems to reduce p53 activity to its basal level, comparable to that of EV. 
However, this effect is likely due to the lower transfection efficiency, as suggested 
by the corresponding Renilla activities. Therefore, it is difficult to conclude 
whether NM23-LV has any suppressive effect on p53 transcriptional activity. 
However, with similar Renilla activity at 16h, the presence of both NM23-LV and 
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MDM2 in H1299 leads to a massive reduction in luciferase activity to a level 
lower than in the presence of MDM2 alone (Figure 3.4.5.1A).  
In double null MEFs, transfection efficiency and luciferase activity profiles for 
both 16h and 24h were relatively similar. Contrary to the results seen in H1299, no 
significant reduction in p53 activity was observed in the presence of NM23-LV. 
However, consistent to H1299, NM23-LV co-transfection with MDM2 in MEFs 
also results in a considerable decrease in luciferase activity (Figure 3.4.5.1C and 
D). These results indicate that NM23-LV alone is unlikely to exert inhibitory 
effect on p53 activity, but may act synergistically with MDM2 to inhibit p53 
activity.  
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Figure 3.4.5.1: Luciferase assay for examining the effect of NM23-LV on p53 
transcriptional activity. Luciferase assay was performed in p53-null H1299 and 
double null MEFs (p53-/-, Mdm2-/-) in triplicate wells of a 48-well plate. Cells 
were transfected with 170 ng pGL4.11-p53RELuc-2, 17 ng pRL-TK, 5 ng pCEP4-
p53, 10 ng pCMVNeoBam-MDM2, 75 ng pcDNA3.1-NM23-LV in combinations. 
Transfected cells were harvested 16h and 24h post-transfection and processed for 
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luciferase assay, as described in Materials and Methods (Section 2.8). A and B 
represent luciferase assay performed in H1299 cells at 16h and 24h post-
transfection, respectively. C. and D. represent luciferase assay performed in 
double null MEFs at 16h and 24h post-transfection, respectively.  
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3.4.6 Analysis of the effects of NM23-LV on cell motility using Boyden 
chamber 
NME proteins are well known for their non-metastatic properties, and thus we 
wanted to examine whether NM23-LV, as a member of the NME family, has any 
effects on cell motility. Boyden chamber motility assay was performed as 
described in Materials and Methods (Section 2.11) to examine the effect of NM23-
LV on cell motility. H1299 cells were transfected with plasmids expressing either 
EV or NM23-LV in triplicates using GeneJuice, as described in Figure 3.4.6.1. 
Cells were harvested for Boyden chamber assay and western blot analysis 24h 
post-transfection. Interestingly, cells transfected with NM23-LV (Figure 3.4.6.1A) 
were shown to have significantly higher motility than EV (p=0.0064) (Figure 
3.4.6.1B). In other words, in the presence of NM23-LV, there was a significantly 
higher number of cells that managed to travel through the membrane pores, as 
illustrated in Figure 3.4.6.1C.  
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Figure 3.4.6: Boyden chamber motility assay for NM23-LV. To examine the 
effect of NM23-LV on cell motility, Boyden chamber motility assay was 
performed as described in Materials and Methods (Section 2.11). H1299 cells 
were transfected with 1 µg of pcDNA3.1-EV or pcDNA3.1-NM23-LV in each 
well of a 6-well plate using GeneJuice. Transfection was performed in triplicate. 
Cells were harvested for Boyden chamber assay and Western blot analysis 24h 
post-transfection. A. Western blot for lysate samples of the transfected cells, 
illustrating the steady-state levels of the indicated proteins. Primary antibodies 
used were anti-β-actin (AC-15), and anti-NME1/2 (C1C3). B. Analysis for 
Boyden chamber motility assay. C. Haematoxylin and eosin staining of the porous 
membranes excised from Boyden chamber after 18h of incubation. Cells that have 
travelled through the membrane would attach to the membrane and be stained for 
counting. Pictures were taken at randomly selected positions of stained 
membranes (Magnification: x10). Arrows indicate the membrane pores. This 
experiment was performed twice with consistent results. 
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3.4.7 Characterisation of NME fusion proteins 
Fluorescent proteins are often used to tag a protein of interest in order to study the 
biology of proteins of interest in vivo. In order to study more functional 
implications of NM23-LV, constructs expressing fluorescence-labelled NME 
fusion proteins were generated, as described in Section 2.1.10.1. We aimed to fuse 
NME with enhanced cyan/yellow fluorescent proteins (ECFP/EYFP), which are 
variants of GFP with enhanced fluorescence properties, to study NME proteins 
behaviour in cells, particularly NM23-LV sub-cellular distribution and interactions 
with other proteins. ECFP is a blue-shifted emission variant of GFP whereas 
EYFP is a red-shifted emission variant of GFP. EYFP and ECFP were selected 
because they function as donor-acceptor pair for fluorescence resonance energy 
transfer (FRET), which could be used for monitoring direct protein-protein 
interactions between EYFP and ECFP fusion proteins in living or fixed cells 
[398]. In order to generate a functional and properly folded fluorescent fusion 
protein, two constructs were designed for each NME, one construct would contain 
NME at the C-terminal and the other at the N-terminal, since many proteins fold 
with their C- and N-terminals exposed on the protein surface, rather than 
embedded in the protein core [399, 400]. A small linker of 7-15 aa was included 
between the fluorescent protein and the NME protein, to provide flexibility and to 
promote proper folding and functioning of the two proteins [400]. 
 
 
As described in Materials and Methods (Section 2.1.10.1), constructs that express 
fluorescence-labelled NME fusion proteins, NME1, NME2, NME2H118F and 
NM23-LV were generated by cloning these NMEs into pEYFP and pECFP 
vectors, resulting in both C- and N- terminally fluorescence-tagged forms of 
NMEs, as illustrated in Figure 2.1.9.1.1. Following NME fragments being 
subcloned into pEYFP and pECFP vectors at ECoRI and BamHI restriction sites, 
the constructs were excised at these two restriction sites to check for insertions 
(Appendix 10).  
 
Expression of the NME fusion constructs was also examined using fluorescence 
microscopy and western blotting (Figure 3.4.7.1). H1299 cells were transfected 
with each of these fusion constructs using GeneJuice. Plasmids expressing C-
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ECFP, C-EYFP, N-ECFP and N-EYFP were included as controls. 24h post-
transfection, cells were imaged using a fluorescence microscope before being 
harvested for Western blot analysis. As shown in Figure 3.4.7.1, cells transfected 
with NME fusion plasmids all expresses their corresponding fluorescent proteins. 
In general, NME proteins seem to fluoresce better when fused to C-terminal of 
ECFP/EYFP and fluorescence for NM23-LV fusion proteins was poorly detected. 
Molecular mass for EYFP/ECFP should be at 27 kDa using anti-GFP antibody. 
Thus NME1, NME2 and NME2H118F fusion proteins should each have a 
molecular mass at about 44 kDa, whereas NM23-LV fusion protein is expected to 
have a molecular mass at approximately 55 kDa. Western blot analyses using anti-
GFP and different antibodies specific for each NMEs demonstrated bands that 
represent the fusion proteins (Figure 3.4.7.1). A summary of antibodies with their 
detectable NME fusion proteins is represented in Table 3.4.7.1. There seems to be 
a truncation of fusion proteins as observed on Western blots probed with anti-GFP 
antibody (Figure 3.4.7.1A). This was a cause for concern, since it might be 
possible that fluorescence detected may not actually be coming from NME fusion 
proteins. However, since different distribution of fluorescence was observed in 
cells transfected with fluorescence-tagged NME, compared to ECFP or EYFP 
controls (which have even distribution throughout the cells), it is likely that most 
of the fluorescence detected in cells represents the expression of NME fusion 
proteins.  
 
Since C-EYFP-NM23-LV can be detected by both anti-GFP and anti-NME1/2 
(C1C3) antibodies at appropriate molecular weights on western blot (Figure 
3.4.7.1A and C) and its fluorescence expression was better than the other 
fluorescence-labelled NM23-LV, C-EYFP-NM23-LV and other C-EYFP fusion 
proteins were used for future transfection experiments. 
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Figure 3.4.7.1 (To be continued) 
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Figure 3.4.7.1 (To be continued) 
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Figure 3.4.7.1 (To be continued) 
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Figure 3.4.7.1: Characterisation of NME1, NME2, NME2H118F and NM23-
LV fusion proteins. H1299 cells were transfected with 1 µg of constructs that 
express fluorescence-labelled NME1, NME2, NME2H118F and NM23-LV fusion 
proteins, in each well of a 6-well plate, using GeneJuice. Plasmids expressing C-
ECFP, C-EYFP, N-ECFP and N-EYFP were included as controls. 24h post-
transfection, cells were harvested for Western blotting using A. anti-GFP; B. Anti-
NME2 (L15); C. Anti-NME1/2 (C1C3); and D. Anti-NME1 (SC465). Downward 
arrows indicate low to high exposures. 
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Figure 3.4.7.2 (To be continued) 
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Figure 3.4.7.2 (To be continued) 
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Figure 3.4.7.2 (To be continued) 
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Figure 3.4.7.2: Fluorescence microscopy for NME1, NME2, NME2H118F and 
NM23-LV fusion proteins. H1299 cells were transfected with 1 µg of constructs 
that express fluorescence-labelled NME1, NME2, NME2H118F and NM23-LV 
fusion proteins, in each well of a 6-well plate, using GeneJuice. Plasmids 
expressing N-ECFP, N-EYFP, C-ECFP and C-EYFP were included as controls. 
24h post-transfection, cells were imaged using a fluorescence microscope. NME 
proteins were fused to A. N-ECFP; B. N-EYFP; C. C-ECFP and D. N-EYFP. PC, 
phase contrast. 
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Table 3.4.7.1 Summary of antibodies and detected NME fusion proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary antibodies 
Fusion proteins Anti-GFP Anti-NME2 (L15) Anti-NME1 (SC465)  Anti-NME1/2 (C1C3)   
C-ECFP-NME1 ? ? ?  
C-ECFP-NME2 ? ? ?  
C-ECFP-NME2H118F ? ? ? ? 
C-ECFP-NM23-LV ?   
C-EYFP-NME1 ? ?  ?  
C-EYFP-NME2 ? ?  ?  
C-EYFP-NME2H118F ? ? ? ? 
C-EYFP-NM23-LV ?  ? 
NME1-N-ECFP ? ? ?  ? 
NME2-N-ECFP ? ? 
NME2H118F-N-ECFP ? ? 
NM23-LV-N-ECFP ? 
NME1-N-EYFP ? ? ?  
NME2-N-EYFP ? ? 
NME2H118F-N-EYFP ?  ? ? 
NM23-LV-N-EYFP ? 
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3.4.8 Examining the cellular localisation of NME fusion proteins using live 
cell imaging 
In order to monitor the behaviour and distribution of NME proteins in cells, 
H1299 cells were transfected with plasmids expressing C-EYFP labelled NME1, 
NME2, NMEH118F and NM23-LV. 24h post-transfection, live cell imaging was 
performed on transfected cells for a duration of 34h, as described in Materials and 
Methods (Section 2.10). Representative movies are available on the attached CD 
(Appendix 11). 
 
As expected, fluorescence signals for cells transfected with C-EYFP only were 
evenly distributed throughout the entire cell, including nucleus and cytoplasm 
(Figure 3.4.8.1A). The distribution of EYFP in cells was unchanged throughout 
the course of live cell imaging. C-EYFP-NME1 seems to predominantly reside in 
the cytoplasm, and has low expression in nuclei. Interestingly, our live cell 
imaging also show that C-EYFP-NME1 proteins slowly localise towards the 
nuclear periphery and the cells undergo apoptosis about 7h later (Figure 3.4.8.1B, 
Cell a). At the same imaging position (Figure 3.4.8.1B, Cell b), C-EYFP-NME1 
was seen to migrate towards the nuclear membrane (Time 09:14:46), forming a 
ring-like structure around the nuclear membrane about one and a half hour later in 
Cell b. This was then followed by accumulation of C-EYFP-NME1 between two 
nuclei of Cell b (Time 12:09:46). However, the accumulation of C-EYFP-NME1 
gradually disappeared within less than 2h and Cell b eventually died. 
 
Live cell imaging for C-EYFP-NME2 transfected cells shows that C-EYFP-NME2 
is also mainly localised in the cytoplasm (Figure 3.4.8.1C). Accumulation of C-
EYFP-NME2 was seen to result in different outcomes. For example, some cells 
were observed to undergo cell death, as seen in Cell c. In Cell d, accumulation of 
C-EYFP-NME2 slowly diffused away and the cell remained viable until the end of 
the imaging. Interestingly, in Cell e, C-EYFP-NME2 proteins slowly localise 
towards the nuclear periphery, forming a ring-like structure around the nuclear 
membrane, as observed in C-EYFP-NME1 transfected Cell b (Figure 3.4.8.1B). 
However, the ring-like structure disappeared, and instead of undergoing cell death 
like Cell b, C-EYFP-NME2 expressing Cell e continued to undergo mitosis 
successfully to produce Cell e1 and e2 (Figure 3.4.8.1C). Interestingly, the NME2 
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fusion protein also seems be more readily found in the nuclei shortly before the 
mitosis process (Figure 3.4.8.1C). 
 
C-EYFP fused with NME2H118F, which lacks kinase activity, seems to have 
similar sub-cellular distribution to NME1 and NME2, but appeared to be more 
readily found in nuclei. Accumulation of C-EYFP-NME2H11F protein generally 
leads to cell death (Figure 3.4.8.1D). Interestingly, similar to an observation in 
NME1 fusion protein (Appendix 11), no accumulation of C-EYFP-NME2H11F 
around the nuclear membrane was observed in Cell f (Figure 3.4.8.1D) before 
proceeding to a successful mitosis. Since fluorescence in Cell f was almost 
exclusive to the cytoplasm, it is likely that the fluorescence detected was not due 
to EYFP alone (as a truncation product of the NME2H118F fusion proteins). 
 
On the other hand, C-EYFP-NM23-LV transfected cells appear to undergo cell 
death about 33h after transfection (Figure 3.4.8.1E). Before the cells die, NM23-
LV proteins accumulate possibly in the endoplasmic reticulum, which indicates 
that the fusion proteins may not be processed properly in endoplasmic reticulum. 
In addition, C-EYFP-NM23-LV was also seen accumulating around the nuclear 
membrane, slowly migrating towards the furrow between two or three nuclei and 
then disappearing without the cell undergoing mitosis or apoptosis (Figure 
3.4.8.1E, Cell g). 
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Figure 3.4.8.1 (To be continued) 
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Figure 3.4.8.1: Examining the cellular localisation of NME fusion proteins 
using live cell imaging. In order to monitor the behaviour and distribution of 
NME proteins in cells, H1299 cells were transfected with 2 µg of plasmid 
expressing either C-EYFP labelled NME1, NME2, NMEH118F or NM23-LV, in 
each well of a 6-well plate, using GeneJuice. 24h post-transfection, live cell 
imaging was performed on transfected cells for a duration of 34h, as described in 
Materials and Methods (Section 2.10). Pictures of fluorescent cells at different 
time frame was illustrated above for cells transfected with A. C-EYFP, B. C-
EYFP-NME1, C. C-EYFP-NME2, D. C-EYFP-NME2H118F and E. C-EYFP-
NM23-LV. Time after transfection (Hours: Minutes: Seconds) was indicated in the 
top left corner of each picture. In the case of mitosis, daughter cells were 
numbered after the same alphabet as their parent cell. Representative movies are 
available on the attached CD (Appendix 11). PC, phase contrast. 
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3.4.9 Examining the effect of NME proteins on cell cycle using flow cytometry  
Live cell imaging data presented in Section 3.4.8 have suggested that 
overexpression of NME proteins may lead to mitotic failure. As the mitotic failure 
seems to happen after accumulation of NME proteins around the nuclear 
periphery, which was often accompanied by multi-nuclei formation, we wanted to 
examine whether overexpression of NME proteins would have any effect on cell 
division. We aimed to examine the effect of NME proteins on cell cycle using 
flow cytometry.  
 
H1299 cells were transfected with plasmids expressing fluorescent fusion proteins 
of NME1, NME2, NME2H118F and NM23-LV, as described in Figure 3.4.9.1. 
Lipofectamine 2000 was used as transfection reagent in order to achieve high 
transfection efficiency. Transfected cells were harvested 24h post-transfection and 
processed for flow cytometry analysis, as described in Materials and Methods 
(Section 2.17). Untransfected cells were used as negative control. 
 
In order to generate cell cycle profiles, the following plots measuring the 
following parameters (x and y axis, respectively) were created for each sample: 
FSC-Area vs. SSC-Area, FL2-Area vs. FL2-Width, FL1-Height (EYFP Log) vs. 
PI, as shown in Figure 3.4.9.1. As single cells are the subjects of analysis, FL2-
Area vs. FL2-Width plots were used to gate single cell and exclude debris and 
aggregates for analysis. Using the collection of single cells, FL1-Height (EYFP 
Log) was plotted to create a gate that is selective for only EYFP positive cells, 
using a threshold determined by the untransfected control. The EYFP gate was set 
so that no more than 0.5% of untransfected cells fall in the EYFP positive range. 
Since the emission spectra of EYFP overlaps with that of PI, it is possible that 
fluorescence from more than one fluorochrome was detected from a single 
channel. This could be a possible explanation for the top right-skewed dot-plot of 
FL1-Height (EYFP Log) vs. PI observed in the fluorescent fusion proteins. Since 
no compensation was used to correct this spectral overlap for this experiment, the 
right-skewed cells were gated out to ensure that only fluorescence detected from a 
particular fluorochrome is used for analysis. Cell cycle profiles for the samples 
were plotted as histograms of Cell Counts vs. PI Area for both singlets only and 
	   257	  
EYFP positive only cells. A summary of cell cycle analysis for EYFP positive 
only cells is represented in Table 3.4.9.1. 
As shown in Table 3.4.9.1, EYFP-NME1, -NME2 and -NM23-LV transfected 
cells appeared to have a slightly lower percentage of cells in G1-phase and a 
higher percentage of cells in S-phase, in comparison to EYFP alone. This is 
particularly noticeable in cells transfected with NM23-LV, with 4.6% less cells in 
G1-phase and 6.7% more cells in S-phase than EYFP. In addition, there are also 
3.61% less cells in G2-phase for NM23-LV transfected cells, compared to EYFP. 
No noticeable difference in cell cycle subpopulations was observed in 
NME2H118F transfected cells compared to EYFP only. In addition, 
overexpression of the NME fusion proteins did not seem to have an effect on DNA 
contents of the cells. However, since this experiment was only performed once 
using n=1, no statistical analysis was produced.  
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Figure 3.4.9.1: Examining the effect NMEs on cell cycle using flow cytometry. 
H1299 cells were transfected with 2 µg of plasmids expressing C-YFP fusion 
proteins of NME1, NME2, NME2H118F and NM23-LV, in each well of a 6-well 
plates, using Lipofectamine 2000. Transfected cells were harvested 24h post-
transfected and processed for flow cytometry analysis, as described in Materials 
and Methods (Section 2.17). 20,000 events were recorded for each run. 
Untransfected cells were used as negative control. Cell cycle analysis was 
performed for A. Untransfected, B. EYFP, C. EYFP-NME1, D. EYFP-NME2, E. 
EYFP-NME2H118F, and F. EYFP-NM23-LV transfected cells. Plots measuring 
the following parameters (x and y axis, respectively) were created: FSC-Area vs. 
SSC-Area, FL-2-Area vs. FL-2-Width, Cell Counts vs. PI, FL-1-Height (EYFP 
Log) vs. PI, Cell Counts vs. PI Area (of singlets gate and only EYFP positive 
gate). FL-2-Area vs. FL-2-Width is used to avoid doublets and clumped cells 
(Singlets gate). FL-1-Height (EYFP Log) vs. PI serves to select only EYFP 
positive cells, with gating threshold determined by running the untransfected 
control. Cell cycle analysis was performed using EYFP positive only cells using 
FlowJo Analysis Software, according to the Watson Pragmatic mathematical 
model to define the G1, S, and G2 phases of the cell cycle [401]. 
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Table 3.4.9.1: Summary of cell cycle analysis for EYFP positive cells. Cell 
cycle analysis was performed using EYFP positive only cells, which was gated 
using a threshold set on untransfected cells. Cell cycle was analysed using FlowJo 
Analysis Software according to the Watson Pragmatic mathematical model to 
define the G1, S, and G2 phases of the cell cycle [401]. Note that not 100% of 
EYFP positive cells fit in the cell cycle analysis, as shown the Total (%) column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
 EYFP positive 
(%) G1 (%) S (%) G2 (%) Total (%) 
Untransfected 0.5 N/A N/A N/A N/A 
EYFP 93.3 48.0 38.5 10.4 96.9 
NME1 72.4 45.3 39.4 12.6 97.3 
NME2 67.2 44.6 41.6 10.7 96.9 
NME2H118F 78.0 48.4 38.8 10.2 97.4 
NM23-LV 46.0 43.4 45.2 6.79 95.39 
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4. Discussion 
4.1 Interplay between MDM2 and NME2  
The global aim of work presented in this thesis was to investigate the mechanism 
of MDM2 in promoting increased cell motility and invasiveness in RCC cells. Our 
results showed that when the Boyden chamber motility assay was used, cells 
expressing high levels of MDM2 via transient transfection were observed to 
display an increase in cell motility that is independent of MDM2 RING-finger 
(Section 3.2.3.2). This result is consistent with the published results of Polański 
and colleagues who demonstrated that MDM2 promotes cell motility and 
invasiveness in a RING-finger-independent manner [384]. Although we could 
detect a change in motility consistent with the published results using Boyden 
chamber motility assay, one possibility as to why no difference in motility could 
be detected using the live cell imaging system lies in the fact that live cell imaging 
system is based on cell migration on a solid surface in a two-dimensional manner, 
which may under-represent the true cell movement in a physiological system. On 
the other hand, Boyden chamber motility assay assesses the ability of cells to 
travel in three-dimension, first moving towards and then squeezing through the 8-
µm pores, which may better resemble cell migration in a real tissue environment.  
 
In order to examine the effects of NME2 on cell motility, Boyden chamber 
motility assays were performed using stable clones expressing shRNA NME2 to 
“knockdown” NME2 expression in H1299 and Clone 9 cells (H1299 
overexpressing MDM2) (lines generated by Dr Maria Maguire). Down-regulation 
of NME2 in both HNME2:Cl.2 and Cl.7 cells resulted in significantly higher 
motility compared to H1299 and Scrambled controls (Figure 3.2.4.1C). Since cell 
motility is closely related to metastasis, this result suggests NME2 may act as a 
tumour suppressor by suppressing cell motility. Clone 9 cells and its derivatives 
NME2 knockdown cells were also more motile compared to their parental H1299. 
This is consistent with published findings that overexpression of MDM2 promotes 
cell motility [103, 384]. However, knockdown of NME2 in Clone 9 cells did not 
further increase cell motility compared to Clone 9, which might suggest that 
NME2 may not be able to exert its motility suppressive effect in cells already 
harbouring high levels of MDM2. Alternatively, it could be that Clone 9 and its 
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NME2 knockdown derivatives have reached their maximum attainable motility 
due to high MDM2 expression, and therefore the motility suppressive effect from 
NME2 is insufficient to reduce motility due to the presence of high levels of 
MDM2.  
 
Since NDPK activity is responsible for the synthesis of nucleic acid precursors, it 
was expected that cell proliferative capacity might be affected in cells lacking 
NME2 expression. In addition, overexpression of NME1 has been positively 
correlated with proliferative activity of lymphoid cells, suggesting a role of NME1 
in cell proliferation [402]. However, MTT analysis (Figure 3.2.4.1D) has shown 
that cell proliferation rate of all NME2 knockdown clones used in the motility 
assay was very similar to wild-type NME2 cells, which provides evidence that the 
difference in cell proliferation rate is unlikely to be responsible for the increase in 
motility observed in NME2 knockdown clones. Cell proliferation rate is an 
important consideration during motility analysis by Boyden chamber since it is the 
total number of cells which have migrated through the membrane which are 
counted and analysed, therefore if cell-lines had different proliferation rates this 
could over- or under- estimate the value and confound interpretation of results. 
 
As expected, all NME2 knockdown clones have shown considerably lower NDPK 
activity levels (Figure 3.2.4.1B). Interestingly, NDPK activity for Clone 9 is lower 
compared to H1299 leading us to speculate that overexpression of MDM2 might 
lower cellular NDPK activity to promote cell motility. However, the same result 
was not observed when NDPK activity assay was repeated with additional clones 
that overexpress MDM2 (MDM2 Cl.1 and Cl.3) (Figure 3.2.5.1), and thus it seems 
that the result seen in Clone 9 cells was likely due to possible differences selected 
through cell cloning. This also suggests that high levels of MDM2 may not have 
any affect on cellular NDPK activity. Nevertheless our results show that 
knockdown of NME2 abrogates most of the endogenous NDPK activity and 
promotes increased cell motility, which leads us to speculate that the role of 
NME2 as a metastasis suppressor may be, at least in part, dependent on NDPK 
activity.  
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Functional redundancy between NME1 and NME2 has been described in a 
number of studies. As mentioned in Section 1.5.3, both NME1 and NME2 
knockout mice are viable with only mild phenotypic differences and both strains 
can survive into adulthood [287, 288]. However, the combination of deleting 
NME1 and NME2 leads to lethality in mice [289], indicating that the viability of 
NME1 and NME2 knockout mice is probably due to redundancy. In addition, it has 
been shown that expression of both NME1 and NME2 proteins in wild-type mice 
is induced during liver regeneration after partial hepatectomy, in parallel with the 
increased hepatocyte proliferation rate [317]. However, NME1-null mice had no 
impact on liver regeneration, suggesting a compensatory mechanism by NME2 
and a dispensable role of NME1 in cell proliferation [317]. Moreover, Boissan et 
al. demonstrated that the lack of an NME1 gene in mice that develop HCC with 
pulmonary metastases had no influence on primary tumour formation [309]. 
However, there is a significant increase in NME2 protein expression in HCC 
tissue compared to non-tumour tissue of NME1-/- mice [309]. The increase in 
NME2 expression observed in NME1 knockout when compared to NME1 wild-
type mice (p=0.034) indicates that there was a compensatory increase in NME2 
protein expression in the tumour tissue in mice lacking NME1 [309]. However, 
our results suggest that there is a lack of compensatory effect between NME1 and 
NME2 in the systems we have studied. It appears that the increase in cell motility 
as a result of NME2 down-regulation is not compensated by motility suppressive 
effect of endogenous NME1 (Figure 3.2.4.1C). In addition, we have found that 
there was a lack of any compensatory increase of NME1 protein levels in response 
to down-regulation of NME2 in H1299 cells (Figure 3.2.15.1A). These 
observations suggest that NME1 and NME2 may have independent roles in certain 
biological functions that are irreplaceable by other isoforms. 
 
The NDPK activity assay used in this study does not discriminate between NDPK 
activity contributed by specific isoforms of NME, but only measures the global 
cellular NDPK activity. Thus, we had to find a way of discriminating between the 
contribution of each NME1, NME2, or both, to cellular NDPK activity, whilst still 
using this assay. To examine the contribution of each individual NME protein 
towards NDPK activity, NME1 and NME2 were down-regulated, individually or 
in combination, in H1299 cells using siRNA. NME1 down-regulation leads to 
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about 20% decrease in NDPK activity, whereas NME2 down-regulation leads to 
more than 50% decrease in activity in H1299 cells, as shown in Figure 3.2.15.1B. 
Interestingly, down-regulation of both NME1 and NME2 results in more than 70% 
decrease in cellular NDPK activity. These data suggest that although NDPK 
activity of NME2 represents a higher fraction of NDPK activity than NME1, it is 
the presence of the two NME isoforms that is responsible for the majority of the 
cellular NDPK activity, suggesting the importance of the oligomeric form of 
NME1 and NME2 [280, 290, 293]. These results are consistent with findings from 
other studies, for example it has been shown that NME1 silencing results in 20% 
and 15% reductions of the total NDPK activity in Hep2 and HCT8/S11 cells 
respectively [317]. Thus our results further support the notion that the NDPK 
intrinsic activity of NME1 only contributes to a minor proportion of the global 
cellular NDPK activity whereas NME2 provides considerably more and may be 
the single most active isoform of NME in terms of NDPK activity.  
 
Since NME2 can exist as oligomeric protein comprised of individual active 
subunits, we wanted to investigate whether an NME2 kinase dead mutant 
competes with wild-type NME2 for limited number of cellular binding sites and 
exerts an allosteric, possibly dominant negative effect on the catalytic functions of 
wild-type NME2. We wanted to determine whether a kinase dead mutant could 
suppress the activity of the hexameric NDPK allosterically and if so, what would 
the effect of MDM2 be on cells expressing such a kinase dead form. For example, 
would a kinase dead NME2 mutant protect cells against the motility promoting 
effects of MDM2? Therefore, we examined the effect of NME2H118F kinase dead 
mutant on wild-type NME2 NDPK activity through co-transfection of plasmids 
encoding the two proteins in H1299 cells, followed by NDPK activity assay. As 
expected, NME2H118F failed to induce any NDPK activity due to the lack of a 
phospho-acceptor histidine 118 residue for the high-energy phospho-protein 
intermediate for the transfer of phosphate groups (Figure 3.2.7.1). NDPK activity 
of NME2H118F was comparable to that of EV control. Unexpectedly, co-
expression of the kinase mutant and wild-type NME2 had no significant effect on 
NDPK activity produced by wild-type NME2. These data indicate that the kinase 
dead mutant NME2H118F has no effect in trans on cellular NDPK activity and 
thus it appears not to have any allosteric effect (assuming it is incorporated into 
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hexamers). This result is surprising because independent studies using clonogenic 
assays have reported that the expression of an NME2H118F mutant was correlated 
with markedly reduced viability in human breast carcinoma and murine melanoma 
cells [285, 378, 403]. Assuming the expression of a kinase mutant is inhibitory for 
clonogen formation, it would suggest that allosteric inhibition or competitive 
inhibition exists. However, we observed no evidence of either, suggesting that 
there is no enzymatic co-operativity between these NME subunits. Intriguingly, 
another study by Hamby et al., in which highly metastatic human melanoma cells 
were stably transfected with wild-type and catalytically inactive NME2H118Y, 
has demonstrated not only that the transfection with catalytically inactive 
NME2H118Y did not affect cellular viability, but also that metastatic potential of 
the melanoma cells was significantly reduced, as compared to transfection with 
wild-type NME2 [404]. The authors claimed that the metastasis suppressive effect 
of NME2H118Y overexpression is likely due to the ability of the catalytic inactive 
NME2H118Y to exert a dominant negative effect on wild-type NME2, possibly by 
competing with endogenous NME2 for binding sites, which implies that it is the 
presence of catalytically active NME2 in specific binding sites that promotes 
metastasis [404]. These results together with our own clearly identify conflicting 
indications of the impact of kinase mutations on cellular processes and on NDPK 
activity. Whilst it is not easy to reconcile these at this time, one possibility is that 
the cell type and/or cellular context may have a significant impact on the 
consequences of expressing NME mutants in a range of processes. Clearly, the 
role of NDPK activity in cellular viability and cancer metastasis requires further 
investigation. 
 
Although it remains unclear whether NDPK activity plays any role in the 
regulation of cellular motility and tumour suppression [241, 278-280], a growing 
body of evidence supports the notion that NDPK activity is dispensable for NME 
function as a suppressor of motility/metastasis [285, 377, 378, 403, 405]. For 
example, it has been shown that the suppressive effect of NME1 on invasion and 
colonisation of human prostate carcinoma cells is not mediated by its NDPK 
activity [405]. Furthermore, cellular NDPK activity was not correlated to the 
suppression of metastatic potential in murine T1735 melanoma cells, suggesting 
that NDPK activity may not be required for metastasis suppression [378]. On the 
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other hand, studies have shown that the NME1H118F mutant, that lacks the 
NDPK activity, exhibited compromised metastasis suppressor activity in a human 
melanoma cell line, suggesting that NDPK activity is required for full metastasis 
suppression [318].  
 
Despite the conflicting views on the role of NDPK activity in NME-mediated 
metastasis suppression, it is difficult to understand how a small protein almost 
entirely spanned by residues that are critical for NDPK activity could suppress 
cellular motility as NME2 does, in an NDPK activity-independent manner. In our 
efforts to decipher the mechanisms of action by which MDM2 inhibits NME2 
motility suppressive effect, we examined the effects of MDM2 on NME2 protein 
level and NDPK activity. Overall our results suggest that overexpression of 
MDM2 plays a role in down-regulation of NME1 and NME2 protein levels and 
possibly in suppression of NDPK activity. It is possible that reducing the protein 
levels of the non-metastatic protein NME would result in an increase in cell 
motility. Nevertheless, this result is in contrast to the published result by Polański 
et al. in which the authors found that ectopically expressed MDM2 has no effect 
upon the stability of NME2 in H1299 [183], which suggests that down-regulation 
of NME2 by MDM2 may not be the mechanism by which MDM2 modulates 
NME2 motility suppressive effect. The more apparent effect of MDM2 in down-
regulating NME1, a paralogue of NME2, is not entirely surprising. NME1 shares 
88% amino acid sequence similarity with NME2 and is well known for its role as 
a metastasis suppressor [406, 407]. Yeast two-hybrid library screening and tandem 
mass spectrometry analysis of MDM2 interacting proteins suggested that NME2 
but not NME1 is a direct MDM2-interacting protein [183]. However, co-
purification of NME1 with MDM2 in fractions from an MDM2 affinity column 
was also observed, suggesting that NME1 and NME2 complex with MDM2, 
perhaps through NME2 acting as a bridge between NME1 and MDM2 [183]. 
Therefore it is possible that NME2 acts as a bridge to bring MDM2 and NME1 
into close proximity so that MDM2 can exert its suppressive effect on NME1 and 
thereby liberating the motility suppressive effect of NME1 on the cells. 
Nevertheless, our results have provided some potential insights into the underlying 
mechanism regarding how the MDM2-NME2 interaction may regulate cell 
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motility, in which cell motility is often regarded as an underlying cause of cancer 
metastasis. 
 
4.2 Sub-cellular localisation of NME proteins 
It remains unclear whether the observed MDM2 suppressive effects on NME 
expression and NDPK activity described in Sections 3.2.10-13 were E3 ligase-
dependent since our data derived from examination of RFM effects on multiple 
occasions were rather inconsistent. As discussed in Section 1.4.2, MDM2 is an E3 
ubiquitin ligase that catalyses both the ubiquitination of its substrate proteins and 
also its own ubiquitination [57]. Mono-ubiquitination often leads to a change in 
sub-cellular localisation of target proteins, whilst poly-ubiquitination generally 
results in proteasomal degradation. Therefore, interaction of NME2 with MDM2 
might promote the ubiquitination of NME2 or NME1 that might be present in the 
same complex, possibly leading to degradation and/or translocation of the NME 
proteins. Therefore, in addition to the observed down-regulation effect of MDM2 
on NME1 and NME2 expression, it is possible that MDM2 may also have an 
effect on NME proteins sub-cellular localisation. Furthermore, it is possible that 
the suppressive effect of MDM2 is a compartmentalised effect and that it occurs, 
for example, in the nucleus, and that the effect could be diluted when the global 
NDPK activity was measured using whole cell lysate sample.  
 
Therefore, in order to gain a better understanding of the consequences of MDM2 
and NME2 interaction, we examined the cellular localisation of MDM2 and NME 
proteins using sub-cellular fractions of U2OS cells (prepared by Dr Carlos Rubbi). 
Western blot analysis of MDM2 has been performed for all fractions (cytosolic, 
nuclear and nucleolar) from untreated and proteasome inhibitor MG132-treated 
U2OS cells. Figure 3.3.1.1 shows that the main 90-kDa MDM2 band was 
abundant in the cytoplasmic fraction and was substantially enriched after MG132 
treatment, noticeably in nucleoli. One possibility is that nucleoli may be involved 
in the regulation of proteasome-dependent degradation of the 90-kDa MDM2. 
Three different NME antibodies have been used for detection of NME proteins in 
fractionated U2Os samples and 17-kDa NME1 and NME2 bands were found 
almost exclusively in the cytoplasmic fraction (Figure 3.3.1.1), consistent with a 
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few published reports that NME1 and NME2 are mainly localised in the cytosol 
[250, 270, 362]. Interestingly, treatment with proteasome inhibitor MG132 did not 
seem to lead to accumulation of either NME1 or NME2 proteins in the 
cytoplasmic fraction. This suggests that NME1 and NME2 might not be subjected 
to proteasomal degradation in the cytoplasm. Whilst we found the observation that 
MDM2 down-regulates NME1 and NME2 without targeting them for proteasomal 
degradation puzzling, we were also intrigued by a distinctive ~30-kDa band, found 
abundantly in both nucleoplasmic and, more noticeably, in nucleolar fractions 
(Figure 3.3.1.1). The nucleolar accumulation might reflect turnover of an ~30-kDa 
NME-related protein that trafficks to or through nucleoli. More interestingly, a 
ladder of bands was detected in the nucleolar fractions when probed with NME-
specific antibodies, indicating that some post-translational modifications of some 
isoforms of NME proteins may occur in nucleoli. The ladder also appeared to be 
slightly more abundant after treatment with MG132 (Figure 3.3.1.1C and E), 
suggesting that the unidentified isoforms of NME could be ubiquitinated in 
nucleoli, possibly for protein shuttling and/or proteasomal degradation and that 
this might be mediated by MDM2.  
 
4.3 NM23-LV, but not NME1 or NME2, is a substrate for MDM2-mediated 
ubiquitination 
As described above, analysis of sub-cellular fractions from U2OS cells for MDM2 
and NME suggest that NME proteins could be targets for MDM2-mediated 
ubiquitination. It is possible that MDM2 mono- or poly-ubiquitinates NME 
protein/s and that this post-translational modification then targets the NME for 
protein localisation or degradation, respectively. Interestingly, in a study using 
stable cell lines expressing 6xHis-biotin-tagged ubiquitin for purification of the 
ubiquitinated proteome, Meierhofer et al. identified NME1 as one of the potential 
substrate for ubiquitination in Hela cells [385]. Furthermore, mass spectrometry 
analyses show that both NME1 and NME2 amino acid sequences share a common 
peptide (VMLGETNPADSKPGTIR) which contains a potential ubiquitination site 
(K100) [385]. These data have prompted us to examine whether the NME proteins 
could be subjected to MDM2-mediated ubiquitination using an in vivo 
ubiquitination assay. 
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Although our results do not support the hypothesis that MDM2 modifies either 
NME1 or NME2 by ubiquitination, there are some questions that remained to be 
answered: (1) what is the 30-kDa band commonly detected in the nucleolar 
fractions when western blot of a fractionation samples was probed with three 
different NME antibodies (Figure 3.3.1.1C, D E)?; and (2) is it possible that there 
are other unknown NME isoforms that have been ubiquitinated by MDM2 as 
suggested by the cell fractionation data (Figure 3.3.1.1C, E) and in vivo 
ubiquitination assay (Figure 3.3.2.1.1C)? In the light of a study by Valentijn et al., 
that identified a novel NME protein named NM23-LV as a 33-kDa product of a 
read-through transcript of the tandemly located NME1 and NME2 genes [250], we 
speculated that the unknown band at 30 kDa may represent NM23-LV, and that 
this long variant may be modified by MDM2 ubiquitination.   
 
We therefore examined whether NM23-LV is a target for MDM2 ubiquitination 
using the same in vivo ubiquitination assay we had used previously in H1299 cells, 
as described in Figure 3.3.2.3.1. Interestingly, Western blot analyses of the affinity 
purified samples probed with an antibody that detects both NME1 and NME2 
(C1C3) clearly displayed two distinctive bands, of estimated molecular weights of 
36 kDa and 40 kDa, in the presence of MDM2 (Figure 3.3.2.3.1B). Considering 
that unmodified NM23-LV migrates at approximately 28 kDa on our western blot 
gels and that each ubiquitin moiety weighs approximately  8.5 kDa, it was possible 
that the doublet of bands were the result of mono-ubiquitinated forms of NM23-
LV. If mono-ubiquitination occurred at different sites on NM23-LV this might 
result in the slight shift observed by Western blot and hence lead to the doublet 
formation. In addition, MDM2 was also shown to poly-ubiquitinate NM23-LV 
(Figure 3.3.2.3.1). The fact that the levels of mono- and poly-ubiquitination 
increased with the amount of wt MDM2 transfected strongly suggests that NM23-
LV was ubiquitinated by MDM2 in a dose-dependent manner. Furthermore, 
NM23-LV ubiquitination was inhibited in cells transfected with RFM (Figure 
3.3.2.3.1B, Lane 8), implying that ubiquitination of NM23-LV is E3 ligase-
dependent.  
 
To ensure that the results described above were not due to non-specific binding of 
antibody and that NM23-LV is a genuine target for MDM2-mediated 
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ubiquitination, the experiment described in Figure 3.3.2.3.1 was repeated using 
HA-tagged NM23-LV plasmid. Since HA is not expressed endogenously, it 
provides a means of detecting the transfected epitope tagged form of NM23-LV in 
a highly specific manner. Our results in Figure 3.3.2.3.3 confirmed that NM23-LV 
is both mono- and poly-ubiquitinated by MDM2, in a RING-finger-dependent 
manner. Since one of the major roles for ubiquitination is to target the modified 
substrate for proteasomal degradation, the question arises as to whether 
ubiquitination of NM23-LV promotes proteasomal degradation. Treatment with 
proteasome inhibitor MG132 resulted in an increase in NM23-LV ubiquitination 
that is accompanied by stabilisation of the long variant compared to cells treated 
with DMSO (Figure 3.3.2.4.1), suggesting that MDM2 ubiquitinates and targets 
NM23-LV for proteasomal degradation.  
 
One question that arises following these studies is how MDM2 selectively 
ubiquitinates NM23-LV but not NME1 or NME2, even though the long variant is 
identical to the amino-terminal end of NME1 and all of NME2. The answer to this 
is unknown but it is likely that the overall structure of NM23-LV is important, for 
example, perhaps exposure of the responsible lysine residue(s) for ubiquitination 
by MDM2 can only occur in NM23-LV or perhaps NM23-LV binds to another as 
of yet unidentified intermediate protein which aids MDM2-mediated 
ubiquitination. Little has been reported on the biological roles of NM23-LV 
(reviewed in Section 1.5.5), but since NM23-LV is a member of the NME family 
and assuming that its NME2 derived component is still functional, it is likely that 
the main function of NM23-LV is to act as a kinase. Therefore, we investigated 
whether NM23-LV functions as an NDPK in an attempt to gain a better 
understanding of the functional consequences of NM23-LV ubiquitination by 
MDM2. 
 
4.4 NM23-LV potentially possesses NDPK activity 
It is difficult to conclude whether NM23-LV possesses NDPK activity, 
considering that the comparatively low expression levels of transfected NM23-LV 
which would make detecting activity from NM23-LV difficult as it would be 
masked by the considerably higher abundance of endogenous NME1 and NME2 
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in H1299 cells (Figure 3.3.2.3.2B). Therefore it was necessary to develop an 
experimental system that will allow us to isolate NM23-LV from cellular NME 
proteins, in order to selectively measure NDPK activity contributed by NM23-LV 
alone. Using an immunoprecipitation approach, we first isolated HA-tagged 
NM23-LV and then examined whether NM23-LV possesses any NDPK activity 
(Figure 3.4.1.1). At the same time, since ubiquitination of a substrate by MDM2 
normally involves MDM2 interacting with the substrate, we also examined the 
ability of MDM2 to interact with NM23-LV in the same experiment. Our results in 
Figure 3.4.1.1B have demonstrated that MDM2 was clearly detected in the 
immunoprecipitated samples upon co-transfection with HA-NM23-LV, but not in 
the absence of HA-NM23-LV. This indicates that MDM2 is able to form a 
complex with NM23-LV. Although this result does not tell us whether the 
interaction between MDM2 and NM23-LV is direct, it is likely that this 
interaction is crucial for the ability of MDM2 to ubiquitinate NM23-LV. 
Furthermore, our result (Figure 3.4.1.1A) has also demonstrated a dramatic 
MDM2 stabilisation in cells co-transfected with HA-NM23-LV and MDM2, 
compared to those without HA-NM23-LV, suggesting that NM23-LV can act to 
significantly stabilise MDM2.  Reciprocally, MDM2 also has an up-regulating 
effect on NM23-LV levels (Figure 3.4.1.1C and E). 
 
Immunoprecipitation of HA-NM23-LV for NDPK activity analysis demonstrated 
that there was a significant increase in NDPK activity in the presence of both 
MDM2 and HA-NM23-LV as compared to cells transfected with HA-NM23-LV 
alone (Figure 3.4.1.1). This suggests that MDM2 increases NDPK activity of 
NM23-LV, most likely by promoting NM23-LV up-regulation. Although we 
anticipated that isolation of NM23-LV by immunoprecipitation could eliminate 
the unwanted NDPK activity from endogenous NME proteins in H1299 cells, we 
have under-estimated the possibility that NM23-LV might interact with 
endogenous NME2, that has also been shown to interact with MDM2 [183]. 
Indeed, NME2 protein has been co-immunoprecipitated with HA-NM23-LV 
(Figure 3.4.1.1F and G, Lanes 3 and 4), particularly with greater abundance in the 
presence of MDM2 (Lane 4). Therefore, the increase in NDPK activity could be 
contributed by the presence of NME2 in the immunoprecipitated samples in 
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Figure 3.4.1.1F, Lanes 3 and 4, probably as a result of NM23-LV oligomerisation 
with NME2 and of the interaction between NME2 and MDM2, respectively [183]. 
 
We next examined the NDPK activity of immunoprecipitated HA-tagged NM23-
LV in NME2 stable knockdown clones of the H1299 cell line (HNME2:Cl.7), to 
minimise possible interaction between NM23-LV and endogenous NME2 and thus 
to try to minimise the contribution of endogenous NDPK activity resulting from 
co-purification with HA-tagged NM23-LV. Our results show that NDPK activity 
increases with the amount of HA-NM23-LV transfected (Figure 3.4.2.1). When an 
equal amount of HA-NM23-LV and HA-NME2 plasmids were used for 
transfection, NDPK activity for cells transfected with HA-NME2 was about 3.3-
fold higher than that of HA-NM23-LV transfected cells. However, densitometry 
analyses for the immunoprecipitated HA-tagged proteins shows that HA-NME2 
expression levels were at least 6.9-fold higher than that of HA-NM23-LV (Figure 
3.4.2.1). Therefore, not only may NM23-LV possess NDPK activity, but we have 
further estimated that if NM23-LV and NME2 were expressed at equal levels, then 
NM23-LV has the potential to produce NDPK activity that is at least two-fold 
higher than NME2. Clearly such estimates are not robust, but the point remains, 
that the experiments suggest that NM23-LV encodes NDPK activity. Given the 
low levels of co-purifying NME1 and NME2 it is unlikely that these provide the 
source of the NDPK activity. Therefore either the activity is derived from NM23-
LV or another, co-purifying protein provides it (possibly NME3 or NME4). 
Further studies will be required to clarify this issue.   
 
The occurrence of a read-through transcript connecting neighbouring genes, 
although rare in higher organisms, is not unprecedented, and some other examples 
are accompanied by functional consequences. For example, one of the functional 
consequences of the fusion of Kua protein with poly-ubiquitination regulator UEV 
(ubiquitin-conjugating enzyme variant) protein is that the domain regulating 
ubiquitination is redirected for localisation to cytoplasmic structures, rather than 
the normal UEV nuclear localisation [408]. As a result of such differences in sub-
cellular localisation, nuclear UEV and cytoplasmic Kua-UEV target different 
substrates for poly-ubiquitination [408]. However, in the case of NM23-LV, the 
fused proteins originally have similar functions and also belong to the same group 
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of the NME family of genes. It is possible that the two proteins encoded by these 
genes (NME1 and NME2) are engaged in the same biochemical pathway, such that 
a requirement for functional interaction would provide driving force for their 
evolutionary fusion. However, as mentioned, NM23-LV lacks exon 5 of NME1 
that houses H118 which is crucial for NDPK activity [250, 280], and thus it seems 
that the function of NDPK activity is not an obvious driver for the fusion process. 
Perhaps other biochemical activities such as the 3’-5’ exonuclease activity or 
alternatively structural requirements for interactions with other proteins for 
functional purposes that are driving the molecular evolution process. To our 
knowledge, neither the 3’-5’ exonuclease activity nor the ability to interact with 
other proteins has been documented for NM23-LV previously. Based on 
observations made during the course of this study (discussed in detail in Section 
3.4) it is unlikely that the presence of an NM23-LV read-through transcript is a 
chance event with no true biological function. 
 
The potential role of NM23-LV in supplying NDPK activity in the cells is 
puzzling, considering that NME1 and NME2 appears to provide sufficient supply 
for the cell. Since NM23-LV is a fusion product of part of NME1 and the entire 
NME2 protein, one could speculate that NM23-LV may negate the need for 
dimerisation since it is already a fusion and thus may resemble pre-formed dimers. 
Thus NM23-LV may provide the structural requirement for rapid assembly of the 
NME isoforms into oligomers, possibly for instant supply of NDPK activity. 
However, the NME monomers consist of four β-sheets whose surfaces are 
partially covered by six α-helices, and the structure of the kinase is based on 
folding of the β-sheets in an antiparallel orientation [284, 409]. Since the normal 
structure of the NME dimer consists of eight β-sheets, it is unlikely that NM23-
LV, which only contains seven β-sheets due to the lack of exon 5 of its NME1 
domain, is able to adapt to the antiparallel β-sheet formation in order to form a 
hexamer [250]. This may not be the whole story however, since our 
immunoprecipitation analysis has shown that NM23-LV and NME2 can co-purify 
as part of a complex (Figure 3.5.1.1F), suggesting the possibility of 
oligomerisation between NME2 and NM23-LV. However, further investigation of 
the direct interaction between the NM23-LV and NME1 or NME2 proteins is 
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required to determine whether NM23-LV is structurally competent for 
oligomerisation and whether the potential NDPK activity detected here can be 
unequivocally demonstrated in vitro.  
 
The NDPK activity of NM23-LV may have distinct functional consequences for 
the cell compared to NME1 and NME2. Intriguingly, our results suggest that 
MDM2 has opposing effects on NDPK activity of NM23-LV when compared to 
the effect on the NDPK activity of NME1. Whilst MDM2 increases NDPK 
activity of NM23-LV, probably through MDM2-mediated stabilisation of NM23-
LV, MDM2 has a suppressive effect on NDPK activity of NME1 and possibly of 
NME2. This specific effect of MDM2 on NM23-LV and NME1 or NME2 may 
reflect differences in the biological pathways regulated by specific NME proteins. 
For example, the suppressive effect of MDM2 on the NDPK activity of NME1 
may reduce the level of NTPs required for microtubule assembly, which is 
important for cell migration and differentiation [295]. On the other hand, the 
increased level of NDPK activity of NM23-LV may only be required for the more 
general role of supplying nucleotides for nucleic acid synthesis or this may have a 
role in providing NDPK activity to a specific sub-cellular location. Nevertheless, it 
is important to further confirm whether NM23-LV possesses NDPK activity 
before more speculations are made, for example, through NDPK activity analysis 
of a NM23-LV mutant that harbours H118F mutation on the NME2 part of the 
long variant. 
 
 
4.5 NM23-LV promotes up-regulation of MDM2 and has inhibitory effects on 
p53 expression and transcriptional activity 
Our study initially focussed on the effect of MDM2 on NM23-LV due to the 
ability of MDM2 to modify NM23-LV by ubiquitination. Therefore, it was 
surprising to discover that NM23-LV has a stabilising/upregulatory effect on 
MDM2 protein. It is well established that MDM2 is a negatively regulator of p53 
[48, 80-83] and based on the stabilising effect NM23-LV has on MDM2, we 
hypothesised that NM23-LV might have a suppressive effect on p53 protein 
levels. Consistent with previous observations presented in this thesis (Figure 
3.4.1.1A), NM23-LV and MDM2 positively regulate the steady-state levels of 
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each other, since co-transfection of MDM2 with NM23-LV results in a marginal 
increase in NM23-LV levels and a substantial increase in MDM2 levels (Figure 
3.4.4.1A, Lane 4). p53 protein levels decrease considerably in the presence of both 
NM23-LV and MDM2 (Lane 4), most likely due to the presence of a large amount 
of MDM2 in the cells as a result of stabilisation by NM23-LV. Interestingly, the 
presence of NM23-LV alone also resulted in a considerable reduction in p53 
protein levels (Figure 3.4.4.1A, Lane 3). However, it is possible that the observed 
reduction in p53 protein levels was due to an increase in endogenous MDM2 level 
induced by transfected NM23-LV, even though the increase in MDM2 protein 
level could not be detected on Western blot (Figure 3.4.4.1A, Lanes 1 and 3).  
 
To examine whether down-regulation of p53 by NM23-LV is independent of 
MDM2, the experiment described above was repeated in double null MEFs (p53-/-, 
Mdm2-/-). Although it was difficult to detect the expression of proteins produced 
from transfected plasmids due to the very low transfection efficiency in double 
null MEFs (Figure 3.4.4.1B), the expression of p53 was clearly detected in 
transfected cells. The effect of NM23-LV on p53 in double null MEFs 
recapitulated that observed in H1299 cells (Figure 3.4.4.1A). Since the presence of 
NM23-LV alone in the MDM2-null cells also resulted in a considerable decrease 
in p53 protein levels (Figure 3.4.4.1B, Lane 3), this suggests that NM23-LV has a 
role in p53 down-regulation that is independent of MDM2. Nonetheless, it seems 
likely that NM23-LV exerts a greater suppressive effect on p53 expression levels 
in the presence of MDM2, probably through stabilising MDM2 levels. The role of 
NM23-LV in p53 down-regulation then led us to examine whether NM23-LV has 
any effect on p53 transcriptional activity by performing luciferase reporter assays 
in p53-null H1299 and double null MEFs (p53-/-, Mdm2-/-) in which a p53 
responsive element regulates luciferase expression. Hindered by the uneven 
Renilla activities we observed, most likely due to low transfection efficiency, it is 
difficult to determine whether NM23-LV alone is capable of suppressing p53 
transcriptional activity. However, our results suggest that the presence of NM23-
LV augments the suppressive effect of MDM2 on p53 transcriptional activity 
since NM23-LV in combination with MDM2 resulted in a greater reduction in 
luciferase expression then MDM2 alone (Figure 3.4.5.1). The combinatorial effect 
of NM23-LV and MDM2 in reducing both protein levels and p53 transcriptional 
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activity can be explained by the stabilising effects of NM23-LV on MDM2 protein 
levels (Figure 3.4.4.1).  Briefly, as explained in Introduction (Sections 1.4.2.1 and 
1.4.4) an increase in MDM2 can lead to increased p53 poly-ubiquitination and 
proteasomal degradation, hence less p53 protein and subsequently less p53 
activity. Conversely, what is less clear is why expression of NM23-LV alone was 
able to reduce protein levels of p53 independently of MDM2. Nonetheless, based 
on these results there appears to be a cumulative effect on p53 repression (both 
protein expression and transcriptional) when MDM2 and NM23-LV are co-
expressed. 
 
The role of NME proteins in regulating p53 functions has been previously 
described. For example, Jung et al. reported that NME1 and its interacting partner 
STRAP physically interact with p53 and induce the dissociation of MDM2 from 
the p53-MDM2 complex to enhance p53 stability [410]. Overexpression of NME1 
and STRAP increases p53-mediated apoptosis and cell cycle arrest suggesting that 
NME1 and STRAP may play an important role in p53 regulation [410]. 
Furthermore, NME1 has also been reported to interact with the macrophage 
migration inhibitory factor (MIF) resulting in dissociation of MIF from MIF-p53 
complexes that seems to be crucial for alleviation of MIF-mediated suppression of 
p53-induced apoptosis and cell cycle arrest [411]. The ability of NME1 to promote 
p53-mediated apoptosis and cell cycle arrest supports the function of NME1 as a 
tumour suppressor.  
 
However, this seems opposite to the effect we have observed for NM23-LV on 
p53 expression levels and transcriptional activity since we have demonstrated that 
NM23-LV has the ability to down-regulate p53 and enhance MDM2-mediated p53 
activity suppression. This suggests that NM23-LV may have opposing effects on 
p53 stability/activity compared to NME1, implying that the NME proteins may 
have different roles in p53-mediated biological functions. Furthermore, the 
opposite effects of NME1 and NM23-LV on p53 stability/activity may be due to 
different mechanisms employed by the NME proteins to regulate p53 
stability/activity. For example, unlike NME1/STRAP, which has been 
demonstrated to increase p53 stability/activity by removing MDM2 from the p53-
MDM2 complex [410], NM23-LV appears to exert its suppressive effect on p53 
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stability/activity through stabilising MDM2. This highlights the multifaceted 
nature of NME proteins and adds another layer of complexity to the regulation of 
p53 activity by NME proteins. 
 
4.6 Functional consequences of NME proteins 
Since the NME family of proteins is well known for its non-metastatic properties 
and the potential for cellular motility is closely related to metastasis, we wanted to 
examine whether NM23-LV has any effect on cellular motility. Using a Boyden 
chamber motility assay, our study has demonstrated that H1299 cells transfected 
with NM23-LV have a significantly higher motility than empty vector control 
(p=0.0064) (Figure 3.4.6.1), suggesting that NM23-LV promotes cell motility. 
This is not entirely surprising, since NM23-LV has been shown in our study to 
dramatically increase the level of MDM2 (Figure 3.4.1.1), which in turn has a role 
in promoting cell motility and invasiveness [103, 384]. Thus, it is possible that 
NM23-LV has a cell motility promoting effect that is dependent of the presence of 
MDM2. However, it is unclear as to whether the putative NDPK activity of 
NM23-LV is responsible for the motility phenotype. Both the kinase dependence 
and role of MDM2 could be tested in future studies, the latter using MDM2-null 
cells. 
 
The discovery of NM23-LV as a highly specific ubiquitination substrate of 
MDM2 and the unexpected roles of NM23-LV in up-regulating MDM2 and 
promoting cell motility have sparked our interest in studying more functional 
implications of NM23-LV. In particular, we have generated constructs expressing 
fluorescence-labelled NME fusion proteins by fusing NME with ECFP/EYFP 
(Section 2.1.9.1) to study NME proteins sub-cellular distribution and their effect 
on cell behaviour.  
 
To begin to study whether the functions of NME proteins can be affected by their 
sub-cellular distribution, H1299 cells were transfected with plasmids expressing 
C-EYFP labelled NME1, NME2, NMEH118F and NM23-LV, followed by live 
cell imaging. Our results showed that C-EYFP-tagged NME proteins were mainly 
found in the cytoplasm (Figure 3.4.8.1), consistent with previously published 
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studies [250, 270]. Another common phenomenon observed was the accumulation 
of NME1, NME2 and NM23-LV fusion proteins at the nuclear periphery. The 
accumulation of the NME fusion proteins appeared to result in three different 
outcomes for the cell: 1) cell undergoes apoptosis; 2) accumulation of NME fusion 
protein disappears and the cell continues to be viable without division until the end 
of the course of live cell imaging; 3) accumulation of NME fusion protein 
disappears and cell divides into two daughter cells successfully (Figure 3.4.8.1). 
No accumulation of NME2H118F fusion protein, which lacks catalytic activity, 
was observed around the nuclear periphery that resulted in a successful mitosis 
(Figure 3.4.8.1D). Based on these observations, and published studies linking 
NME1 with cytokinesis [379], it is tempting to speculate that the accumulation of 
NME1 and NME2 around the nuclear periphery is generally required for mitosis 
and cytokinesis, perhaps to supply GTPs for the cell division process. It is also 
possible that NME1 and NME2 act as NDP kinases in providing local supply of 
nucleotides for GTPase dynamin function, as suggested in a study by Conery et al. 
in NME1 [379, 412]. In addition, Pinon et al. has also claimed that as well as 
cytosol distribution, NME1 and NME2 also partly localise to microtubules to 
support a role of NME in nucleotide channelling and in cell motility regulation 
[270]. This may explain our observation using live cell imaging (Appendix 11) 
which suggests that NME1 fusion proteins migrate towards the nuclear membrane 
in an ordered way, possibly along the microtubules. However, our result needs 
further verification, such as using specific marker for labelling the microtubule 
network.  
 
On the other hand, it has been suggested that NME1 can translocate to the nucleus 
upon treatment with DNA-damaging agents, such as cisplatin and UV radiation, 
possibly to carry out DNA repair processes [272]. For example, it has been 
reported that, upon a pro-apoptotic stimulus triggered by cytotoxic T-lymphocytes, 
NME1 found in an ER-associated complex with other proteins is transported to the 
nucleus where it carries out a DNA cleavage reaction [413]. Therefore, apart from 
cell division purpose, the association of NME proteins with nuclei as demonstrated 
our live cell imaging may also appear to be required for DNA repair purposes. 
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It is unclear why cells transfected with C-EYFP-NM23-LV undergo cellular death 
(study was not supported by quantitative analysis) (Figure 3.4.8.1E). It is possible 
that NM23-LV may have toxic effects on cells and therefore these cells could not 
tolerate high levels of NM23-LV. Since our results have shown that NM23-LV 
fusion proteins accumulate possibly in the ER in cells that are about to undergo 
cellular death, it is also possible that the fusion proteins were not being processed 
properly in the ER. Another possibility is that NM23-LV fusion protein might be 
too large in size (~55 kDa) for a free diffusion through nuclear pore complexes, 
which typically accept proteins smaller than 40 kDa, and thus cannot enter the 
nucleus where ubiquitination of NM23-LV may normally occur. Perhaps it is the 
accumulation of NM23-LV fusion proteins, as a result of these proteins not being 
able to enter the nucleus, that leads to cell death. These are all just speculations 
since our analysis was limited by the absence of organelle markers to assist 
examination of the dynamic distribution of NME proteins in different sub-cellular 
compartments. More experimental evidence is necessary for verification and to 
address questions that remain unanswered, for example, where does the interaction 
of MDM2 and NM23-LV take place? Does ubiquitination of NM23-LV by 
MDM2 occurs in the nucleus or nucleolus?  
  
Our live cell imaging results have suggested that NME proteins overexpression 
may play a role in causing mitotic failure, which was often accompanied by multi-
nuclei formation and seems to happen after accumulation of NME proteins around 
the nuclear periphery. This has led us to investigate the effect of NME proteins 
expression on cell cycle using flow cytometry in H1299 cells (Figure 3.4.9.1). We 
have found that cells expressing NME1, NME2 or NM23-LV fusion proteins have 
a slightly lower percentage of cells in G1-phase but a higher percentage of cells in 
S-phase, as compared to cells that expressed EYFP only. The higher percentage of 
cells in S-phase is in line with the role of NDPK in DNA synthesis. Furthermore, 
overexpression of the NME fusion proteins seems to have no effect on the DNA 
ploidy, suggesting that NME proteins may not play a role in causing cytokinesis 
failure. Nevertheless, before confident conclusions can be made, this study needs 
to be repeated with higher number of replicates and with appropriate 
compensation to correct the emission spectral overlap between EYFP and PI to 
avoid sampling bias. 
	   283	  
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   284	  
5. Conclusion 
In our efforts to unravel the mechanisms of action by which high levels of MDM2 
promotes cell motility or metastasis, we examined how MDM2 inhibits NME2 
motility suppressive effect by studying the roles of MDM2 on NME2 NDPK 
activity and protein levels. Overall our results suggest that overexpression of 
MDM2 plays a role in down-regulation of NME1 and NME2 protein levels and 
possibly suppression of NDPK activity. More interestingly perhaps, our current 
studies have identified NM23-LV as a novel and highly specific substrate for 
MDM2-mediated ubiquitination that is dependent on MDM2 E3 ligase activity. 
Furthermore, our results have also shown that NM23-LV can promote MDM2 
stabilisation (Figure 3.4.1.1A), which may serve as an explanation for the 
observed motility promoting effects of NM23-LV. Considering the canonical 
tumour suppressive effect of the NME protein family, these findings have 
highlighted the pleiotropic effects of the NME proteins and expanded the 
complexity of the regulation between MDM2 and NME family members. The 
complicated interplay between MDM2 and NME proteins is illustrated in our 
model (Figure 5.1). NM23-LV-induced MDM2 overexpression may represent an 
alternative but functionally synonymous means of p53 inactivation. Although this 
does not explain the co-expression of MDM2 and p53 in RCC, our findings have 
undoubtedly unveiled a novel and potentially critical mechanism for MDM2 up-
regulation as well as identifying a new substrate for MDM2 ubiquitination. The 
former observation raises the question whether NM23-LV has an inhibitory effect 
on MDM2 auto-ubiquitination. Perhaps NM23-LV increases MDM2 expression 
levels by inhibiting MDM2 auto-ubiquitination or preventing the transport of 
ubiquitinated MDM2 to proteasomes. This, however, requires further 
investigation. 
 
Many cellular proteins are ubiquitinated at some stage in their life cycle. Whilst 
poly-ubiquitination has almost become a synonym for protein degradation, it is 
worth noting that protein ubiquitination has a plethora of signalling functions 
outside the proteasome pathway. There seems to be a high degree of specificity in 
MDM2-mediated ubiquitination of NM23-LV, since MDM2 does not seem to 
ubiquitinate closely related NME1 and NME2 proteins. This may highlight the 
stringent regulation of ubiquitination that is important for the orchestration of 
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cellular behaviour. It is possible that MDM2 plays a dual role in regulating NM23-
LV. For example, our data have suggested that MDM2 can poly-ubiquitinate 
NM23-LV to target it for proteasomal degradation. Perhaps MDM2-mediated 
mono-ubiquitination of NM23-LV plays a role in determining sub-cellular 
localisation, membrane trafficking or endocytosis [84, 414, 415].  Some of the key 
questions we need to address include: What stimulates mono- or poly-
ubiquitination of NM23-LV by MDM2? Does NM23-LV ubiquitination occur in 
the nucleoli? What are the downstream pathways regulated by NM23-LV 
ubiquitination? Can the status of NM23-LV ubiquitination be reversed by DUBs 
as a mean of NM23-LV regulation? Perhaps most importantly, what is the 
function of NM23-LV? Understanding the ubiquitin signals in these pathways will 
be beneficial for basic biochemical research and development of therapeutics 
targeting the ubiquitin system. Although the present study has demonstrated that 
NM23-LV is a substrate for ubiquitination by MDM2 and that NM23-LV has a 
substantial effect on MDM2 upregulation, more physiological evidence regarding 
the functional consequence of these effects is required. Tissue analysis has 
demonstrated that NM23-LV is ubiquitously expressed at the mRNA level, with 
the exception of the kidney [250]. Therefore, it will be important to determine the 
expression or status of NM23-LV in RCC to examine whether NM23-LV plays a 
role in the development of the disease.  
 
In conclusion, our studies have established a novel and apparently highly specific 
relationship between MDM2 and NM23-LV. This relationship not only identifies 
a new direction for studying the regulation of MDM2 and the possible related 
cancer diseases, but may also add to the functional range of the NME family. 
Thorough understanding of the specificity of MDM2 interaction with NM23-LV, 
as well as of mono- and poly-ubiquitination of NM23-LV, will help us to define 
the physiological functions and regulation of these proteins, which could allow 
development of potential therapeutic targets for RCCs and possibly other cancers. 
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Figure 5.1: A schematic model of the interplay between p53, MDM2 and 
NME proteins. Ub, mono-/poly-ubiquitination. 
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7. Appendices 
Appendix 1: Conditions for amplification of NME DNA fragments by PCR. 
A. DNA templates and primers; B. PCR components and; C. conditions used for 
amplification of NME DNA fragments. 
A 
Template Forward primer Reverse primer 
pCEP4-NME2 NME2-1F+ECoRI  NME2-dSTOP-R+BamHI  
pCEP4-NME2 NME2-1F+ECoRI  NME2-R+BamHI  
pCEP4-NME2H118F NME2-1F+ECoRI  NME2-R+BamHI  
pCEP4-NME2H118F NME2-1F+ECoRI  NME2-dSTOP-R+BamHI  
pCEP4-NME1 NME1-1F+ECoRI-S NME1-dSTOP-R+BamHI  
pCEP4-NME1 NME1-1F+ECoRI-S  NME1-R+BamHI  
pcDNA3.1-NM23-LV  NME1-1F+ECoRI-S  NME2-dSTOP-R+BamHI  
pcDNA3.1-NM23-LV  NME1-1F+ECoRI-S  NME2-R+BamHI 
 
B   
Components for PCR / 50 µ l 
5x Phusion HF Buffer  x 1 
dNTPs 200 µM 
F-primer 0.1 µg  
R-primer 0.1 µg  
Phusion DNA polymerase 1 unit 
Template DNA 5 ng 
Nuclease-free H2O To 50 µl 
C 
 Phusion High-Fidelity DNA polymerase 
Initial denaturisation 98°C 30 sec 
15 cycles 
Denaturisation 
Anneal 
Extend 
 
98°C 
60°C 
72°C 
 
10 sec 
30 sec 
15 sec 
Final extension 72°C 7 minutes 
Hold 4°C 
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Appendix 2: List of primers used in this study. 
Name Sequence 5’→3’ 
F- forward 
R- reverse 
F- CAGCCCACAGGAACTGGAAGCA ADAMTS1 
R- GGCTGCCACCGAAAACAACGTG 
F- TAAGGCGGTCGCTCCGGGAAA PCDHB2 
R- TGCTCCAGCTCTGGCTCACGT 
F- GTTGGTGCTGGCAAAAAGTGAGC RPS24 
R- TCTTGCGAAAAATCCACAGTGGCC 
F- CCGCAGCCGCTACTTAAGAGGC TUBA1B 
R- AGATGCACTCACGCATAGTGGC 
F- GTGTTGGATATAAGCCAGACTTTGTT HPRT 
R- AACTCAACTTGAACTCTCATCTTAGGC 
NME1-1F+EcoRI-S F- gagaGAATTCtgGAACCATGGCCAACTGTGAGCGTACCT 
NME1-dSTOP-R+BamHI R- gagaGGATCCctTTCATAGATCCAGTTCTGAGCA 
NME1-2R+BamHI R- gagaGGATCCctCCTCCTGTCATTCATAGATCC  
NME2-1F+EcoRI F- gagaGAATTCtgCCCGGACCATGGCCAACCTGGA 
NME2-dSTOP-R+BamHI R- gagaGGATCCctTTCATAGACCCAGTCATGAGCA 
 
NME2-2R+BamHI-S R- gagaGGATCCTCCACCTCTTATTCATAGACCC 
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Appendix 3: The list of genes found to be mutually up-regulated in Clone 9 and 
RFM9 compared to H1299 (Batch 1) cells. Statistical analysis was performed using 
Student’s t-Test. (Data analysis was performed by Dr Bryony Llyod). 
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Appendix 4: The list of genes found to be mutually up-regulated in Clone 9 
and RFM9 compared to H1299 (Batch 2) cells. Statistical analysis was 
performed using Student’s t-Test. (Data analysis was performed by Dr Bryony 
Llyod). 
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Appendix 4 (Continued): The list of genes found to be mutually up-regulated 
in Clone 9 and RFM9 compared to H1299 (Batch 2) cells. Statistical analysis 
was performed using Student’s t-Test. (Data analysis was performed by Dr Bryony 
Llyod). 
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Appendix 4 (Continued): The list of genes found to be mutually up-regulated 
in Clone 9 and RFM9 compared to H1299 (Batch 2) cells. Statistical analysis 
was performed using Student’s t-Test. (Data analysis was performed by Dr Bryony 
Llyod). 
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Appendix 5: Analysis of the effects of NME2, NME2 kinase dead mutant 
NME2H118F, MDM2 and MDM2 RING finger mutant on cell motility. 
Representative movies are available on the attached CD. 
 
 
Appendix 6: Analysis of the effects of MDM2 overexpression on cell motility. 
Representative movies are available on the attached CD. 
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Appendix 7: Testing of the anti-NME1/2 (C1C3) antibody. Down-regulation of 
NME using siRNA NME1 oligo 9 and NME2 oligo 8 (40 pmol for each well of a 
6-well plate, i.e. a total of 80 pmol/well). Transfected cells were harvested 48h 
post-transfection for western blot and probed with A. anti-NME1/2 (ab31019) B. 
anti-NME1/2 (C1C3) for comparison. Mock (only transfection reagent) and 
Scrambled siRNA serve as negative controls. Red areas indicate saturation of 
signal as a result of overexposure. Similar to anti-NME1/2 (ab31019), C1C3 also 
recognises both NME1 and NME2, except that there were fewer non-specific 
bands at molecular weight above 30 kDa present when blots were probed with 
C1C3 antibody. Therefore, we concluded that anti-NME1/2 (C1C3) is a suitable 
replacement antibody for ab31019. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!"#$%&''
()*+$,$-.'
/0!
"
#$
'
"
12
3'
42
5)
6
*7
89
'
/0!
"
#&
'
/0!
"
#$
:&
'
$;<'
=,'
<='
>?'
+,'
&<'
$;'
;'
$;<'
=,'
<='
>?'
+,'
&<'
$;'
;'
@'
"A'
3B)'
C'
$;<'
=,'
<='
>?'
+,'
&<'
$;'
;'
/0!
"
#$
'
"
12
3'
42
5)
6
*7
89
'
/0!
"
#&
'
/0!
"
#$
:&
'
$;<'
=,'
<='
>?'
+,'
&<'
$;'
;'
!"#$%&''
(D$D+.'
	   320	  
Appendix 8: Sequencing results for pcDNA3.1-NM23-LV and pcDNA3.1-HA-
NM23-LV (plasmid kindly provided by Dr Linda Valentijn). 
pcDNA3.1-NM23-LV 
 
5’ NM23-LV 3’ 
 
DNA sequence 
 
CCCCGCTAGTTTACTTTAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGA
ATTCGATTGCCGGAGTTCAAACCTAAGCAGCTGGAAGGAACCATGGCCAACTGTGAG
CGTACCTTCATTGCGATCAAACCAGATGGGGTCCAGCGGGGTCTTGTGGGAGAGATTA
TCAAGCGTTTTGAGCAGAAAGGATTCCGCCTTGTTGGTCTGAAATTCATGCAAGCTTC
CGAAGATCTTCTCAAGGAACACTACGTTGACCTGAAGGACCGTCCATTCTTTGCCGGC
CTGGTGAAATACATGCACTCAGGGCCGGTAGTTGCCATGGTCTGGGAGGGGCTGAATG
TGGTGAAGACGGGCCGAGTCATGCTCGGGGAGACCAACCCTGCAGACTCCAAGCCTG
GGACCATCCGTGGAGACTTCTGCATACAAGTTGGCAGGACCATGGCCAACCTGGAGC
GCACCTTCATCGCCATCAAGCCGGACGGCGTGCAGCGCGGCCTGGTGGGCGAGATCAT
CAAGCGCTTCGAGCAGAAGGGATTCCGCCTCGTGGCCATGAAGTTCCTCCGGGCCTCT
GAAGAACACCTGAAGCAGCACTACATTGACCTGAAAGACCGACCATTCTTCCCTGGGC
TGGTGAAGTACATGAACTCAGGGCCGGTTGTGGCCATGGTCTGGGAGGGGCTGAACG
TGGTGAAGACAGGCCGAGTGATGCTTGGGGAGACCAATCCAGCAGATTCAAAGCCAG
GCACCATTCGTGGGGACTTCTGCATTCAGGTTGGCAGGAACATCATTCATGGCAGTGA
TTCAGTAAAAAGTGCTGAAAAAGAAATCAGCCTATGGTTTAAGCCTGAAGAACTGGTT
GACTACAAGTCTTGTGCTCATGACTGGGTCTATGAATAAGAGGTGGACACAACAGCAG
TCTCCTTCAGCACGGCGTGGTGTGTCCCTGGACACAGCTCTTCATTCCATTGACTTAGA
GGCAACAGGATTGATCATTCTAATCACTAGTGAATTCTGCAGATATCCAGCACAGTGG
CGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGGCTTCCTTGACCCTGGAAAGT
GGCACTCCCACTGGCCTTTCCTAATAAAATGAGGAAATTGCATCCCATTGTCTGAATA
GGTGCATTCTATCTGGGGGGGGGGGTTGGGCCA 
 
 
 
Amino acid sequence 
 
P L V Y F S L V P S S D P L V Q C G G I R L P E F K P K Q L E G T Met A N C E R T F I A I 
K P D G V Q R G L V G E I I K R F E Q K G F R L V G L K F Met Q A S E D L L K E H Y V D 
L K D R P F F A G L V K Y Met H S G P V V A Met V W E G L N V V K T G R V Met L G E 
T N P A D S K P G T I R G D F C I Q V G R T Met A N L E R T F I A I K P D G V Q R G L V 
G E I I K R F E Q K G F R L V A Met K F L R A S E E H L K Q H Y I D L K D R P F F P G L V 
K Y Met N S G P V V A Met V W E G L N V V K T G R V Met L G E T N P A D S K P G T I R 
G D F C I Q V G R N I I H G S D S V K S A E K E I S L W F K P E E L V D Y K S C A H D W 
V Y E Stop E V D T T A V S F S T A W C V P G H S S S F H Stop L R G N R I D H S N H Stop 
Stop I L Q I S S T V A A A R V Stop R A R L N P L I S L D C A F Stop L P A I C C L P L P R 
G F L D P G K W H S H W P F L I K Stop G N C I P L S E Stop V H S I W G G G L G 
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Appendix 8 (Continued): Sequencing results for pcDNA3.1-NM23-LV and 
pcDNA3.1-HA-NM23-LV (plasmid kindly provided by Dr Linda Valentijn). 
 
pcDNA3.1-HA-NM23-LV 
 
  5’ HA-linker-NM23-LV 3’ 
 
DNA sequence 
 
CCCGCTCGTTTACTTTAGCTTATGTACCCATACGATGTTCCAGATTACGCTGGATCCAT
GGCCAACTGTGAGCGTACCTTCATTGCGATCAAACCAGATGGGGTCCAGCGGGGTCTT
GTGGGAGAGATTATCAAGCGTTTTGAGCAGAAAGGATTCCGCCTTGTTGGTCTGAAAT
TCATGCAAGCTTCCGAAGATCTTCTCAAGGAACACTACGTTGACCTGAAGGACCGTCC
ATTCTTTGCCGGCCTGGTGAAATACATGCACTCAGGGCCGGTAGTTGCCATGGTCTGG
GAGGGGCTGAATGTGGTGAAGACGGGCCGAGTCATGCTCGGGGAGACCAACCCTGCA
GACTCCAAGCCTGGGACCATCCGTGGAGACTTCTGCATACAAGTTGGCAGGACCATGG
CCAACCTGGAGCGCACCTTCATCGCCATCAAGCCGGACGGCGTGCAGCGCGGCCTGGT
GGGCGAGATCATCAAGCGCTTCGAGCAGAAGGGATTCCGCCTCGTGGCCATGAAGTTC
CTCCGGGCCTCTGAAGAACACCTGAAGCAGCACTACATTGACCTGAAAGACCGACCAT
TCTTCCCTGGGCTGGTGAAGTACATGAACTCAGGGCCGGTTGTGGCCATGGTCTGGGA
GGGGCTGAACGTGGTGAAGACAGGCCGAGTGATGCTTGGGGAGACCAATCCAGCAGA
TTCAAAGCCAGGCACCATTCGTGGGGACTTCTGCATTCAGGTTGGCAGGAACATCATT
CATGGCAGTGATTCAGTAAAAAGTGCTGAAAAAGAAATCAGCCTATGGTTTAAGCCTG
AAGAACTGGTTGACTACAAGTCTTGTGCTCATGACTGGGTCTATGAATAAGAGGTGGA
CACAACAGCAGTCTCCTTCAGCACGGCGTGGTGTGTCCCTGGACACAGCTCTTCATTC
CATTGACTTAGAGGCAACAGGATTGATCATTCTAATCACTAGTGAATTCTGCAGATAT
CCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCT
CGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGA
CCCTGGAAAGGTGCCACTCCCACTGGCCTTTCCTAATAAAATGAGGAAATTGCATCGC
ATTGGCTGAATAGGTGCATTCTATCTGGGGG 
 
 
 
Amino acid sequence 
 
P A R L L Stop L Met Y P Y D V P D Y A G S Met A N C E R T F I A I K P D G V Q R G L V 
G E I I K R F E Q K G F R L V G L K F Met Q A S E D L L K E H Y V D L K D R P F F A G L 
V K Y Met H S G P V V A Met V W E G L N V V K T G R V Met L G E T N P A D S K P G T I 
R G D F C I Q V G R T Met A N L E R T F I A I K P D G V Q R G L V G E I I K R F E Q K G F 
R L V A Met K F L R A S E E H L K Q H Y I D L K D R P F F P G L V K Y Met N S G P V V 
A Met V W E G L N V V K T G R V Met L G E T N P A D S K P G T I R G D F C I Q V G R N 
I I H G S D S V K S A E K E I S L W F K P E E L V D Y K S C A H D W V Y E Stop E V D T T 
A V S F S T A W C V P G H S S S F H Stop L R G N R I D H S N H Stop Stop I L Q I S S T V 
A A A R V Stop R A R L N P L I S L D C A F Stop L P A I C C L P L P R A F L D P G K V P L 
P L A F P N K Met R K L H R I G Stop I G A F Y L G 
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Appendix 9: Expression of NM23-LV protein. In order to examine the 
expression of NM23-LV and HA-NM23-LV plasmids (provided by Dr. Linda 
Valentijn), H1299 cells were transfected with 4 µg of NM23-LV, HA-NM23-LV, 
or empty vector, as indicated, in each well of a 6-well plate using Lipofectamine 
2000. Transfected cells were harvested 24h post transfection for western blot 
analysis using anti-NME2 (L15), anti-NME1/2 (C1C3), anti-NME1 (SC465) and 
anti-HA (12CA5), as indicated. White arrow ( ) indicates the position of NM23-
LV; grey arrow ( ) indicates the position of NME1; black arrow ( ) indicates the 
position of NME2. 
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Appendix 10: Digest results for constructs expressing NME fusion proteins. 
Constructs that express fluorescence-labelled NME fusion proteins, NME1, NME2, 
NME2H118F and NM23-LV were generated by cloning these NMEs into pEYFP and 
pECFP vectors, resulting in both C- and N- terminally fluorescent-tagged forms of NMEs. 
Following NME fragments being subcloned into pEYFP and pECFP vectors at ECoRI 
and BamHI restriction sites, the insertions were confirmed by excising at these two 
restriction sites. 
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Appendix 10 (Continued): Digest results for constructs expressing NME fusion 
proteins. 
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Appendix 11: Examining the cellular localisation of NME fusion proteins 
using live cell imaging. Representative movies are available on the attached CD. 
Each field is represented by two files: One for fluorescence only (F), and the 
other for fluorescence with phase contrast (F+PC). The fluorescence 
brightness for NM23-LV fusion protein was adjusted for visualisation since 
the level of protein expression was too low. F, fluorescence; PC, phase 
contrast.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
